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A B S T R A C T
Background
The World Health Organization (WHO) recommends treating all school children at regular intervals with deworming drugs in areas
where helminth infection is common. The WHO state this will improve nutritional status, haemoglobin, and cognition and thus will
improve health, intellect, and school attendance. Consequently, it is claimed that school performance will improve, child mortality will
decline, and economic productivity will increase. Given the important health and societal benefits attributed to this intervention, we
sought to determine whether they are based on reliable evidence.
Objectives
To summarize the effects of giving deworming drugs to children to treat soil-transmitted intestinal worms (nematode geohelminths)
on weight, haemoglobin, and cognition; and the evidence of impact on physical well being, school attendance, school performance,
and mortality.
Search methods
In February 2012, we searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, EMBASE, LILACS, mRCT,
and reference lists, and registers of ongoing and completed trials.
Selection criteria
We selected randomized controlled trials (RCTs) and quasi-RCTs comparing deworming drugs for geohelminth worms with placebo
or no treatment in children aged 16 years or less, reporting on weight, haemoglobin, and formal test of intellectual development.
In cluster-RCTs treating communities or schools, we also sought data on school attendance, school performance, and mortality. We
included trials that included health education with deworming.
Data collection and analysis
At least two authors independently assessed the trials, evaluated risk of bias, and extracted data. Continuous data were analysed using
the mean difference (MD) with 95% confidence intervals (CI). Where data were missing, we contacted trial authors. We used GRADE
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to assess evidence quality, and this is reflected in the wording we used: high quality (“deworming improves....”); moderate quality
(“deworming probably improves...”); low quality (“deworming may improve....”); and very low quality (“we don’t know if deworming
improves....”).
Main results
We identified 42 trials, including eight cluster trials, that met the inclusion criteria. Excluding one trial where data are awaited, the 41
trials include 65,168 participants.
Screening then treating
For children known to be infected with worms (by screening), a single dose of deworming drugs may increase weight (0.58 kg, 95%
CI 0.40 to 0.76, three trials, 139 participants; low quality evidence) and may increase haemoglobin (0.37 g/dL, 95% CI 0.1 to 0.64,
two trials, 108 participants; low quality evidence), but we do not know if there is an effect on cognitive functioning (two trials, very
low quality evidence).
Single dose deworming for all children
In trials treating all children, a single dose of deworming drugs gave mixed effects on weight, with no effects evident in seven trials, but
large effects in two (nine trials, 3058 participants, very low quality evidence). The two trials with a positive effect were from the same
very high prevalence setting and may not be easily generalised elsewhere. Single dose deworming probably made little or no effect on
haemoglobin (mean difference (MD) 0.06 g/dL, 95% CI -0.06 to 0.17, three trials, 1005 participants; moderate evidence), and may
have little or no effect on cognition (two trials, low quality evidence).
Mulitple dose deworming for all children
Over the first year of follow up, multiple doses of deworming drugs given to all children may have little or no effect on weight (MD
0.06 kg, 95% CI -0.17 to 0.30; seven trials, 2460 participants; low quality evidence); haemoglobin, (mean 0.01 g/dL lower; 95% CI
0.14 lower to 0.13 higher; four trials, 807 participants; low quality evidence); cognition (three trials, 30,571 participants, low quality
evidence); or school attendance (4% higher attendance; 95% CI -6 to 14; two trials, 30,243 participants; low quality evidence);
For time periods beyond a year, there were five trials with weight measures. One cluster-RCT of 3712 children in a low prevalence area
showed a large effect (average gain of 0.98 kg), whilst the other four trials did not show an effect, including a cluster-RCT of 27,995
children in a moderate prevalence area (five trials, 37,306 participants; low quality evidence). For height, we are uncertain whether there
is an effect of deworming (-0.26 cm; 95% CI -0.84 to 0.31, three trials, 6652 participants; very low quality evidence). Deworming
may have little or no effect on haemoglobin (0.00 g/dL, 95%CI -0.08 to 0.08, two trials, 1365 participants, low quality evidence);
cognition (two trials, 3720 participants; moderate quality evidence). For school attendance, we are uncertain if there is an effect (mean
attendance 5% higher, 95% CI -0.5 to 10.5, approximately 20,000 participants, very low quality evidence).
Stratified analysis to seek subgroup effects into low, medium and high helminth endemicity areas did not demonstrate any pattern of
effect. In a sensitivity analysis that only included trials with adequate allocation concealment, we detected no significant effects for any
primary outcomes.
One million children were randomized in a deworming trial from India with mortality as the primary outcome. This was completed
in 2005 but the authors have not published the results.
Authors’ conclusions
Screening children for intestinal helminths and then treating infected children appears promising, but the evidence base is small. Routine
deworming drugs given to school children has been more extensively investigated, and has not shown benefit on weight in most studies,
except for substantial weight changes in three trials conducted 15 years ago or more. Two of these trials were carried out in the same
high prevalence setting. For haemoglobin and cognition, community deworming seems to have little or no effect, and the evidence in
relation to school attendance, and school performance is generally poor, with no obvious or consistent effect. Our interpretation of
this data is that it is probably misleading to justify contemporary deworming programmes based on evidence of consistent benefit on
nutrition, haemoglobin, school attendance or school performance as there is simply insufficient reliable information to know whether
this is so.
P L A I N L A N G U A G E S U M M A R Y
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Deworming drugs for treating soil-transmitted intestinal worms in children: effects on nutrition and school performance
The main soil-transmitted worms are roundworms, hookworms, and whipworms. Infections are common in tropical and subtropical
areas, particularly in children from low-income areas where there is inadequate sanitation, overcrowding, low levels of education, and
lack of access to health care. These infections sometimes cause malnutrition, poor growth, and anaemia in children, and some experts
believe they cause poor performance at school. While improved sanitation and hygiene are likely to be helpful, drugs can also be used.
In one approach, individuals found to be infected on screening are treated. Evidence from these trials suggests this probably improves
weight and may improve haemoglobin values, but the evidence base is small. In another approach, currently recommended by the
WHO, and much more extensively investigated, all school children are treated. In trials that follow up children after a single dose of
deworming, and after multiple doses with follow up for over a year, we do not know if these programmes have an effect on weight,
height, school attendance, or school performance; they may have little or no effect on haemoglobin or cognition.
One trial of a million children examined death and was completed in 2005 but the authors have not yet published the results.
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B A C K G R O U N D
Description of the condition
The three soil-transmitted helminth (STH) infections, ascariasis
(roundworm), trichuriasis (whipworm), and hookworm, are the
main intestinal helminth infections in humans (Bethony 2006; de
Silva 2003b). Specialists estimate that each type of infection causes
between 600-800 million cases worldwide each year (Hotez 2009,
de Silva 2003b), withmore than a quarter of theworld’s population
infected with one or more of the soil-transmitted intestinal worms
(Chan 1997). Estimates from 2003 suggest that global prevalence
of STH infections is declining, with marked improvement in the
Americas and Asia, but a static picture in sub-Saharan Africa (de
Silva 2003b). STH infections particularly affect children living in
poverty, where inadequate sanitation, overcrowding, low levels of
education, and lack of access to health care make themparticularly
susceptible (Bethony 2006, de Silva 2003b). In 1993, the World
Bank ranked STH infection as a greater cause of ill health in
children aged 5 to 15 years than any other infection (World Bank
1993), but there has been considerable variation in the quoted
estimates of global burden (de Silva 2003b), which are currently
being updated.
Policy makers are concerned that the long-term effects of worm
infestation impair childhood nutritional status, school perfor-
mance, and long-term cognitive development (Bethony 2006). It
is thought that iron status may mediate these effects, since hook-
worm and whipworm disease are associated with iron-deficiency
anaemia (Crompton 2000; de Silva 2003a), and a fall in blood
haemoglobin levels is associated with increasing intensity of infec-
tion (Crompton 2003). Furthermore, hookworm-induced iron-
deficiency anaemia has been associated with decreased physical
activity and worker productivity (Crompton 2003).
Worms are associated with malnutrition, impaired growth, and
poor school performance. Roundworms obtain their nutrition
from gastrointestinal contents. The association with malnutrition
is possibly mediated through impaired fat digestion, reduced vi-
tamin absorption (particularly vitamin A), and temporary lactose
intolerance (WHO 2002). Whipworm infection has been associ-
ated with malnutrition, although the precise mechanism for this
is unclear (Cappello 2004). Some suggest that the effects on nutri-
tion are through appetite suppression, increased nutrient loss, and
decreased nutrient absorption and utilization (Stephenson 2000;
de Silva 2003a).
Roundworm, hookworm, and whipworm disease have all been as-
sociated with impaired growth in school children (de Silva 2003a).
Observational studies have reported an association between worm
infection and lower scores on tests of school performance (Sakti
1999; Kvalsvig 2003). In a multiple-regression model based on
cross-sectional data, Sakti 1999 found that hookworm infection
was associated with worse scores in six out of 14 cognitive tests in
Indonesian school children. Severewhipworm (Trichurisdysentery
syndrome) was associated with low IQ, school achievement, and
cognitive function after a four-year follow up of a specific group
of Jamaican children with severe infection (Callender 1998).
While these associations would suggest potential benefits of de-
worming, the associations could equally be caused by the con-
founding factor of poverty. Even with adjustment for known con-
founding factors, residual confounding could be a problem. Fur-
thermore, the causal link between chronic infection and impaired
childhood development is extrapolated from the recorded im-
provement in these features after deworming (Bethony 2006).
Hence, reliable randomized controlled trials are required to assess
whether policies are effective. These can examine the effectiveness
of treating worm infection in an individual, as evidence of effi-
cacy, and treatment in schools or communities, as evidence of the
effectiveness of programmes. The latter studies are ideally cluster-
RCTs, and thus able to detect any externalities (benefits to other
children) accruing as a result of reduced transmission.
Description of the intervention
Public health interventions to tackle worm infection include those
that improve sanitation and hygiene, or those that administer drug
therapy to populations or targeted groups in the community, of-
ten coupled with health education. The work of the Rockefeller
Sanitary Commission in the early 1900s led to the recognition
that sanitary reform was needed alongside chemotherapeutic ap-
proaches to have an effect on worm prevalence (Horton 2003).
In Japan, worms virtually disappeared over a 20-year period after
the Second World War; this has been credited to an integrated
programme of sanitary reform combined with screening and treat-
ment of positive cases (Savioli 2002; Horton 2003). A similar ex-
perience occurred in Korea (Savioli 2002). The current global de-
cline in worm prevalence has been credited to economic develop-
ment and deworming programmes (de Silva 2003b). The impact
of the chemotherapeutic element is difficult to assess. In countries
where an improvement in sanitation and hygiene has occurred as
a component of economic growth, a parallel decline in the preva-
lence of geohelminths has occurred: for example, in Italy between
1965 and 1980, the trichuriasis prevalence dropped from 65% to
less than 5% without control activity (Savioli 2002).
The World Health Organization (WHO) policy outlines three
categories of public health drug treatment policies (WHO 2002):
• Selective: individual deworming based on a diagnosis of
infection.
• Targeted: group deworming where a (risk) group is treated
without prior diagnosis.
• Universal: population deworming in which the whole
community is treated irrespective of infection status.
The WHO and others promote targeted treatment. They do not
recommend individual screening since the cost is four to 10 times
that of the treatment itself. The policy’s aim appears to be to con-
trol morbidity by reducing the intensity of infection in the most
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vulnerable populations. The strategy is to target drug treatment
at groups: pre-school-age children (between one and five years);
school-age children (between six and 15 years); and women of
childbearing age. The strategy requires a population survey for
prevalence and intensity of infection to determine the population
worm burden. This determines the recommended frequency of
treatment, updated in a WHO field manual in 2006: once per
year for low-risk communities with 20 to 50% prevalence, or twice
per year for high-risk communities with >50% prevalence (WHO
2006b).
The policy promotes the use of schools, maternal and child health
clinics, and vaccination campaigns to reach at-risk groups. The
WHO advocate school-based programmes in particular, as it is
easy to deliver medicines through teaching staff, with estimated
costs varying from US$ 0.05 to 0.65 per child per year for annual
dosing (Savioli 2002; WHO 2002). In areas with a high preva-
lence, the current policy recommends treatment three times per
year (WHO 2006b), based on modelling and reinfection preva-
lence studies. Following drug treatment worm populations tend to
return rapidly to pretreatment levels; in less than a year for round-
worm and whipworm (Anderson 1991). Anderson 1991 suggests
that to control morbidity in areas of endemic infection, targeted
treatment should be repeated every three to fourmonths for round-
worm and whipworm, with longer intervals acceptable for longer-
lived species such as hookworm. The WHO recommends moni-
toring with a range of impact indicators, including prevalence and
intensity, incidence, morbidity and mortality (WHO 2010). The
control programme is intended to reduce the worm burden in the
10% to 15% of children who are most heavily infected in a partic-
ular population and to keep it low through repeated treatments.
It is also argued that treating individuals in communities reduces
transmission in the community as a whole (Anderson 1991), and
that this can lead to health and schooling benefits for the whole
population, including those who have not received deworming
treatment (Bundy 2009). These ’spill over’ effects, or externali-
ties, are not captured in individually randomized controlled trials,
since any benefit in the control group reduces the overall treat-
ment effect. A cluster design is therefore required to identify these
additional putative effects.
How the intervention might work
It is argued that deworming programmes improve nutrition, hae-
moglobin, and cognition. As a result of these benefits, children
are thought to have increased physical well being, with improved
intellect, and are better able to attend school. As a result, perfor-
mance at school is enhanced, and mortality is reduced; over the
long-term this benefits society as a whole, and reduces poverty
(Figure 1) (WHO 2005).
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Figure 1.
In this review, the primary outcomes sought are the main ef-
fects (increased haemoglobin, nutrition, and improved cognition);
measurable aspects of the mediating pathways (school attendance
and physical well being); and measurable aspects of impact (mor-
tality and school performance; Figure 1 ).
Clinical observation of treating children heavily infected with
worms indicated weight gain was sometimes marked, and so in
this review we include community studies that measure effects af-
ter a single dose of deworming drugs (’efficacy’ measures in the
individual), as well as studies of multiple doses with follow-up
under a year (showing early benefits) and studies with follow-up
beyond a year. The latter studies are likely to detect externalities
and potential long term benefits.
Why it is important to do this review
The intended impacts of deworming programmes - to reducemor-
tality, and increase children’s long term economic productivity -
are clearly worthwhile goals and are heavily promoted by advocates
in the field such as the WHO (Montresor 2002; WHO 2002;
WHO 2006b), and the World Bank (World 2011). Furthermore,
deworming with albendazole was recently endorsed in the 2012
Copenhagen consensus statement, as the 4th highest ranking so-
lution to address ’big issues facing the planet’ in terms of cost and
benefit (Copenhagen Consensus Center 2012). The widely-cited
cost-effectiveness estimates from the Disease Control Priorities in
Developing Countries (DCP2) report (Jamison 2006) state that
deworming for STH infections was one of the most cost-effec-
tive interventions for global health. The reliability of these esti-
mates, however, has been questioned recently by the organization
GiveWell, which suggests they have been overstated by a factor of
about 100 (GiveWell 2011).
Advocates point to the favourable cost-effectiveness estimates for
deworming programmes, with a focus on the putative effect on
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schooling outcomes, and productivity (Deworm theWorld 2012).
The evidential basis for this draws on a range of study designs,
including historical econometric studies such as Bleakely 2004,
which analysed the Rockefeller Sanitary Commission’s campaign
to eradicate hookworm in the American South. This showed an as-
sociation between areas with higher levels of hookworm infection
prior to the campaign and greater increases in school attendance
and literacy after the intervention, and an association with income
gains in the longer-term. Another influential study isMiguel 2004
(Cluster), which is included in this review.
Current policies have become even more challenging to assess,
as global specialists conflate the evidence on different helminths.
Some advocates describe the benefits of treating all helminths,
including schistosomiasis, filariasis, and STH infections. For ex-
ample, the WHO states that deworming treatment against schis-
tosomes and STH infections helps (1) eradicate extreme poverty
and hunger; (2) achieve universal primary education; (3) promote
gender equality and empower women; (4) reduce child mortal-
ity and improve maternal health; and (5) combat HIV/AIDS,
malaria, and other diseases (WHO 2005). The evidence for the
benefit of treating populations with schistosomiasis is fairly clear
(Danso-Appiah 2008), as the infection has a very substantive ef-
fect on health. However, this does not mean that a different drug
treating a different helminth species is equally effective.
Despite the lack of rigour in considering the evidence for separate
components of these policies, they are moving forward globally
with large scale purchases of drugs. The current Neglected Trop-
ical Disease (NTD) policy focus has been on addressing ’poly-
parasitism’ by treating the parasites that cause ascariasis, trichuri-
asis, hookworm, lymphatic filariasis, onchocerciasis, schistosomi-
asis, and trachoma with ivermectin, albendazole, azithromycin,
and praziquantel (Hotez 2009). These four drugs are donated by
pharmaceutical companies, and the ’overlapping specificity’ would
meanmultiple pathogenswould be targeted (Hotez 2006b). Thus,
mass drug administration for NTDs is promoted as “one of the
lowest cost and cost-efficient mechanisms for both improving ma-
ternal child health and lifting the bottom billion out of poverty”
(Hotez 2011b). Significant resources are being invested in this
agenda, with the UK Department for International Development
committing £50 million in 2008, and the US government (USG)
committing US$65 million in 2010 as part of the US Global
Health Initiative (GHI) (Hotez 2011a).
Given the amount of investment of public money in these pro-
grammes, it is important to be clear whether mass or targeted drug
administration is able to contribute to health and development in
such a substantive way - not least because if it does then major in-
vestment is justified. Indeed, international donors and developed
country governments and tax payers are contributing to the efforts
to tackle STH infections in the belief that they will improve the
health of children in the way that theWHO claim (WHO 2005).
Thus this reviewof reliable evidence fromcontrolled trialswill help
delineate whether there is an impact of these drugs in populations
with STH infections (ascariasis, trichuriasis, and hookworm).
History of this review
In 2007, we systematically reviewed the reliable evidence from
controlled trials about the effects of anthelminth drugs for STH
infection on child growth and cognition (Taylor-Robinson 2007).
This systematic review demonstrated uncertainty around the as-
sumed benefit and concluded that deworming may be effective in
relation to weight gain in the short-term in some areas, but not in
others; the potential long-term impact on weight was unclear. For
school performance, data were very limited, and no convincing
treatment effect was demonstrated.
New trials have been recently published, and other unpublished
studies have been made available to us. In this review update,
we have reapplied the inclusion criteria, repeated data extraction,
added new trials, added haemoglobin as a primary outcome, re-
structured the analysis, and used GRADE to assess the quality of
the evidence. We were also able to:
• combine trials with nutritional outcomes as change and end
values in the same meta-analysis, as this has been shown to be
valid.
• stratify the analysis by endemicity of worms, as the policy
question is whether deworming should be given in all areas, or
only high prevalence areas.
In addition, following correspondence with the authors of a large
study that measured schooling as an outcome, we have included
this in the current edition (Miguel 2004 (Cluster)).
Unfortunately, we have been unable to include a trial of over a
million children completed in 2005 (DEVTA (unpublished).This
is despite our best efforts in trying to elicit public disclosure of the
results.
This Cochrane Review does not cover deworming and pregnancy,
which is covered elsewhere (Haider 2009).
O B J E C T I V E S
In deworming programmes for soil-transmitted intestinal worms
(nematode geohelminths) in children, to summarise the effects
on nutritional indicators, haemoglobin, cognition, school atten-
dance; and the impacts on school performance and mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Randomized and quasi-randomized controlled trials (RCTs). We
included cluster-RCTs, provided more than two clusters were al-
located to each treatment arm.
Types of participants
Children aged 16 years or less in community studies. We excluded
trials of sick children or children being treated for malnutrition.
Types of interventions
Intervention
Deworming drugs for geohelminth worms, administered at any
location (including health facilities, schools, and communities).
We included studies examining effects after a single dose, and after
multiple doses.
The dewormingdrugswe included are those included in theWHO
Model List of Essential Medicines for deworming drugs of geo-
helminths (WHO 2006a). This includes albendazole, levamisole,
mebendazole, pyrantel, and ivermectin. Other drugs used are ni-
tazoxanide, piperazine, tetrachlorethylene, and thiabendazole.
We included studies that provided health education to the inter-
vention arm alone. Studies that provided other additional inter-
ventions (eg growth monitoring, micronutrient supplementation,
malaria chemoprevention, or other drugs) were included when the
additional intervention was given to both the control and inter-
vention arm.
Control
Placebo or no treatment.
Types of outcome measures
Primary
• Weight.
• Haemoglobin.
• Psychometric tests of cognition.
Secondary
• Other nutritional indicators:
◦ Height.
◦ Mid-upper arm circumference.
◦ Skin fold thickness (eg tricep and subscapular skin
fold).
◦ Body mass index.
• Measures of physical well being (eg Harvard Step Test).
• School attendance:
◦ Days present at school.
◦ Number of children dropping out.
• School performance (measured by examination results).
• Death.
Adverse events
• Serious adverse events (death, life-threatening events, or
events leading to hospitalisation).
• Other adverse events.
Search methods for identification of studies
The authors along with the Cochrane Infectious Diseases Group
Information Specialist attempted to identify all relevant trials re-
gardless of language or publication status (published, unpublished,
in press, and in progress).
The Information Specialist searched the following databases using
the search terms and strategy described in Table 1: Cochrane In-
fectious Diseases Group Specialized Register (15 February 2012);
Cochrane Central Register of Controlled Trials (CENTRAL),
published in The Cochrane Library (2011, Issue 4); MEDLINE
(2000 to 15 February 2012); EMBASE (2000 to 15 Febru-
ary 2012); and LILACS (2000 to 15 February 2012). The
metaRegister of Controlled Trials (mRCT) was also searched using
’helminth* OR anthelminth*’ (15 February 2012).
We also searched the same databases for the effect of administration
of deworming drugs on haemoglobin, using the search terms listed
inTable 2.This additional searchwas conducted inFebruary 2012.
In addition, we drew on existing reviews of the topic and we
checked the citations of all the trials identified by the above meth-
ods. We also re-appraised the studies identified in the previous
versions of this review (Dickson 2000a; Taylor-Robinson 2007).
Data collection and analysis
Selection of studies
David Taylor-Robinson (DTR) checked the results of the search
for potentially relevant trials and retrieved full articles as required.
DTR and Paul Garner (PG) independently assessed the trial el-
igibility using an eligibility form based on the inclusion criteria;
where there was uncertainty, all five authors participated in the
decision about inclusion. We checked that trials with multiple
publications were managed as one study. We recorded reasons for
the exclusion of studies and we contacted authors of unpublished
studies for information on when they intended to publish their
results.
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Data extraction and management
DTR, Nicola Maayan (NM), Sarah Donegan (SD), and Karla
Soares-Weiser (KSW) independently extracted data using data ex-
traction forms. PG extracted and cross-checked the data from a
selection of papers. We resolved any differences in opinion by dis-
cussion. Where methods, data, or analyses were unclear or miss-
ing, we contacted authors for further details.
For each treatment group of each trial, we extracted the number of
patients randomized. For each outcome of interest, we extracted
the number of participants analysed in each treatment group of
each trial.
RCTs that randomize individuals
For dichotomous outcomes, we planned to extract the number
of patients with the event. For continuous outcomes, we aimed
to extract means and standard deviations. Where these data were
not reported, we extracted medians and ranges or any other sum-
mary statistics. Where change from baseline results were presented
alongside results purely based on the end value, we only extracted
the change from baseline results.
RCTs that randomize clusters
For each cluster-RCT, we extracted the cluster unit, the number
of clusters in the trial, the average size of clusters, and the unit of
randomization (eg household or institution). Where possible, we
extracted the statistical methods used to analyse the trial alongwith
details describing whether these methods adjusted for clustering
or other covariates. When reported, estimates of the intra-cluster
correlation coefficient (ICC) for each outcome were extracted.
Where a cluster-RCT adjusted for clustering in their analysis, we
extracted the cluster adjusted results. When the trial did not ac-
count for clustering in their analysis, we extracted the same data
as for trials that randomize individuals.
Assessment of risk of bias in included studies
DTR, PG, NM, SD, and KSW independently assessed the risk of
bias (Higgins 2011b). Differences were resolved by discussion. On
occasion, we corresponded with trial investigators when methods
were unclear.
For RCTs that randomized individuals we addressed six compo-
nents: sequence generation; allocation concealment; blinding; in-
complete outcome data; selective outcome reporting; and other
biases. For RCTS randomized by cluster, we addressed additional
components: recruitment bias; baseline imbalance; loss of clusters;
incorrect analysis; compatibility with RCTs randomized by indi-
vidual. For each component, we placed judgments of low, high,
or unclear/unknown risk of bias as described in Appendix 1. We
displayed the results in risk of bias tables, a risk of bias summary,
and a risk of bias graph.
Measures of treatment effect
Continuous data (means and standard deviations) were sum-
marised using the mean differences. We planned to use the risk
ratio to compare the treatment and control groups for dichoto-
mous outcomes. All treatment effects were presented with 95%
Confidence Intervals (CIs).
Unit of analysis issues
For a particular cluster-RCT when the analyses had not been ad-
justed for clustering, we attempted to adjust the results for clus-
tering by estimating the design effect calculated as 1+(m-1)*ICC
where m is the average cluster size and ICC is the intra-cluster
correlation coefficient. To make the adjustment, we estimated a
treatment effect that did not adjust for clustering and then multi-
plied the standard errors of the estimate by the square root of the
design effect. When the true ICC was unknown, we estimated it
from other included cluster-RCTs.
Dealing with missing data
We aimed to conduct a complete-case analysis in this review, such
that all patients with a recorded outcome were included in the
analysis.
Assessment of heterogeneity
We inspected the forest plots to detect overlapping CIs, applied
the Chi2 test with a P value of 0.10 used to indicate statistical
significance, and also implemented the I2 statistic with values of
30 to 60%, 59 to 90%, and 75 to 100% used to denote moderate,
substantial, and considerable levels of heterogeneity, respectively.
Assessment of reporting biases
We decided not to construct funnel plots to look for evidence of
publication bias because there were a limited number of trials in
each analysis.
Data synthesis
KSW, NM, DTR, and SD analysed data with Review Manager 5.
The analysis was structured into five sections:
Screened for infection: included trials that only included children
who were identified as infected
• after a single dose;
• after multiple doses (outcomes measured in the first year).
Target population treated: included trials that included screened
and unscreened children
• after a single dose;
• after multiple doses (outcomes measured in the first year);
• after multiple doses (outcomes measured after the first year).
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In the analyses of the target population, we stratified the analy-
sis into three categories based on prevalence and intensity: High
prevalence or high intensity areas (referred to as ’high prevalence’);
moderate prevalence and low intensity (referred to as ’moderate
prevalence’); and low prevalence with low intensity (referred to as
’low prevalence’). We used the WHO technical guidelines classi-
fication (WHO 2002; Table 3), rather than the simplified preva-
lence based field guide categories that are now used to determine
treatment frequency (WHO 2006b; Table 3). In trials where in-
formation on intensity was not provided, we estimated the com-
munity category on the basis of quoted prevalence; it is possible
that the community category has been underestimated in these
trials (as per Table 3).
Cluster-RCTs that adjusted for clustering and RCTs that random-
ized individuals were combined usingmeta-analysis. We presented
results of cluster-RCTs that were not adjusted for clustering in an
additional table. We used a fixed-effect meta-analysis when the
assessments of heterogeneity did not reveal heterogeneity. In the
presence of heterogeneity, random-effects meta-analysis was used.
For continuous data, we combined change from baseline results
with end value results providing they were from distinct trials
(Cochrane Collaboration 2002; Higgins 2011a). Labels on the
meta-analyses indicate when end values were used.
We presented data that could not be meta-analysed in additional
tables and reported on in these each section, under a heading,
’other data’.
Subgroup analysis and investigation of heterogeneity
In the presence of statistically significant heterogeneity, we planned
to explore the following potential sources using subgroup anal-
yses: age group (< five years versus ≥ five years); manufacturer;
treatment setting (community, school, health post, hospital). We
did not carry out these analyses because there were too few studies
in the analyses.
Sensitivity analysis
We carried out sensitivity analyses including only those trials with
a low risk of bias regarding allocation concealment.
Summary of findings table
We interpreted results using a summary of findings (SOF) table,
which provides key information about the quality of evidence for
the included studies in the comparison, the magnitude of effect
of the interventions examined, and the sum of available data on
the main outcomes. Data were imported from Review Manager
5 using the GRADE profiler (GRADE 2004). We selected the
primary outcomes for the review in the SOF, and added height,
school attendance, anddeath formultiple dose comparisons. Thus,
our SOF table included:
• Weight (kg)
• Height (cm) (for Comparison 4: Multiple dose, outcomes
measured > 1 year only)
• Haemoglobin (g/dL)
• Psychometric tests of cognition
• School attendance (for Comparison 4: Multiple dose,
outcomes measured < 1 year only; and Comparison 5: Multiple
dose, outcomes measured > 1 year only)
• Death (for Comparison 5: Multiple dose, outcomes
measured > 1 year only): awaiting publication (DEVTA
(unpublished).
In addition, physical fitness was measured in two studies after one
dose of deworming medicine, and this measure was also included
in the SOF table for this comparison only.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
We identified 42 trials reported in 53 articles thatmet the inclusion
criteria (see Characteristics of included studies); this includes one
study of onemillion children, completed in 2005, for whichwe are
unable to report outcomes because it has not yet been published
(DEVTA (unpublished)). A second study, completed in 2006, has
never been published, but we were able to use the data from the
manuscript supplied by the authors (Hall 2006 (Cluster)).
For Alderman 2006 (Cluster), the authors did not adjust the CIs
to take into account clustering for the primary outcome. For this
review, we used the corrected values supplied by the author.
Thirty-eight trials were excluded (see Characteristics of excluded
studies), and two trials are ongoing (see Characteristics of ongoing
studies).
Location
The included trials were undertaken in 23 different countries:
Bangladesh (four trials); Ethiopia (two trials); Haiti (two trials);
India (five trials); Indonesia (two trials); Jamaica (two trials); Kenya
(five trials); South Africa (two trials); Vietnam (three trials); Zanz-
ibar (two trials); Benin, Botswana, Cameroon, Guatemala, Java,
Malaysia, Nigeria, Philippines, Sierra Leone, Tanzania, Uganda,
Zaire (one trial in each); China, Philippines and Kenya (one mul-
ticentre trial).
Population
Children were recruited from school populations in 20 trials, com-
munities in 16 trials, and in health facilities or by health workers
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in six trials. One of these recruited children on discharge from
hospital (Donnen 1998). Olds 1999 also included adolescents 17
to 19 years, but the participants were predominantly under 16
years old.
Thirty-five trials were based on mass targeted treatment of an un-
screened population. Fourteen trials were conducted in popula-
tions where worms were of high prevalence or intensity (com-
munity category 1), 10 in populations with moderate prevalence
and low intensity (category 2), and 11 in populations with low
prevalence and low intensity (category 3). Seven trials studied chil-
dren that were screened and selected on the basis of their having
high worm loads (Freij 1979a; Freij 1979a; Kvalsvig 1991a; Nokes
1992; Adams 1994; Simeon 1995; Sarkar 2002), and the purpose
of three of these trials was tomeasure cognitive outcomes (Kvalsvig
1991a; Nokes 1992; Simeon 1995). Stephenson 1993 also studied
an infected subgroup of the larger unscreened study population
for cognitive and haemoglobin outcomes.
Interventions
Albendazole studies
• Twenty-four trials had albendazole only in one treatment
arm (Adams 1994; Alderman 2006 (Cluster); Awasthi 2000;
Awasthi 2001 (Cluster); Awasthi 2008 (Cluster); DEVTA
(unpublished); Beach 1999; Dossa 2001; Fox 2005; Hadju
1997; Hall 2006 (Cluster); Kirwan 2010; Koroma 1996; Kruger
1996; Nga 2009; Nokes 1992; Olds 1999; Palupi 1997; Simeon
1995; Solon 2003; Stephenson 1989; Stephenson 1993; Sur
2005; Watkins 1996).
• In addition, some of these trials had arms with
combinations with albendazole (with praziquantel (Olds 1999);
ivermectin (Beach 1999)); but these interventions were also
included in the control arms.
• One trial included antigiardial treatment in both
intervention and control arms (Goto 2009).
• One trial was a deworming programme that included
deworming drugs for STHs, praziquantel to treat schistosomiasis
in schools with >30% prevalence, and health promotion
interventions (Miguel 2004 (Cluster).
Other anthelminths
• Mebendazole: eight trials (Donnen 1998; Garg 2002;
Kloetzel 1982; Kvalsvig 1991a; Le Huong 2007; Rousham 1994
(Cluster); Stoltzfus 1997 (Cluster); Stoltzfus 2001); and in
combination with pyrantel, two trials (Lai 1995; Rousham 1994
(Cluster)).
• Other deworming drugs used included pyrantel pamoate
(Hadju 1996; Hadju 1997; Sarkar 2002), piperazine (Freij
1979a; Freij 1979b), piperazine citrate (Greenberg 1981),
tetrachloroethylene (Michaelsen 1985), and levamisole (Willett
1979).
Control groups
Placebo or no treatment was used as a control in the majority
of studies (see Characteristics of included studies). Others used
vitamin A (Donnen 1998), vitamin C (Beach 1999; Fox 2005),
or calcium powder (Awasthi 2000).
There were 13 trials where both the treatment and control group
received nutritional supplementation: multi-nutrient (Kruger
1996, Nga 2009, Solon 2003); vitamin B (Sur 2005); iron
(Dossa 2001, Le Huong 2007, Palupi 1997, Stoltzfus 2001); vi-
tamin A (Awasthi 2001 (Cluster); Awasthi 2008 (Cluster); Hall
2006 (Cluster); DEVTA (unpublished)); or child health package
(Alderman 2006 (Cluster)).
Study design
Eight trials were cluster randomized (Alderman 2006 (Cluster);
Awasthi 2008 (Cluster); Awasthi 2001 (Cluster); DEVTA
(unpublished); Hall 2006 (Cluster); Rousham 1994 (Cluster);
Stoltzfus 1997 (Cluster)), one was a study with quasi-random al-
location of the 75 clusters (Miguel 2004 (Cluster)). The rest used
the individual as the unit of randomization.
Five out of the eight cluster-RCTs used an appropriate method to
take clustering into account. Awasthi 2001 (Cluster) and Awasthi
2008 (Cluster) used urban slums as the unit of randomization
(50 and 124 respectively), and DEVTA (unpublished) used 72
rural administrative blocks. These three trials were analysed at the
cluster level (mean of cluster mean values and associated standard
deviations). Stoltzfus 1997 (Cluster) randomized 12 schools and
adjusted for within-school correlations using generalized estimat-
ing equations. Miguel 2004 (Cluster) adjust for clustering in their
regression estimates, and present robust standard errors.
We encountered problems with the adjustment in the three re-
maining cluster-RCTs:
• Alderman 2006 (Cluster) had not adjusted the primary
outcome for clustering in this study of 48 parishes containing
27,955 children in total. The authors upon request sent us the
adjusted values which we have used in the analysis.
• Hall 2006 (Cluster) had 80 units of randomization
(schools) containing 2659 children in total, and had not adjusted
for clustering. We used the ICC calculated from the Alderman
data to adjust the primary weight outcome for inclusion in meta-
analysis. As the average cluster size for Hall 2006 (Cluster) (ie 33
children) differed somewhat from that of Alderman 2006
(Cluster) (ie 582 children), the true ICC for Hall 2006 (Cluster)
may be different to that of Alderman 2006 (Cluster), therefore
the adjusted result for weight is merely an approximation.
• Rousham 1994 (Cluster) had 13 units of randomization
(villages) containing 1476 children in total and had also not
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adjusted for clustering, but no outcomes from this study were
suitable for meta-analysis.
Four trials had a factorial design. DEVTA (unpublished) random-
ized clusters to usual care, six-monthly vitaminA, six-monthly 400
mgalbendazole, andboth vitaminA and albendazole. Kruger 1996
randomized individual participants to albendazole or placebo, and,
also, three of the five schools in the trial received soup fortifiedwith
vitamins and iron, and two received unfortified soup. Le Huong
2007 randomized individual participants to iron-fortified noodles
and mebendazole, noodles without iron fortification and meben-
dazole, iron-fortified noodles and placebo, noodles without iron
fortification and placebo, and iron supplementation and meben-
dazole. Stoltzfus 2001 randomized households to iron, with ran-
dom allocation of mebendazole by child, stratified by iron allo-
cation and age grouped households; disaggregated data for each
treatment allocation group was not provided for each outcome.
Follow-up periods for the trials that used a single dose ranged from
one to 11 months, while the follow-up periods for trials that used
multiple doses ranged from six months to 5 years.
Miguel 2004 (Cluster) included 75 schools with a total of 30,000
pupils enrolled. The intervention was a deworming package that
was phased over time. The package included public health lectures,
wall charts, teacher education, and health education in handwash-
ing. In addition, a number of schools in the study were also mass
treated for schistosomiasis. We previously excluded this study on
the basis of confoundingby schistosomiasis treatment.We received
clarification from the authors that allowed inclusion of the study
in this review update. The authors kindly provided data excluding
17 of the 75 schools that were mass treated for schistosomiasis.
Overall, this analysis showed very similar results so we have in-
cluded the data from the published paper.
InMiguel 2004 (Cluster), there were two potential quasi-random-
ized comparisons, one in 1998 and one in 1999. Included schools
were stratified by zone, their involvement with other NGO pro-
grammes, and then listed alphabetically and every third school
assigned to start the programme in 1998, to start it in 1999, or
to be a control. The schools were thus divided into three groups:
Group 1 schools were in the treatment group throughout; Group
2 schools were in the control group for the 1998 comparison, but
in the treatment group in the 1999 comparison; Group 3 schools
were in the control group throughout. Two comparisons were thus
identified: Group 1 schools versus Group 2 and 3 schools in 1998;
and Group 1 and 2 schools versus Group 3 schools in 1999.
The authors clarified that there were no health outcome data for
Group 3 schools for 1999. This left one quasi-randomized com-
parison with contemporary health information in both treatment
and control, which was 1998, Group 1 versus Group 2 and 3.
However, results for health outcomes were presented for the 1998
comparison of Group 1 (25 schools) versus Group 2 (25 schools).
Details of the outcomes we extracted and present are:
• Haemoglobin. This was measured in 4% of the randomized
population (778/20,000). It was unclear how the sample were
selected.
• Weight and height. This was measured in an unknown
sample of the 20,000 children. No sampling method was given.
• School attendance with up to a year follow-up was
calculated as the weighted average school participation rate
among all pupils enrolled, comparing Group 1 to Groups 2 and 3
(1998), and Group 2 versus Group 3 (1999), with approximately
20,000 children per group. Pupils present on the day of an
unannounced NGO visit were considered participants. Pupils
had 3.8 observations on average per year. School attendance with
follow up over one year was also reported in 1999, comparing
Group 1 and Group 3. However, the authors did not give any
baseline values for attendance, so it was not possible to know
whether differences detected are the results of the intervention or
random differences in average attendance between groups.
• Exam performance was measured, but the authors did not
provide the results by the quasi-randomized comparisons eligible
for this review, and it was unclear how many children
contributed to this outcome (1998 Group 1 versus Group 2 and
3; 1999 Group 1 and 2 versus Group 3).
Cognitive tests results were collected in 2000 for all three groups,
but the authors did not report these results.
Outcome measures
Nutritional outcomes
Nutritional indicators were measured in 42 trials. Some trials re-
ported absolute values, or changes in absolute values of weight and
height (or other anthropometric measures). Many trials presented
anthropometric data in terms of z-scores or percentiles of weight-
for-age, weight-for-height, and height-for-age, and compared the
trial results to an external reference. Sometimes these values were
dichotomised and presented as the prevalence of underweight,
stunting or wasting (defined as -2SD z-scores). The external stan-
dard was usually quoted as the National Centre for Health Statis-
tics (NCHS) standard, but a variety of references was quoted (eg
anthropometric computer packages or country standards). These
data have not been used in the meta-analyses as the results were
already incorporated in the values for weight and height. Further-
more, in some trials, outcome data were not reported or were in-
complete and could not be used in meta-analysis. A number did
not report summary outcome data for each trial arm, and the re-
sults were reported in terms of regression modelling outcomes or
subgroup analyses. The results of these trials are described in Table
4.
Haemoglobin
Seventeen trials measured haemoglobin. Of these, two trials did
not report the measured haemoglobin results (Olds 1999; Solon
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2003), two trials only measured this outcome in a subset of
the participants (DEVTA (unpublished), Miguel 2004 (Cluster))
and one trial did not report results by randomized comparisons
(Stephenson 1993).
Psychometric tests of cognition
Ten trials measured intellectual development using formal tests
(Table 5).
Measures of physical well being
Two studies (Stephenson 1989; Stephenson 1993)measured phys-
ical well being using the Harvard Step Test.
School attendance
Three trials measured school attendance (Table 6).
School performance
Exam performance was measured by Miguel 2004 (Cluster).
Death
DEVTA (unpublished) provided data on mortality although these
data are not yet in the public domain so we are unable to report
them.
Adverse events
Two trials provided information on adverse events (Michaelsen
1985; Fox 2005).
Risk of bias in included studies
See Figure 2 and Figure 3 for Summaries of the risk of bias and
‘Characteristics of included studies’ for details of the risk of bias
and methods used in each trial.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Generation of sequence
In the 35 individually randomized trials, the risk of bias was low
in 10 trials (see Figure 2 and Figure 3), high in five, and unclear in
the other trials. For the eight cluster-RCTs, the risk of bias was low
in one trial (Alderman 2006 (Cluster)), high in two trials (Awasthi
2008 (Cluster); Miguel 2004 (Cluster) ) and unclear in five trials.
Allocation concealment
For the 35 individually randomized trials, the risk of bias was low
in seven trials (Fox 2005; Garg 2002; Le Huong 2007; Nga 2009;
Olds 1999; Stoltzfus 2001; Sur 2005), high in two trials (Awasthi
2000; Kirwan 2010), and unclear in the other trials.
The risk of bias was low in one of the eight cluster-RCTs (Hall
2006 (Cluster)), high in two trials (Awasthi 2008 (Cluster);Miguel
2004 (Cluster)), and unclear in the remaining five trials.
Blinding
Fifteen trials were double blinded (Beach 1999; Fox 2005; Goto
2009; Kirwan 2010; Le Huong 2007; Nga 2009; Olds 1999;
Rousham 1994 (Cluster); Sarkar 2002; Solon 2003; Stephenson
1989; Stephenson 1993; Sur 2005; Watkins 1996; Willett 1979)
and judged to be at a low risk of bias. Five trials were at high risk
of bias as they did not use blinding (Alderman 2006 (Cluster);
Awasthi 2008 (Cluster); Garg 2002; Lai 1995; Miguel 2004
(Cluster)). Details of blinding were unclear in the remaining 22
trials.
Incomplete outcome data
Twenty-four trials had a low risk of bias for incomplete out-
come data (Adams 1994; Awasthi 2000; Awasthi 2001 (Cluster);
Awasthi 2008 (Cluster); Beach 1999; Donnen 1998; Fox 2005;
Freij 1979b; Garg 2002; Goto 2009; Greenberg 1981; Hadju
1996; Le Huong 2007; Lai 1995; Nga 2009; Palupi 1997; ;
Rousham 1994 (Cluster); Sarkar 2002; Simeon 1995; Stephenson
1989; Stephenson 1993; Stoltzfus 1997 (Cluster); Sur 2005;
Watkins 1996), in seven trials the risk of bias was unclear (DEVTA
(unpublished); Freij 1979a; Hall 2006 (Cluster); Kloetzel 1982;
Kvalsvig 1991a; Olds 1999; Solon 2003), and in the remaining
trials there was a high risk of bias.
Overall, the percentage of randomized participants that were
evaluable ranged from 4% to 100%, with 18 trials including 90%
ormore of the randomized participants (low risk cut-off ). The per-
centage was particularly low in two of the trials measuring school
performance and cognitive outcomes: 73% in Nokes 1992; and
52% in Stoltzfus 2001, and in one trial measuring haemoglobin:
26% in Kirwan 2010. In Miguel 2004 (Cluster), for haemoglobin
approximately 4% (778/20,000) of eligible participants were as-
sessed, but it is unclear how these were selected, and for nutritional
outcomes the number assessed was unclear.
Selective outcome reporting
Thirteen trials had evidence of selective reporting and were judged
to be at high risk of bias (Goto 2009; Greenberg 1981; Kirwan
2010; Koroma 1996; Nga 2009; Nokes 1992; Olds 1999; Simeon
1995; Solon 2003; Stoltzfus 1997 (Cluster); Stoltzfus 2001; Sur
2005; Willett 1979). The remaining trials did not show evidence
of selective reporting.
Other biases
Quality of the design of the eight cluster-RCTs was judged as
low risk for recruitment bias (five trials), baseline imbalance (eight
trials), loss of clusters (eight trials), compatibility with RCTs that
randomized individuals (one trial) and incorrect analysis (seven
trials). Alderman 2006 (Cluster) did not adjust for clustering in
the published trial, but gave us the adjusted data (see study design
above), and we used this to adjust the analysis in Hall 2006
(Cluster).
Effects of interventions
See: Summary of findings for the main comparison Multiple
dose deworming drugs for treating soil-transmitted intestinal
worms in children: effects on nutrition and school performance
(outcomes measured at more than 1 year)
The effects were grouped into:
• trials where children were screened for infection
(comparisons 1 and 2);
• trials treating whole populations (comparisons 3 to 5).
Comparison 3 is after a single dose of deworming drug,
comparison 4 after multiple doses with follow up for up to a
year, and comparison 5 after multiple doses with follow up of
one year or more.
In the trials treating whole populations, we stratified the results
by community worm prevalence. Prevalence strata are detailed in
Table 3 (high prevalence or high intensity areas (referred to as ’high
prevalence’); moderate prevalence and low intensity referred to
as (’moderate prevalence’); and low prevalence with low intensity
referred to as ’low prevalence’). Within each section, we present
the results of the meta-analysis, and then report any other data
from trials that we could not include in the meta-analysis.
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Only infected children included
These trials screened for infection, and thenonly included children
with proven infection. None of these trials provided data for the
outcomes school attendance (number of children dropping out),
school performance, mortality or adverse events.
Single dose (comparison 1)
For nutritional measures, trials measured weight (n = 3), height
(n = 2),MUAC (n = 3), triceps (n = 2), subscapular (n = 1) skinfold
and BMI (n = 1). The trials demonstrated weight gain (0.58 kg,
95% CI 0.40 to 0.76; 149 participants, three trials; Analysis 1.1);
and gains in MUAC, triceps and subscapular skinfold values (
Analysis 1.3; Analysis 1.4; Analysis 1.5). No difference in height
or body mass index was detected after a single dose (Analysis 1.2;
Analysis 1.6). Nokes 1992 did not provide data for nutritional
outcomes as nine weeks was cited as too short a follow-up period
to demonstrate a change (Table 4).
For haemoglobin, the mean value was slightly higher at the end
of the study with deworming (mean difference 0.37 g/dL, 95%
CI 0.10 to 0.64; 108 participants, two trials; Analysis 1.7).
For psychometric tests of cognition, two trials reported on for-
mal tests (Table 5). Kvalsvig 1991a did not clearly report change in
cognitive scores; Nokes 1992 did not report unadjusted data, but
results of multiple regression suggest an improvement in treated
children in three of the 10 tests carried out (fluency, digit span
forwards, digit span backwards).
Multiple doses (comparison 2)
Simeon 1995 gave screened children albendazole at 0, 3 and 6
months and then carried out measurements two weeks after the
last dose.
For nutritional measures, the authors reported end values of
body mass index, and did not demonstrate a difference (mean
difference -0.20 cm, 95% CI -0.46 to 0.06; 407 participants, one
trial, Analysis 2.1). They also reported height for age z-score and
did not detect a difference.
For psychometric tests of cognition, the authors measured in-
tellectual development using a wide range achievement test in the
main study, and digit spans and verbal fluency tests in subgroups.
The authors reported that deworming had no effect on intellectual
development scores, but did not report the data (Table 5).
For school attendance (days present at school), deworming had
no demonstrable effect on school attendance rates of children ac-
tively attending school (mean difference -2.00, 95% CI -5.49 to
1.49; 407 participants, one trial; Analysis 2.2).
Whole population treated
Single dose (comparison 3)
No trials provided data for the outcomes school attendance, ad-
verse events and mortality.
For nutritional measures, trials were in high (n = 4), moderate (n
= 2) and low (n = 3) prevalence areas. Across prevalence categories
for weight, height, MUAC, and skinfold (triceps and subscapular)
no effect was evident in seven trials; but a substantive effect was
seen in two trials (Stephenson 1989 and 1993) for weight,MUAC,
and skinfold (both triceps and subscapular) (Analysis 3.1; Analysis
3.3; Analysis 3.4; Analysis 3.5), with an average weight gain of over
one kilogram in both studies. These trials were in a high prevalence
area of Kenya. Stephenson 1989 also showed the gain in height
was higher in the albendazole group by 6 mm over six months,
but Stephenson 1993 did not detect a difference (Analysis 3.2).
The high level of heterogeneity precludesmeta-analysis in the high
prevalence groups, but in moderate and low prevalence areas the
meta-analysis suggests no marked effect, although the CIs do not
exclude a clinically important effect (3058 participants, nine trials;
Analysis 3.1).
For haemoglobin, two studies were in moderate prevalence areas,
and one in low prevalence areas. No effect was demonstrable in
individual studies or on meta analysis (mean difference 0.06 g/
dL, 95% CI -0.05 to 0.17; 1005 participants, three trials; Analysis
3.6).
For psychometric tests of cognition, Solon 2003 measured cog-
nitive ability using a standardized writtenmental-abilities test, and
reported that deworming had either no effect or a negative effect
on mental ability scores, but did not report the data. Nga 2009
reported no effects on any cognitive tests measured (Table 5).
For measures of physical well being, two trials in the same high
prevalence area of Kenya measured performance on the Harvard
Step Test (Stephenson 1989; Stephenson 1993). This indicated
benefit (Analysis 3.7; mean difference 6.00, 95% CI 4.31 to 7.69;
86 participants, two trials).
For adverse events, Fox 2005 reported none in 46 patients given
albendazole.Michaelsen 1985 reported a number of adverse events
with tetra-chloroethylene, a drug no longer used (Table 4).
Other data
Six trials did not provide data in a form that we could use in
meta-analysis. We have collated these data in Table 4, and this
information is summarized below:
• Beach 1999 did not detect a nutritional benefit of
treatment after four months for the entire study population (no
figures provided).
• Fox 2005 only reported on subgroups infected with worms.
• Greenberg 1981 stated there was no significant difference
for all measured anthropometric variables for the total group and
for subgroups defined by severity of infection (no figures
provided).
• Kloetzel 1982 reported the proportion of treatment or
control group that improved, deteriorated, or experienced no
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change, but it is not known what anthropological measures were
used.
• Koroma 1996 found significant increases in weight-for-
height, weight-for-age, and height-for-age z-scores recorded in
rural and urban treatment groups at six months.
• Michaelsen 1985 found no significant difference in change
in mean for haemoglobin or weight for height at five months.
Sensitivity analysis
In the sensitivity analysis including only trials where the risk of
bias for allocation concealment was low, no significant difference
between treatment and control groups in weight, height, mid-
upper arm circumference, or haemoglobin was evident (Analysis
6.1; Analysis 6.2; Analysis 6.3; Analysis 6.4).
Multiple doses, less than a year of follow up (comparison 4).
No trials provided data for the outcomes adverse events, school
attendance (number of children dropping out) and mortality.
For nutritional outcomes, studies were carried out in high (n =
2), moderate (n = 2) and low (n = 3) prevalence areas. For weight,
overall there was no evidence of an effect (Analysis 4.1), although
one trial (Stephenson 1993) showed a large weight gain in the
treatment group (900 g); notably this effect had been detected after
a single dose (see ’single dose’ section above). Overall, the meta-
analysis did not demonstrate a difference in weight gain between
intervention and control (mean difference 0.06 kg, 95% CI -0.17
to 0.30; 2460 participants, seven trials), but the heterogeneity was
high (I2 = 80%). When the trials were stratified by community
category, heterogeneity was not explained. On the other hand, no
significant effect was apparent in any subgroup. For MUAC, and
triceps skinfold, no effects were evident in the studies measuring
this (Dossa 2001, Watkins 1996, Donnen 1998), apart from
Stephenson 1993, who reported large effects for MUAC, triceps
and subscapular skinfold thickness (Analysis 4.3; Analysis 4.4;
Analysis 4.5). No effect in height was demonstrated in any of the
six trials measuring this (Analysis 4.2).
For haemoglobin, four trials reported this, with no difference
between intervention and control apparent (Analysis 4.6).
For psychometric tests of cognition, three trials measured this
(Table 5). Watkins 1996 measured reading and vocabulary, and
Stoltzfus 2001 measured motor and language development, and
reported that no effect was demonstrated. Miguel 2004 (Cluster)
measured a range of cognitive tests. The results were not reported,
but the authors state that no deworming effect was demonstrated.
For school attendance (days present at school), two trials report
this (Watkins 1996; Miguel 2004 (Cluster); Table 6 Analysis 4.7).
Watkins reports attendance rates of children actively attending
school, at baseline and after treatment, and no effect was demon-
strated. Miguel 2004 (Cluster) reports on end value differences in
attendance for girls under 13 and all boys. In 1998, betweenGroup
1 versus Group 2 and 3: there was a difference of 9.3% in school-
ing attendance detected, and in 1999, Group 2 versus Group 3,
a difference of 5.5% was detected. No comparable baseline values
of attendance were given so it was unclear whether these reflect
differences in baseline or true effects. As the two comparisons in
the Miguel 2004 (Cluster) trial were not independent (the con-
trol children in 1998 become the intervention children in 1999),
they could not be meta-analysed together, so we carried out two
separate meta-analyses (Analysis 4.7), the first with Miguel (1998
comparison) + Watkins; and the second with Miguel (1999 com-
parison) + Watkins. Neither meta-analysis demonstrated a signif-
icant effect on school attendance (using 1998 data: mean differ-
ence 4%, 95% CI -6 to 14; using 1999 data, mean difference 2%,
95% CI -4 to 8%).
For school performance,Miguel 2004 (Cluster) measured exam
score performance (English,Mathematics and Science-Agriculture
exams in pupils in grades 3 to 8), but did not report results by the
quasi-randomized comparisons.
Other data
Six trials did not provide data in a form that we could use in
meta-analysis. We have collated these data in Table 4, and this
information is summarized below:
• Goto 2009 reported no significant differences in mean z-
scores or prevalence of stunting, underweight or wasting between
the intervention groups, and the changes between intervals (eg
between weeks 0 to 12, 0 to 24, 0 to 36, 12 to 24, etc) did not
differ significantly between groups.
• Hadju 1997 reported no significant differences detected
between treatment groups on basis of multivariate analyses.
• Le Huong 2007 reported no obvious trend in nutritional
variable.
• Miguel 2004 (Cluster) demonstrated no significant effect
on weight-for-age z score, height-for-age z score, and
haemoglobin (only 4% of quasi-randomized participants
followed up for haemoglobin outcome; the proportion followed
up for nutritional outcomes is unclear).
• Stoltzfus 2001 reported that mebendazole significantly
reduced the prevalence of mild wasting malnutrition in a
subgroup of children aged < 30 months.
• Stoltzfus 1997 (Cluster) reported that in a subgroup of
under 10 year olds, the twice-yearly treated group experienced
significantly greater weight gain (kg) compared to control (2.38
(SE 0.08) versus 2.11 (SE 0.08), P < 0.05).
• Willett 1979 reported no statistical difference in growth
rates in terms of height and weight between the two groups.
Sensitivity analysis
Including only trials with low risk of bias for allocation of con-
cealment: no significant difference between treatment and con-
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trol groups was detected in weight or haemoglobin (Analysis 7.1;
Analysis 7.2).
Multiple doses, follow up of one year or more (comparison
5).
No trials provided data for adverse events and school attendance
(number of children dropping out).
For nutritional indicators, one study (Awasthi 2008 (Cluster))
showed a very large effect of 0.98 kg average difference in weight
gain - with all the others showing small average non-significant
differences of less than 0.2 kg (Analysis 5.1; 37,306 participants:
302 clusters and 1045 individually randomized participants, five
trials). The high level of heterogeneity in the low prevalence group
precludes meta-analysis. Of the five trials, all but one reported
change in weight, and one reported end values only. For height,
gain was similar in the deworming and control groups (mean dif-
ference -0.26 cm, 95% CI -0.84 to 0.31; 6652 participants: 174
clusters and 1045 individually randomized participants, three tri-
als; Analysis 5.2).
For haemoglobin, deworming drugs did not increase haemoglo-
bin compared with control (mean difference 0.00 g/dL, 95% CI
-0.08 to 0.08; 1365 participants, two trials; Analysis 5.3).
For psychometric tests of cognition, Awasthi 2000 measured
developmental status using the Denver Questionnaire, and Hall
2006 (Cluster) measured mathematics and Vietnamese test scores
(Table 5). Both trials reported that they did not demonstrate an
effect of deworming (3720 participants: 80 clusters and 1061 in-
dividually randomised participants).
For school attendance (days present at school), (Miguel 2004
(Cluster) Table 6; Analysis 5.4) reported on end values for at-
tendance rates of children (1999, Group 1 versus Group 3), and
found no significant effect (mean difference 5%, 95% CI -0.5
to 10.5; around 20,000 participants in 50 clusters). No baseline
values were given so there is potential for any random differences
between the groups to confound the end values.
For death, data from the DEVTA trial are awaited (DEVTA
(unpublished)).
Other data
Four trials reported narratively on results, collated in Table 4. In
summary:
• Awasthi 2008 (Cluster) reported 23 deaths during the
study, 13 of which were in the usual care arm, and 10 were in the
treatment arm.
• Lai 1995 found no difference in height or weight between
treatment and control group at the end of two-year follow up.
• Hall 2006 (Cluster) reported no difference in final and
change in height.
• Rousham 1994 (Cluster) ANOVAS of the change in z-
scores revealed no significant improvement with treatment.
Sensitivity analysis
Only one study had low risk of bias for allocation of conceal-
ment. In Hall 2006 (Cluster), no significant difference between
treatment and control groups was detected in weight or height
(Analysis 8.1; Analysis 8.2)
D I S C U S S I O N
Summary of main results
1. Selective deworming
What is the effect of a dose of deworming drug given to
children infected with worms in populations screened for
intestinal helminths?
It may increase weight gain
In three trials, the meta-analysis shows a mean difference of 0.58
kg, 95% CI 0.40 to 0.76; 149 participants; low quality evidence;
Analysis 1.1 .
It may increase haemoglobin levels
In two trials, the meta-analysis shows a mean difference of 0.37 g/
dL, 95% CI 0.10 to 0.64; 108 participants, low quality evidence;
Analysis 1.7.
We do not know whether there is an effect on cognition
Two trials reported on formal tests of intellectual development,
using different outcomes. One trial did not report the outcome,
and one trial reported and improvement in 3/10 tests of cognitive
function in treated children: very low quality evidence; Table 5 .
See Summary of findings (A), Table 7.
2. Targeted deworming (one dose)
What is the effect of one dose of deworming drug given to
all children living in an endemic area?
We do not know the effect on weight gain
Deworming increased weight gain in two early trials, both car-
ried out in the same location, but had no effect in seven trials
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conducted subsequently (3058 participants, nine trials; very low
quality evidence; Analysis 3.1).
It probably has no effect on haemoglobin levels
In three trials, meta-analysis of haemoglobin difference was not
significant (mean difference 0.06 g/dL, 95% CI -0.05 to 0.17;
1005 participants, three trials moderate quality evidence; Analysis
3.6).
It may have no effect on cognition
One trial reported that deworming had either no effect or a neg-
ative effect on mental ability scores, but did not report the data,
and one trial reported no effect (1361 participants, two trials, low
quality evidence;Table 5 .
It may have an effect on physical well being
Two trials in the same high prevalence area of Kenya indicated
benefit (Harvard Step Test mean difference 6.00, 95% CI 4.31
to 7.69; 86 participants, two trials, low quality evidence; Analysis
3.7)
See Summary of findings (B), Table 8.
3. Targeted deworming (multiple doses)
Eight of the 42 trials in this systematic review were cluster-RCTs
and assessed multiple doses of deworming, and thus will poten-
tially capture any population effects as a result of interrupting
transmission.
What is the effect of multiple doses of deworming drugs to
all children (follow up for up to a year)?
It may have little or no effect on weight gain
Deworming increased weight gain in one trial in a high prevalence
location, decreased weight in one trial in a low prevalence area,
but had no effect elsewhere (mean difference 0.06 kg, 95% CI -
0.17 to 0.30; 2460 participants, seven trials, low quality evidence;
Analysis 4.1 )
It may have little or no effect on haemoglobin levels.
In four trials, the the meta-analysis shows a mean difference of -
0.01 g/dL, 95% CI -0.14 to 0.13; 807 participants, low quality
evidence; Analysis 4.6.
It may have no effect on cognition
Three trials measured formal tests of intellectual development us-
ing different outcomes. All three trials reported no effect of de-
worming (30,571 participants; 75 clusters and 571 individually
randomized participants low quality evidence: Table 5 .)
It may have no effect on school attendance
In two trials (30,243 participants, 75 clusters and 243 individu-
ally randomized participants), the mean difference was 4% higher
attendance; 95% CI -6 to 14, low quality evidence;Table 6 .
See Summary of findings (C), Table 9.
What is the effect of multiple doses of deworming drugs to
all children (follow up for over a year)?
This outcome will capture both deworming effects and any effects
as a result of a potential reduction in transmission.
It may have no effect on weight gain
Deworming increased weight gain in one early trial in a low preva-
lence location, but had no effect in two subsequent trials in the
same location, or in higher prevalence locations. Four out of five
trials in this analysis were cluster-RCTs so capturing both the indi-
vidual effect and any additional population level effect as a result of
interrupting transmission (37,306 participants; 302 clusters and
1045 individually randomized participants, five trials, low quality
evidence; Analysis 5.1)
We do not know the effect on height gain
In three trials, 6652 participants (174 clusters and 1045 individ-
ually randomized participants), the meta-analysis shows a mean
difference of -0.26 cm, 95% CI -0.84 to 0.31, very low quality
evidence; Analysis 5.2 .
It may have no effect on haemoglobin levels
In two trials, no difference was detected (mean 0.00 g/dL, 95%CI
-0.08 to 0.08; 1365 participants, two trials; low quality evidence;
Analysis 5.3).
It may have no effect on cognition
Two trials reported on formal tests of intellectual development us-
ing different outcomes. Both trials reported no effect of deworm-
ing (3720 participants; 80 clusters and 1061 individually random-
ized participants; low quality evidence; Table 5 .
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We do not know the effect on school attendance
In one trial themean difference in school attendance was 5%, 95%
CI -0.5 to 10.5 (approximately 20,000 participants in 50 clusters,
very low quality evidence; Table 6.)
For mortality
A large trial of around onemillion children carried out in Lucknow
was completed in 2005, but the results have not been published
(DEVTA (unpublished).
See Summary of findings for the main comparison.
Secondary outcomes
For anthropometry, results were broadly consistent with the pri-
mary outcomes.
Key messages
Selective deworming may increase weight and haemoglobin in
children confirmed to have worms on the basis of screening.
Targeted deworming:
• has sometimes demonstrated a substantive early impact on
weight gain (three trials), but in the majority of studies no effect
has been shown on nutritional indicators;
• does not appear to have an effect on haemoglobin;
• may have an effect on physical well being;
• may have little or no effect on cognition;
• has not been shown to have a convincing effect on school
attendance.
Mortality has been evaluated in a large trial completed in 2005
but this has not been published.
Overall completeness and applicability of
evidence
Review question:The review indicates that screening and treating
children infected with worms is promising, but the evidence base
is small. However, when the intervention is used in the way the
WHO currently recommends - targeted treatment to high risk
populations - the effect is not so clear. An effect on weight was only
seen in the two Stephenson trials assessing single-dose deworming
in the same high prevalence school (Stephenson 1989; Stephenson
1993), where more than 90% of the children were infected with
both hookworm and Trichuris, with heavy worm loads; and a
cluster-RCT assessing long-term multiple dosing in a low-burden
community undertaken in 1995 in India (Awasthi 2008 (Cluster)).
What is also interesting in the two Stephenson studies in Kenya is
that effects were seen after a single dose only, and the effects in the
results of ’multiple-doses, outcomes less than one year of follow-
up’ can be mainly attributed to the effect seen after one dose of the
deworming drug. Trials conducted subsequently, some of them
large cluster-RCTs, have not demonstrated significant effects.
Ten trials measured intellectual development using formal tests.
Only one of these trials demonstrated an effect on cognitive out-
comes in 3/10 of the outcomes measured (Nokes 1992, Table 5,
Table 6). The trials used a range of cognitive tests, which seems
to reflect the difficulty inherent in choosing appropriate cognitive
performance tests since there is no accepted test battery that can be
applied across cultures and settings, and, as Miguel 2004 (Cluster)
points out, the mechanisms for any putative effects are unknown.
For school attendance, one quasi-randomized trial (Miguel 2004
(Cluster) reported an effect, which was apparent in only one of
the two comparisons in up to a year of follow up, and not appar-
ent in the one comparison after one year. Miguel 2004 (Cluster)
measured attendance outcomes directly, unlike the other two trials
(Simeon 1995; Watkins 1996) which measured attendance using
school registers, which may be inaccurate in some settings. How-
ever, in Miguel 2004 (Cluster) , the values for school attendance
were end values and not corrected for baseline. Thus random dif-
ferences in baseline attendance between the two groups could have
confounded any result.
Completeness of the analysis: Critics of a previous version of
this review (Dickson 2000a) stated that the impact must be con-
sidered stratified by the intensity of the infection (Cooper 2000;
Savioli 2000). We have done this comprehensively in this edition
and no clear pattern of effect has emerged. Other criticisms were
that studies of short-term treatment cannot assess the long-term
benefits of regular treatment (Bundy 2000). However, this analysis
clearly examines long-term outcomes from trials conducted over
the last 10 years.
Extrapolating evidence on selective deworming to targeted de-
worming: It could be argued that evidence of benefit seen in selec-
tive deworming provides an evidential base for targeted deworm-
ing, because the latter reduces costs due to diagnostic screening.
However, the data on targeted deworming is limited (three small
trials, n = 149); the quality of the evidence is ’low’ for weight and
haemoglobin; and the intervention itself is different. For example,
having been screened, and then told they have worms, children are
more likely to comply with treatment, and alter their behaviour.
Choking: TheWHO has raised concerns about the prevalence of
choking in young children (aged between 1 to 3 years), with sev-
eral pages of recommendations about how to administer albenda-
zole in tablet formwithout children choking (http://www.who.int/
wormcontrol/newsletter/PPC8˙eng.pdf ) WHO 2007. Although
common sense might suggest this is a rare occurrence, neverthe-
less some might argue there is a lack of evidence on the safety of
administering deworming drugs to young children in tablet form
in a community setting.
Polyparasitism: Individuals and communities are often infected
with more than one helminth infection (Molyneux 2005) and the
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WHO is currently promoting the large-scale use of ’preventive
chemotherapy’. This involves use of multiple anthelminthic drugs
to treat a range of diseases, including STHs, schistosomiasis, and
filariasis. Engels 2009 comment on the need for a comprehensive
assessment of the impact of deworming. In the absence of such evi-
dence, there is a need to demonstrate that a drug is effective against
a particular parasite and to quantify its effects on humans before
combining all the drugs into a basket treatment for all helminth
infections, and assuming that all components are effective.
Secular trends in worm burden: Evidence of benefit of deworm-
ing on nutrition appear to depend on three studies, all conducted
more than 15 years ago, with two from the same area of Kenya
where nearly all children were infected with worms and worm
burdens were high. Later and much larger studies have failed to
demonstrate the same effects. It may be that over time the inten-
sity of infection has declined, and that the results from these few
trials are simply not applicable to contemporary populations with
lighter worm burdens.
Quality of the evidence
Conducting field trials to test this intervention is complex and
challenging, and researchers have worked hard to generate this
body of research evidence. There is now a reasonable amount of
evidence from studies in a range of settings, including high, mod-
erate, and low burden areas. There have also been five studies
(Analysis 5.1) that have assessed the long-term effects of multiple
doses of deworming, four of which were cluster-RCTs. These are
particularly important, because they can detect the ’real life’ com-
munity level effects of treatment that include possible effects from
a reduction in worm transmission (Bundy 2009).
We formally assessed the quality of the evidence using the stan-
dard GRADE methods.The quality of evidence was downgraded
due to ’risk of bias’, ’consistency’ and ’indirectness’. For ’Risk of
bias’ the study designs were often wanting: only one trial out of
42 provided complete information to assure good methodologi-
cal quality (Fox 2005). Allocation concealment was adequate in
only eight trials (20%), and 18 trials (42%) included 90% of the
randomized participants in the analysis. ’Consistency’ relates to
variation (unexplained heterogeneity) between the studies, which
leads to uncertainty about the pooled estimates. There was marked
heterogeneity (above 80%) in the analyses of weight gain in un-
screened populations, which was not explained by stratification of
the results by worm prevalence. We had concerns about ’indirect-
ness’ in the context of the two Stephenson studies, which were car-
ried out in the same school (Stephenson 1989; Stephenson 1993).
Evidence from this very high worm burden population may not
be applicable to other populations.
Potential biases in the review process
Publication bias:We are uncertain about the number of unpub-
lished trials in this area. We know of two unpublished trials.
1. Hall 2006 (Cluster) is a large trial from Vietnam, with two
years follow-up and did not demonstrate a significant difference in
weight gain. Clustering was not taken into account in the analysis,
which artificially narrows the CIs. In this update we included the
results of this trial in meta-analysis by imputing an intra-cluster
correlation coefficient, calculated from the adjusted data from
Alderman 2006 (Cluster).
2. (DEVTA (unpublished); the world’s largest ever RCT, which in-
cludes over a million children randomized in a cluster design with
mortality as the primary outcome, remains unpublished six years
after completion. We have corresponded with the senior author
on several occasions. We also wrote a letter to the Lancet in June
2011, asking for publication of this important study. When this
letter was accepted, the authors submitted the manuscript to the
Lancet within a week, and we withdrew our letter.However, at the
time of writing (October 2012) the paper remains unpublished.
Statistical errors in analysis:Of the eight cluster-RCTs, three did
not take adequate account of cluster randomization (Alderman
2006 (Cluster), Hall 2006 (Cluster), Rousham 1994 (Cluster).
This has a substantive impact on the interpretation of the tri-
als. For example, the significant difference between intervention
and control quoted on the cover of the BMJ for Alderman 2006
(Cluster), assumed 27,995 children had been individually ran-
domized. When we clarified this with the authors, they provided
the BMJ with a correction, which showed that no significant dif-
ference was detected in weight gain between intervention and con-
trol groups; this corrected result has been used in themeta-analysis
in this study.
Nutritional outcomes: The included trials reported a range of
nutritional status outcomes. For meta-analysis, we did not use
nutritional data expressed as z-scores or percentile scores calculated
on the basis of reference standards, or dichotomised z- or percentile
scores (eg proportion stunted with height-for-age z-score <-2). As
these data were derived from the absolute values, we used these
values for evidence of benefit.We knew the nutritional data would
be captured in the absolute values and wanted to reduce selective
reporting through collection of multiple variables frompapers that
are all derived from the same basic outcomes measured in the
trial. We noted that in some trials there was a discrepancy between
what was measured and what was reported; for example, Nokes
1992 recorded but did not report anthropometric data. This is a
concern as it may indicate selective reporting. However, we have
systematically reported all relevant outcomes not included inmeta-
analysis in Table 4.
Subgroup analyses: Some trials presented data from subgroups,
selected on the basis of factors such as infection status (Beach
1999, Fox 2005, Greenberg 1981), location (Koroma 1996), age (
Stoltzfus 2001), frequency of treatment (Stoltzfus 1997 (Cluster)),
and sex (Lai 1995). These comparisons were not randomized and
have not been included in meta-analysis. Two trials, one of which
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onewas a cluster-RCT, demonstrated improvements in nutritional
outcomes in subgroup analyses (Stoltzfus 1997 (Cluster); Stoltzfus
2001). These data are reported in Table 4.
Agreements and disagreements with other
studies or reviews
A review and meta-analysis by Hall et al (Hall 2008), funded
by the World Bank, presents evidence in favour of an effect of
deworming on weight gain (mean difference 0.21 kg 95% CI
0.17 to 0.26, 11 studies). This analysis differs from our analyses of
weight gain in a number of respects: it was not a protocol driven
systematic review; the review excluded studies in lower prevalence
areas (< 50%); pooled results were presented without exploration
of significant heterogeneity; it combined trials that included both
screened and unscreened children; it included trials excluded from
our study on the basis of methodological quality; it included data
from subgroup analyses; and included data unadjusted for cluster
randomization.
The narrative review (Albonico 2008) explored the evidence for
the impact of deworming on pre-school age children, and con-
cluded that deworming has been shown to improve growth. Their
analysis differed from our analyses in a number of ways: a different
population was considered, although our review considers data
from this subgroup; it was not a protocol driven systematic review;
it included trials excluded from our review; it was a narrative sum-
mary rather than meta-analysis of data; it reported results from
subgroup analyses; it reported point estimates without taking into
account statistical significance; and it included data unadjusted
for cluster randomization. The authors state: “A few studies have
failed to show any impact of deworming on growth”. This is at
odds with our interpretation of the reliable randomized compar-
isons of nutritional outcomes in this review, which suggests that
the majority of studies have failed to show an effect on nutrition.
Gulani and colleagues undertook a systematic review of the effects
of deworming on haemoglobin, and reported a marginal increase
in mean values that could translate into small reduction (5% to
10%) in anaemia in a population with a high prevalence of intesti-
nal helminths (Gulani 2007). This systematic review differs from
our analysis of haemoglobin in a number of respects: it included
studies in adults and pregnant women; included studies excluded
from our study on the basis of methodological quality.
Other advocates of deworming, such as Bundy 2009, have ar-
gued that many of the underlying trials of deworming suffer from
three critical methodological problems: treatment externalities in
dynamic infection systems, inadequate measurement of cognitive
outcomes and school attendance, and sample attrition. We agree
with these points. However, externalities will be detected by large
cluster-RCTs with a year or more follow up, and there are now
five trials such as this included in this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In examining the logic model in relation to targeted treatment
(Figure 1), the evidence for the main effects is weak.
An effect on nutrition has only been demonstrated in the studies
mentioned above; haemoglobin does not seem to improve; and
cognition may not improve. Evidence for the mediating pathways
is more sparse: there are no data on intellect, the data on physical
well being are encouragingbut from same studies showing substan-
tive weight gain after a single dose of deworming drug (Stephenson
1989; Stephenson 1993); and the data on school attendance are
insufficient to demonstrate an effect. Evidence of impact, in terms
of school performance, is unknown; it was measured in one study
but not reported by the comparison, and in terms of mortality,
the data have been collected in one study, but not yet published.
In conclusion:
• Selective deworming - screening school children for
intestinal helminths, and then treating those infected - may have
some value in relation to weight and haemoglobin but the
evidence base is small. The frequency of the screening and the
effectiveness of subsequent doses is not known.
• There is insufficient evidence to recommend deworming
drugs in targeted community programmes. The research has not
shown an effect in most studies, although clearly there was an
impact on weight gain reported in some older studies. Exactly
what makes the intervention effective in these and not more
recent studies is not clear. There is no direct evidence from trials
to show that this depends on background helminth prevalence or
intensity.
• It is probably misleading to justify deworming on the basis
of effects on school performance or attendance. There is simply
insufficient reliable information to know whether this is so.
• The evidence of deworming externalities - in terms of
impacts on nutrition, haemoglobin and cognitive function in
groups of people treated over a longer period of time - has not
been clearly demonstrated in the studies included, although one
study in India did show a large effect on weight.
• The WHO should review its guidelines and policies in this
area, using currently recommended methods for guideline
development, drawing on summaries such as this review and
GRADE assessment in transparent decision making processes.
• Guideline developers and policy makers at global, national,
and local levels should be allowed to consider the evidence
carefully before committing to investing existing resources in
delivering these programmes. Governments funding deworming
programmes should consider current evidence before
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committing public funds to programmes where the evidence
base from RCTs is so limited.
Implications for research
• Our view is that the tools exist to answer the research
questions investigated in this review, particularly through cluster-
RCTs. Further research will be needed, however, if policymakers
want to predict when it is worthwhile to implement deworming
in a community, and to determine if and when treating all
schoolchildren is effective.
• Further research is required before policymakers can be
clear whether the intervention is of benefit or not on children’s
long-term nutrition and school performance.
• Further research is needed to determine the impact of
deworming packages that include multiple interventions. These
studies are important, but the results are more difficult to
generalise to other settings since it is often not clear which
component of an intervention is effective.
• Trial authors are encouraged to present trial data in line
with CONSORT guidelines (Moher 2001).
• Authors of cluster-RCTs should report their data adjusting
for design effects. We recommend trials that use current
standards of design and are planned together to allow an
individual patient data meta-analysis to correct for clustering and
to help explore subgroup effects.
• Authors of trials, whether they are small or large, should
publish the results of the trials irrespective of the findings, in line
with the basic principles of research integrity.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adams 1994
Methods Randomized controlled trial
Length of follow up: 2.25 months (9 weeks)
Participants Number analysed for primary outcome: 55
Inclusion criteria: children in nursery and standard 1 classes of Mvindeni Primary School
in Kwale, Kenya; > 500 eggs/g hookworm or > 1000 eggs/g Trichuris or Ascaris; pre-
pubertal; > 5 years old
Exclusion criteria: severe anaemia (haemoglobin < 75 g/L)
Interventions Single dose versus placebo
1. Albendazole: 3 x 400 mg doses on 3 consecutive days
2. Identical placebo
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean mid-upper arm circumference
6. Mean change in mid-upper arm circumference
7. Mean triceps skinfold thickness
8. Mean change in triceps skinfold thickness
9. Mean subscapular skinfold thickness
10. Mean change in subscapular skinfold thickness
11. Mean haemoglobin post-treatment
12. Activity levels (a measure of gross motor activity of legs)
13. Self rating of appetite
Not included in review: helminth prevalence and intensity (arithmetic and geometric
mean eggs/g); baseline and post-intervention values for armmuscle area and arm fat area;
z-scores for weight, height, weight-for-height, mid-upper-arm circumference, triceps
skinfold, subscapular, arm muscle, and arm fat area
Notes Location: Kenya
Community category: 1
Source of funding not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects were grouped according to sex
and paired according to hookworm inten-
sity,- one of each pair was allocated at ran-
dom to the albendazole-treated group or
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Adams 1994 (Continued)
the placebo group.” Method not reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant lost to follow-up in the
placebo group, data for this subject were
omitted from analyses. No details of rea-
son for drop out. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 98% (55/56)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious source of bias.
Alderman 2006 (Cluster)
Methods Cluster-randomized controlled trial
Method to adjust for clustering: multivariate regression models in Stata for table 3.
Primary outcome of weight gain not adjusted for clustering in BMJ paper
Cluster unit: parish
Average cluster size: 560
ICCs: not reported but calculated from adjusted ands unadjusted figures to be 0.01
Length of follow up: 3 years
Participants Number analysed for primary outcome: 27,995 in 48 clusters
Age range: 1 to 7 years
Inclusion criteria: children aged 1 to 7 in 50 parishes in Uganda selected by the govern-
ment on the basis that around 60% of children aged 5 to 10 years in these parishes were
infected with intestinal nematodes
Exclusion criteria: sick children
Interventions Multiple dose versus no treatment
1. Albendazole: 400 mg tablet (Zentel, GSK) every 6 months, although in the event a
year elapsed between the first and second treatment round; given in conjunction with a
child health package including vaccinations, vitamin A, and health promotion
2. Child health package including vaccinations, vitamin A, and health promotion
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
Notes Location: Uganda
Community category: 2
Weight gain data taking into account the effects of cluster randomization provided by
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Alderman 2006 (Cluster) (Continued)
the author
Source of funding: the nutrition and early child development project, government of
Uganda, the Institute of Public Health and the research committee of the World Bank
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Coin toss “The randomization was done
by a member of the research team (HA)
by assigning numbers to all of the parishes
and converting these to base two and then
determining which of the parishes were to
be in the treatment by coin flips”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
High risk None. “It was not possible for us to carry
out a double blind trial because of the scale
of the programme and because we aimed
to assess the effectiveness of giving albenda-
zole […] during standard child health days
without any study specific inputs”
Incomplete outcome data (attrition bias)
All outcomes
High risk 75% (27,995/37,165) of randomized par-
ticipants were evaluated
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: low risk
Baseline imbalance: Characteristics similar
(low risk)
Loss of clusters: nil (low risk)
Incorrect analysis:primary outcome in pa-
per not adjusted for clustering, butwas sub-
sequently corrected (low risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Awasthi 2000
Methods Quasi-randomized controlled trial
Length of follow up: 2 years
Participants Number analysed for primary outcome: 1045
Age range: 1.5 to 3.5 years
Inclusion criteria: children living in 32 randomly selected urban slums; registered with
an Anganwadi worker (health worker); between 1.5 to 3.5 years of age
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Awasthi 2000 (Continued)
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Albendazole powder: 600 mg every 6 months for 2 years
2. Placebo: calcium powder
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Developmental status (Denver Questionnaire): reported as proportion with normal
development
6. Haemoglobin
Not included in review: prevalence of underweight and stunting over 2 years as defined by
z-scores, haemoglobin (visual colour estimation), stool examination (non-concentration
method), incidence of illness, and death
Notes Location: Lucknow, India
Community category: 3
Source of funding: International Clinical Epidemiology Network (INCLEN), Philadel-
phia, USA grant #2002-94-623 under the Clinical Economics Small Grants Program
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk 32 Anganwadi centres randomly selected,
and then children allocated to a serial num-
ber; those with odd or non-zero ending
numbers were assigned to placebo
Allocation concealment (selection bias) High risk Not concealed
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Single blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/610 children in the albendazole group
and 7/451 in the placebo group were lost
to follow-up
Inclusion of all randomized participants
(number evaluable/number randomized):
98% (1045/1061)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other obvious source of bias
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Awasthi 2001 (Cluster)
Methods Cluster-randomized controlled trial
Method to adjust for clustering: cluster used as unit of analysis
Cluster unit: urban slums
Average cluster size: 13.5
ICCs: not reported.
Length of follow up: 1.5 years
Participants Number analysed for primary outcome: 124 slums randomized containing 1672 children
Inclusion criteria: clusters selected if they have functional community workers in slum
areas of Lucknow; within each cluster, children recruited if aged between 0.5 and 1 year,
on basis of survey register held by each worker of their particular area
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Albendazole plus placebo: albendazole suspension (concentration not stated) (Zentel,
SZB) every 6 months and 100,000 units of vitamin A every 6 months
2. Placebo: 100,000 units of vitamin A every 6 months
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4.Mean change in height post-treatment (not used due to question over quoted standard
error)
Not included in review: stool smear for Ascaris prevalence on a subsample of the group;
death rates
Notes Location: Lucknow, India
Community category: 3
Means of cluster means used in analysis. The results (weight gain) in the abstract differ
from the text
Source of funding: International Clinical Epidemiological Network (INCLEN) Inc,
USA and Clinical Trials Unit (CTSU), Oxford, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Cluster-randomized trial, no further details
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis; 13.9% lost to
follow-up in albendazole group and 16.2%
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Awasthi 2001 (Cluster) (Continued)
in the placebo group. Inclusion of all ran-
domized participants (number evaluable/
number randomized): 83% (1672/2010)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Recruitment bias: Unclear (Not known if
children shift clinics in the light of the in-
tervention)
Baseline imbalance: Characteristics similar
(low risk)
Loss of clusters: No loss reported (low risk)
Incorrect analysis: Cluster adjusted (low
risk)
Comparability with RCTs randomising in-
dividuals: low (Analysis 5.1 and Analysis
5.2)
Awasthi 2008 (Cluster)
Methods Cluster-quasi-randomized controlled trial
Method to adjust for clustering: cluster used as unit of analysis
Cluster unit: urban slum
Average cluster size: 74
ICCs: not reported.
Length of follow up: 2 years
Participants Number analysed for primary outcome: 3712
Age range: 1 to 4 years
Inclusion criteria: children aged 1 to 4 from 50 urban slums in Lucknow selected on the
basis of geographic convenience
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Albendazole plus placebo: 400 mg albendazole plus 2 mL vitamin A every 6 months
2. Placebo: 2 mL vitamin A every 6 months
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
2. Mean change in height post-treatment
Notes Location: Lucknow, India
Community category: 3
Trail carried out in 1995 and published in 2008.
Weight data taken from Awasthi 2008 published document. Height data from INCLEN
1995 monograph. Means of cluster means used in analysis; details of correspondence
fromprevious review suggest that trial was ongoing; data for 3-year followup are provided
from R Dickson’s correspondence with the author for the Dickson 2000a Cochrane
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Awasthi 2008 (Cluster) (Continued)
Review, but the loss to follow up is very high: only 24% analysed
Source of funding: Clinical Trial Service Unit (CTSU), University of Oxford, United
Kingdom, and co-funded by the International Clinical Epidemiology Network Inc.
, Philadelphia, United States of America. Albendazole was donated by SmithKline
Beecham (now GlaxoSmithKline)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized: “Random allocation
was done by SA, listing the anganwadi cen-
ters of each slumarea serially in alphabetical
order, numbering them from 1 to 50, and
then generating a single random number
by computer that allocated either all odd or
all even numbers to a specific intervention
type.”
Allocation concealment (selection bias) High risk Not concealed
Blinding (performance bias and detection
bias)
All outcomes
High risk Cluster RCT with health staff and partic-
ipants knowing which group they were al-
located to
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1852/1968 children in the treatment group
completed all follow-up visits; 1860/1967
children in the usual care group completed
all follow-up visits. Inclusionof all random-
ized participants (number evaluable/num-
ber randomized): 94% (3712/3935)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Recruitment bias: Unclear (Not known if
children shift clinics in the light of the in-
tervention)
Baseline imbalance: Unclear
Loss of clusters: Low (none reported)
Incorrect analysis: Cluster adjusted (low
risk)
Comparability with RCTs randomising
individuals: unclear (Analysis 5.1 and
Analysis 5.2)
40Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school
performance (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Beach 1999
Methods Randomized controlled trial
Length of follow up: 4 months
Participants Number analysed for primary outcome: 853
Inclusion criteria: all children attending 5 schools (grades 1 to 4)
Exclusion criteria: haematocrit < 22%
Interventions Single dose versus placebo
1. Albendazole: 400 mg (SmithKlineBeecham, Philadelphia or generic BeltaPharm,Mi-
lan)
2. Ivermectin: 200 to 400 µg/kg (mean 282.7 µg/kg) (Merck, West Point, PA)
3. Albendazole plus ivermectin
4. Placebo: 250 mg vitamin C
Treatment strategy: randomized and treated all children
Outcomes 1. Height
2. Weight
3. Stool examination for helminth prevalence and intensity (geometric mean)
4. Haematocrit
Notes Location: Haiti
Community category: 3
Results presented in a stratified analysis as per individual infection: disaggregated results
not presented; measures of error not given in tables
Source of funding: USAID.
Invermectin provided byPhilippeGaxotte (Merck, Inc.) and albendazole by JohnHorton
(SmithKline Beecham)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, provider, and assessors were
blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 29/229 were lost to follow-up in the
placebo group and 25/244 were lost to fol-
low-up in the albendazole group. Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 88.4%
(853/965)
Selective reporting (reporting bias) Low risk All stated outcomes reported
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Beach 1999 (Continued)
Other bias Low risk No other obvious source of bias
DEVTA (unpublished)
Methods Cluster-randomized controlled trial
Method to adjust for clustering: cluster used as unit of analysis (’means of block-specific
numbers of deaths per AWC’)
Cluster unit: a block of 10,000-20,000 children
Average cluster size: 9259 approximately (under-5 population 1 million/108 clusters)
ICCs: not reported.
Length of follow up: 5 years
Participants Number analysed for primary outcome: 8338 ICDS-staffed preschool centres in 72
administrative blocks (under-5 population 1 million)
Inclusion criteria: All preschool children then aged 1-6·0 in 72 participating blocks near
Lucknow that were considered to have a well-functioning ICDS system with willing
district and block directors and with paid workers in most of the block’s anganwadi
centres
Exclusion criteria: severe anaemia (haemoglobin < 75 g/L)
Interventions Multiple doses versus placebo
Factorial design in four arms:
1. Usual care - no placebo;
2. 6-monthly vitamin A [for 5 years];
3. 6-monthly 400 mg albendazole;
4. Both 6-monthly vitamin A and 6-monthly 400 mg albendazole
Outcomes 1. Mortality
Notes Location: Lucknow, India
Community category: 3
Annually about 30 non-randomly selected preschool children were surveyed for growth,
nutritional and morbidity outcomes from one randomly selected AWC per block (10,
000 to 20,000 children in about 120 AWCs per block)
Source of funding: UKMedical Research Council, USAIDOMNI project,World Bank.
Albendazole (Zentel) was donated by SmithKlineBeecham
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”; “Randomisation (in
Oxford) was stratified in groups of 4 neigh-
bouring blocks, where possible in the same
district.”
Allocation concealment (selection bias) Unclear risk See above
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DEVTA (unpublished) (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk All cause mortality is the outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89 AWCs (2%) in the albendazole block
lost to follow-up, 86 AWCs (2%) in the
placebo block lost to follow-up. “Loss to
follow-up is defined by having only 1-6
follow-up visits (mean only 3, as against
12 in the included AWCs), and was gener-
ally because the AWC had ceased to func-
tion.” Inclusion of all randomized partici-
pants (number evaluable/number random-
ized): Denominator for mortality was all
children. A subset of 5165 children were
assessed for other outcomes
Selective reporting (reporting bias) Low risk Mortality is the single outcome for this trial
Other bias Low risk Recruitment bias: unclear.
Baseline imbalance: unclear.
Loss of clusters: unclear.
Incorrect analysis: Cluster adjusted (low
risk).
Comparability with RCTs randomising in-
dividuals: unclear.
Donnen 1998
Methods Randomized controlled trial
Length of follow up: 1 year
Participants Number analysed for primary outcome: 222
Inclusion criteria: children aged 0 to 72months eligible on discharge fromhospital where
primary cause for admission is malnutrition
Exclusion criteria: none stated
Interventions Multiple doses versus placebo and no treatment
1. Mebendazole: 500 mg at start and every 3 months
2. Placebo: 60 mg vitamin A at start and 3 months
3. No treatment
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean mid-upper arm circumference
43Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school
performance (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Donnen 1998 (Continued)
6. Mean change in mid-upper arm circumference
Not included in review: vitamin A levels; z-scores for height-for-age, weight-for-age,
weight-for-height (NCHS reference); egg counts (eggs/g: Kato Katz method)
Notes Location: Zaire
Community category: 3
Unadjusted data not provided in original paper; results of multiple-regression models
presented on basis of stratifications into vitamin A status and sex; results in meta-anal-
ysis from R Dickson’s correspondence with author when preparing the Dickson 2000a
Cochrane Review.
Source of funding: Fonds de la Recherche Scientifique et Medicale (FRSM), contract 3.
4505.94 and the David and Alice Van Buuren Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized”, no further details reported.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 6% of children were lost to follow-
up, with approximately equal proportions
from each group. During the follow- up
period, 25 children died. The final sample
included 311 children Inclusion of all ran-
domized participants (number evaluable/
number randomized): 86% (311/358)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious source of bias.
Dossa 2001
Methods Randomized controlled trial
Length of follow up: 10 months
Participants Number analysed for primary outcome: 65
Inclusion criteria: children aged 3 to 5 years; not acutely unwell
Exclusion criteria: none stated
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Dossa 2001 (Continued)
Interventions Multiple doses versus placebo
1. Albendazole plus iron: 200 mg albendazole per day for 3 consecutive days repeated 1
month later plus iron
2. Placebo plus iron
3. Albendazole: 200 mg per day for 3 consecutive days repeated 1 month later plus iron
placebo
4. Placebo plus placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
2. Mean change in height post-treatment
3. Mean change in mid-upper arm circumference
4. Mean change in triceps skinfold thickness
5. Mean haemoglobin post-treatment
Not included in review: weight-for-height z-score and height-for-age z-score at 3 and 10
months (both after 2 doses)
Measured but not reported: z-scores for weight-for-height, height for age using NCHS
reference data; egg count (arithmetic and geometric mean); prevalence, intensity; food
intake over 3 days in subset at end of trial (not at baseline)
Notes Location: Benin
Community category: 2
Source of funding: TheNestle Foundation (Lausanne, Switzerland).Smithkline Beecham
provided the deworming and placebo tablets
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”, no further details
provided
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double-blind”, no further details pro-
vided
Incomplete outcome data (attrition bias)
All outcomes
High risk 175/177 children finished the study, but
140 were included in the final analysis:
“One child was treated for severe worm
infection and 34 children received other
pills during the study period (iron, vita-
mins/minerals or dewormingpills thatwere
not provided by our research team).” Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 79%
(140/177)
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Dossa 2001 (Continued)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias High risk No obvious other source of bias
Fox 2005
Methods Randomized controlled trial
Length of follow up: 6 months
Participants Number analysed for primary outcome: 626
Inclusion criteria: children aged 5 to 11 years attending any of 12 primary schools in
Haiti where no other deworming activity was taking place
Exclusion criteria: none stated
Interventions Single dose versus placebo:
1. Albendazole 400 mg plus placebo (250 mg vitamin C tablet)
2. 6 mg/kg diethylcarbamazine (DEC) plus placebo (250 mg vitamin C tablet)
3. Albendazole 400 mg plus single dose of 6 mg/kg diethylcarbamazine (DEC)
4. Placebo plus placebo (2 x 250 mg vitamin C tablets)
Treatment strategy: randomized and treated all children
Outcomes 1. Weight: final and change in weight
2. Height: final and change in height
3. Adverse effects
Not included in review: worm intensity and prevalence; microfilarial density
Notes Location: Haiti
Community category: 2
Weight and height outcomes are only presented for a subgroup of children infected with
Trichuris
Source of funding: Emerging Infections Program of the Centers for Disease Control and
Prevention and an Institutional Strengthening Grant from the World Health Organiza-
tion to the Hopital Sainte Croix
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table
Allocation concealment (selection bias) Low risk Centrally-coded allocation system broken
after baseline measures taken
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind”. Laboratory personnel,
measurement teams and personnel evaluat-
ing students for adverse reactions were all
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Fox 2005 (Continued)
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 626/646 participants analysed for the pri-
mary outcome. Reasons for loss to follow-
up unclear
Inclusion of all randomized participants
(number evaluable/number randomized):
97% (626/646)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other source of bias
Freij 1979a
Methods Quasi-randomized controlled trial
Length of follow up: 28 days
Participants Number analysed for primary outcome: 13
Inclusion criteria: boys attending mother and child clinic with Ascaris on stool smear;
aged 1.5 to 5 years with no history of diarrhoea for preceding 2 weeks; no fever; no
respiratory symptoms; no signs of severe disease
Exclusion criteria: children diagnosed with other parasites; excluded girls to eliminate
the contamination of samples with urine
Interventions Single dose versus placebo
1. Piperazine: 3 g single dose
2. Placebo syrup: single dose
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Weight
2. Mid-upper arm circumference
3. Triceps skinfold thickness
Not included in review: Ascaris worm count
Notes Location: Ethiopia
Community category: unclear
The authors mention that boys were matched in pairs so that if there were drop outs they
could be replaced. They do not indicate if there were any drop outs. Standard deviations
calculated from individual data
Freij 1979a and Freij 1979ai were reported in the same article.
Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research
Council
Risk of bias
Bias Authors’ judgement Support for judgement
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Freij 1979a (Continued)
Random sequence generation (selection
bias)
High risk Quasi-randomized controlled trial: boys
matched into pairs of equal age and nutri-
tional status
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind, no further de-
tails reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 100% (13/13) of enrolled participants were
evaluated. The authors mention that boys
were matched in pairs so that if there were
drop outs they could be replaced. They do
not indicate if there were any drop outs.
Inclusion of all randomized participants
(number evaluable/number randomized):
100% (13/13)
Selective reporting (reporting bias) Low risk Authors had intended tomeasure bicep and
tricep skinfolds, but staff were unable to
take these measurements
Other bias Low risk No obvious other source of bias
Freij 1979b
Methods Quasi-randomized controlled trial
Length of follow up: 34 days
Participants Number analysed for primary outcome: 44
Inclusion criteria: 92 children 1 to 5 years from a community morbidity study
Interventions Single dose versus placebo
1. Piperazine: 3 g/day for 2 days
2. Placebo: for 2 days
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Mid-upper arm circumference
2. Morbidity
Not included in review: weight in % of Harvard standard; authors had intended to
measure bicep and tricep skinfolds, but staff were unable to take these measurements
Notes Location: Ethiopia
Community category: 3
Freij 1979a and Freij 1979ai were reported in the same article.
Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research
Council
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Freij 1979b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized controlled trial: chil-
dren matched into pairs of equal age and
nutritional status
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind, no further de-
tails reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% (44/44) of enrolled participants were
evaluated. Inclusion of all randomized par-
ticipants (number evaluable/number ran-
domized): 100% (44/44)
Selective reporting (reporting bias) Low risk Authors had intended tomeasure bicep and
tricep skinfolds, but staff were unable to
take these measurements
Other bias Low risk No obvious other source of bias
Garg 2002
Methods Randomized controlled trial
Length of follow up: 6 months
Participants Number analysed for primary outcome: 347
Inclusion criteria: sick children 2 to 4 years old presenting to 3 government health centres
in Bungamo district, without palmar pallor
Exclusion criteria: children with palmar pallor
Interventions Single dose versus placebo
1. Mebendazole: 500 mg (Vermox, Janssen, Belgium)
2. Placebo: sucrose starch capsule
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean haemoglobin post-treatment
6. Mean change in haemoglobin post-treatment
Not included in review: z-scores for weight-for-age, height-for-age, and weight-for-
height; egg count (formol-ethyl acetate concentration method) in categories of intensity
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Garg 2002 (Continued)
Notes Location: Kenya
Community category: 3
Source of funding: the Centers for Disease Control and Prevention, Atlanta, USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random num-
bers
Allocation concealment (selection bias) Low risk Drugs kept in envelope until after baseline
assessment
Blinding (performance bias and detection
bias)
All outcomes
High risk “the trial was not double-blinded” Asses-
sors were blinded; participants unclear;
provider not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93%(347/370) of randomizedparticipants
were evaluated, loss to follow-up balanced
across groups. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 93% (347/370)
Selective reporting (reporting bias) Low risk All stated outcomes included
Other bias Low risk No obvious other source of bias
Goto 2009
Methods Randomized controlled trial
Length of follow up: 36 weeks
Participants Number analysed for primary outcome: 410
Inclusion criteria: infants under 11 months of age in the local area
Exclusion criteria: Not stated.
Interventions Multiple doses versus placebo
1. anti-Giardia (secnidazole every 4 weeks) and anthelminthic (albendazole every 12
weeks)
2. anti-Giardia treatment only (secnidazole every 4 weeks) and placebo.
3. Placebo and placebo
Treatment strategy:
Secnidazole: a 70 mg/mL suspension with about 0.5 g of sweetener was made up, and
0.5 mL per kg body weight was given by spoon. If the infant was sick immediately,
secnidazole was re-administrated
Albendazole: A 200 mg (5 mL) suspension given by spoon.
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Goto 2009 (Continued)
Outcomes 1. Hb (g/L) (endpoint week 36)
Not included in review:
2. Height-for-age z-score (endpoint week 36)
3. Weight-for-age z-score (endpoint week 36)
4. Weight-for-height z-score (endpoint week 36)
5. Plasma albumin (g/L) (endpoint week 36)
6. IgG (g/L) (endpoint week 36)
7. Alpha-1-acid glycoprotein (g/L) (endpoint week 36)
8. Giardia-specific IgM titre (endpoint week 36)
9. Lactulose/mannitol ratio (endpoint week 36)
10. Prevalence of Giardia-specific IgM titre, % (week 0,12,24,36)
11. Prevalence of Giardia cysts, % (week 0,12,24,36)
12. Prevalence of Ascaris/Trichuris, % (week 0,12,24,36)
13. Prevalence of Intestinal mucosal damage, % (week 0,12,24,36)
14. Prevalence of Anaemia, % (week 0,12,24,36)
Notes Location: Dhamrai Upazila, located 40km northwest of Dhaka, Bangladesh
Community category: 3. “Prevalences and intensities of geohelminths were consistently
low throughout the intervention”
Drug source: Dhaka, Bangladesh (Essential Drugs Company Ltd for secnidazole; Square
Pharmaceuticals Ltd for the secnidazole placebo; Opsonin Chemical Industries Ltd for
albendazole; and UniMed and UniHealthManufacturing Ltd for albendazole placebo)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Randomized on the basis of their age, sex,
height-for-age, weight-for-age and weight-
for-height z-scores, socio-demographic and
economic data andpresence of any parasitic
infection
Allocation concealment (selection bias) Unclear risk Unclear whether the allocation was con-
cealed since patients were randomized by
their characteristics
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
“Bottles containing the two medications
and placebo suspensions were labelled with
different colours corresponding to the three
intervention groups, but the assistants did
not know the relationship between the
colour codings and the contents of the bot-
tles.”
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Goto 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 394/410 (96.10%) of randomized partici-
pants were evaluated.
“A total of 16 infants were excluded from
the study, as they had either moved away
from the study area (n = 12), or were ab-
sent during the study period (n = 2) or the
parents subsequently refused to participate
(n = 2). Of the infants who completed the
study (n = 394), data on 96 infants was
incomplete (ie they did not provide infor-
mation for all the ten z-scores and four in-
testinal permeabilities, serological variables
and prevalences of parasite infections), and
severe anaemic infants were also omitted
from the study” Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 96% (394/410)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other source of bias
Greenberg 1981
Methods Randomized controlled trial
Length of follow up: 11 months
Participants Number analysed for primary outcome: 152 aged 1.5 to 8 years
Inclusion criteria: children aged 1.5 to 8 years living in Nandipara, Bangladesh; 50%
entered into study; only those who provided stool sample and had anthropometric
measurements taken at first visit entered
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Piperazine citrate: 80 mg/kg added to flavoured syrup; 2 doses in 2-week period
2. Placebo: syrup only
Treatment strategy: randomized and treated all children
Outcomes 1. Cure rates
2. Reinfection rates
3. Weight-for-height
4. Height-for-age (NCHS reference)
5. Weight-for-age (graphically)
6. Other measured parameters not reported: weight; height; triceps skinfold thickness;
mid-upper arm circumference; chest circumference; abdominal girth; egg counts (Dunn’s
method); prevalence; triceps skinfold for age; mid-upper arm circumference for age
(Tanner reference charts)
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Greenberg 1981 (Continued)
Notes Location: Bangladesh
Community category: 1
Groups stratified by intensity of Ascaris infection
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”, no further details
provided
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double-blind”. Participants blinded both
placebo and treatment given as a flavoured
syrup, no information about provider and
assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 82% (152/185) of randomized partici-
pants were evaluated. Reasons for leav-
ing the study early not reported. Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 82%
(152/185)
Selective reporting (reporting bias) High risk Not all stated outcomes reported
Other bias Low risk No obvious other source of bias
Hadju 1996
Methods Quasi-randomized controlled trial
Length of follow up: 1.75 months (7 weeks)
Participants Number analysed for primary outcome: 64
Inclusion criteria: boys aged 6 to 10 years attending second grade at 3 primary schools;
completed assessment and provided a stool sample; randomized by descending hook-
worm count (all treated)
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Pyrantel pamoate: 10 mg/kg
2. Placebo
Treatment strategy: randomized and treated all children
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Hadju 1996 (Continued)
Outcomes 1. Mean weight post-treatment
2. Appetite: consumption test (mL porridge) and self assessment
Not included in review: egg counts arithmetic and geometric means (Kato-Katz); weight-
for-age (NCHS reference)
Notes Location: Indonesia
Community category: 1
Large drops in geometric mean egg counts in placebo noted
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized: “Randomly assigned“ by de-
scending A. lubricoides egg count”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double-blind”. Participants blinded both
placebo and treatment identical round
white tablets, no information about
provider and assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 85% (64/75) of randomized participants
were evaluated. Reasons for loss to fol-
low-up included: moved away, refused to
be examined, did not return a stool sam-
ple, absent during examination. Not clear
how many lost from each treatment group.
Inclusion of all randomized participants
(number evaluable/number randomized):
85% (64/75)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other source of bias.
Hadju 1997
Methods Randomized controlled trial
Length of follow up: 12 months
Participants Number analysed for primary outcome: 330; mean age 8.3 years
Inclusion criteria: all primary school children in grades 1, 2, and 3 in 2 schools in slum
areas in Indonesia; randomized according to Ascaris egg count and age
Exclusion criteria: children > 11; signs of puberty; signs of severe protein energy malnu-
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Hadju 1997 (Continued)
trition
Interventions Multiple doses versus placebo
1. Pyrantel pamoate: 10 mg/kg
2. Pyrantel pamoate: 10 mg/kg repeated at 6 months
3. Albendazole: 400 mg
4. Albendazole: 400 mg repeated at 6 months
5. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Stool (Kato-Katz) prevalence and intensity
2. Weight
3. Height
4. Mid-upper arm circumference
5. z-scores: weight-for-age, height for age, weight-for-height, and mid-upper arm cir-
cumference
Results of multivariate analysis using z-scores presented and could not be used in meta-
analysis; unadjusted results not reported
Notes Location: Indonesia
Community category: 1
Placebo group showed an unexplained drop in egg counts at the 3-month exam
Source of funding: Directorate of Higher Education, Department of Education and
Culture, Government of Indonesia through Hibah Bersaing Project I & II. Albendazole
and placebo provided by Smithkline Beecham Pharmaceuticals Indonesia.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned “by sex and egg count”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 65% (330/507) of randomized partici-
pants were evaluated, number lost from
each treatment group not reported. Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 65%
(330/507)
Selective reporting (reporting bias) Low risk All stated outcomes reported
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Hadju 1997 (Continued)
Other bias Low risk No obvious other source of bias
Hall 2006 (Cluster)
Methods Cluster-randomized controlled trial
Method to adjust for clustering: not adjusted (review authors adjusted using the ICC
from Alderman 2006)
Cluster unit: school
Average cluster size: 33
ICCs: not reported.
Length of follow up: 2 years
Participants Number analysed for primary outcome: 80 schools randomized containing 2659 children
in class 3
Mean age: 104.5 months
Inclusion criteria: children from class 3 and born in 1990 of 80/81 schools in the Red
River delta of north Vietnam
Interventions Multiple doses versus placebo
1. Albendazole (GlaxoSmithKline): 400 mg every 6months and 200,000 IU retinol after
first 6 months only
2. Retinol: 200,000 IU after first 6 months followed by inert placebo every 6 months
Treatment strategy: randomized and treated all children
Outcomes Measured:
1. Hookworm, Trichuris, and Ascaris prevalence
2. Eggs/g faeces
3. Weight and height
4. Mathematics test score, Vietnamese test score
Notes Location: Vietnam
Community category: 1
It is unclear what is meant by “randomization was adjusted so that there were equal
numbers of schools in each district of the study group”. It is also appears as if the analysis
has not taken into account the effects of cluster randomization
Source of funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomization was adjusted so that there
were equal numbers of schools in each dis-
trict of the study group” (unclear what this
means)
Allocation concealment (selection bias) Low risk Central allocation. “...using a list provided
by the Ministry of Education”
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Hall 2006 (Cluster) (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Placebo was used, blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions. 80 schools containing 56,444 pupils
randomized, and those from class 3 used
in study. Inclusion of all randomized par-
ticipants (number evaluable/number ran-
domized): unclear; 80 schools containing
56,444 pupils randomized, and those from
class 3 used in study
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Although not adjusted for clustering, we
used estimates to adjust in the review
Recruitment bias: Low (schools)
Baseline imbalance: Low (characteristics
similar)
Loss of clusters: Low (no loss reported)
Incorrect analysis: not cluster adjusted
(high risk)
Comparability with RCTs randomising in-
dividuals: Unclear
Kirwan 2010
Methods Randomized controlled trial
Length of follow up: 14 months
Participants Number analysed for primary outcome: 320
Inclusion criteria: Pre-school children aged 12 to 59 months, either sex
Exclusion criteria: Severe anaemia less than 5 g/dL, severe malaria
Interventions Multiple doses versus placebo
1. Albendazole
2. Placebo
Treatment strategy: 200 mg (one tablet) albendazole was given to children aged 1 year,
400 mg (two tablets) albendazole was given to children aged 2, 3 and 4 years. Children
who were in the placebo group were given one or two (1 year) placebo (2-4 years) tablets.
Treatment or placebo was given at baseline, 4, 8 and 12 months and then followed up for
the last time at 14 months. Children in the placebo group were treated with albendazole
at 14 months
Outcomes 1. Haemoglobin, measured at baseline and 4, 8, 12 and 14 months
Unable to use: Nutritional status and anthropometric measures, at baseline and 14
months, no data was reported for these outcomes
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Kirwan 2010 (Continued)
Not included in review: Infection with soil-transmitted helminths, measured at baseline
and 4, 8, 12 and 14 months (eggs or worms in stool sample). Incidence of malaria and
malaria attacks, measured at baseline and 4, 8, 12 and 14 months. Adverse events not
fully reported for albendazole treatment versus placebo
Notes Location: 4 semi-urban villages, Osun State, Nigeria
Community category: 3
No adverse events reported in the Albendazole treatment group. Not reported for control
group
Source of funding: Health Research Board (HRB) (Ireland). GlaxoSmithKline sponsored
the drug albendazole which
was used in the study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized, “During the first as-
sessment each alternate child was assigned
tablet B”
Allocation concealment (selection bias) High risk Alternation, one of the investigators
“placed the albendazole and placebo tablets
in containers labelled either A or B” later
“The treatment coordinator [...] oversaw
the allocation of treatments to the children”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded. “Experienced physicians […] en-
rolled all participants, measured all study
endpoints, and were kept masked to treat-
ment allocation of children. Field workers
involved in data collection and mothers of
participating children were also masked to
the treatment allocation.”
“Albendazole and placebo tablets were
identical”
Incomplete outcome data (attrition bias)
All outcomes
High risk 320 children (out of 1228, 26.1%) com-
plied with all the follow-up assessments
and were included in the analyses. Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 26%
(320/1228)
Selective reporting (reporting bias) High risk Nutritional status and anthropometric
measures not reported. Main paper states
these outcomes are reported in the com-
panion paper; no data reported for these
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Kirwan 2010 (Continued)
outcomes in the companion paper
Other bias Low risk No obvious other source of bias
Kloetzel 1982
Methods Randomized controlled trial
Length of follow up: 10 months
Participants Number analysed for primary outcome: 337; unclear how many randomized; aged 1 to
8 years old
Inclusion criteria: enlisted from 9 rural communities in Pariquera-Acu state of Sao Paulo
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Mebendazole: 100 mg twice per day for 3 days
2. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Weight
2. Height
3. Head, chest, and mid-arm circumference
4. Triceps skinfold
5. Stool egg counts (Kato-Katz)
Notes Location: Cameroon
Community category: 1
Results reported as changes in nutritional status grouped into 3 categories: improved,
deteriorated, no change (unclear onbasis ofwhich parameter), andproportions compared
Source of funding: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized”, no further details provided
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind, no details re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details about losses to follow-up re-
ported; “the present report only deals with
those 337 that could be followed through-
out the entire 10 months”. Inclusion of
59Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school
performance (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kloetzel 1982 (Continued)
all randomizedparticipants (number evalu-
able/number randomized): unclear (337
analysed).
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other sources of bias
Koroma 1996
Methods Randomized controlled trial
Length of follow up: 6 months
Participants Number analysed for primary outcome: 187
Inclusion criteria: selected (unclear how) urban and rural school primary children aged
6 to 10 years
Exclusion criteria: not stated
Interventions Single dose versus placebo
1. Albendazole: 400 mg
2. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Prevalence and intensity (arithmetic mean eggs/g)
2. z-scores (no reference category stated): weight-for-height, weight-for-age, and height-
for-age
Notes Location: Sierra Leone
Community category: 2
Source of funding: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized”, no further details provided
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 76%(187/247) of randomizedparticipants
were evaluated. Reasons for loss to follow-
up not reported. Inclusion of all random-
ized participants (number evaluable/num-
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Koroma 1996 (Continued)
ber randomized): 76% (187/247)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other sources of bias
Kruger 1996
Methods Randomized controlled trial
Length of follow up: 11 months
Participants Number analysed for primary outcome: 74 aged 6 to 8 years
Inclusion criteria: 65 pupils in first year of school randomly selected from each of 5
primary schools; schools included in a feeding scheme
Exclusion criteria: age > 9 years; current use of iron supplements; inclusion in an iron
fortification trial; infection (raised white cell count)
Interventions Multiple doses versus placebo
1. Albendazole: 2 x 200 mg repeated at 4 months, daily unfortified soup
2. Placebo: daily unfortified soup
Also: whole population
3/5 schools also allocated soup fortified with 20 mg elemental iron per day, and 100 mg
vitamin C for 6 months; unclear whether this intervention was cluster randomized. All
schools taking part in feeding programme providing bread, soup, and peanut butter to
all pupils
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
2. Mean change in height post-treatment
3. Mean change in haemoglobin post-treatment
Not included in review: other iron indices; stool egg counts (Visser filter method); z-
scores for weight-for-age, height for age, and weight-for-height
Notes Location: South Africa
Community category: 3
In the Dickson 2000a Cochrane Review, the data were combined irrespective of the pos-
sible confounding effects of iron allocation; data extracted for albendazole-iron placebo
versus placebo-placebo groups only for this review
Data stratified by baseline iron stores into 2 groups that were combined for meta-analysis
Source of funding: Fortified and unfortified soup provided by Funa Foods, Zentel and
placebo provided by SmithKline Beecham Pharmaceuticals (Pty) Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”, no further details
provided
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Kruger 1996 (Continued)
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 72%(179/247) of randomizedparticipants
were evaluated. Reasons for loss to follow-
up not reported. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 72% (179/247)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other source of bias
Kvalsvig 1991a
Methods Randomized controlled trial
Length of follow up: 1 month
Participants Number analysed for primary outcome: unclear; age range unclear
Inclusion criteria: most severely infected 100 children in a primary school
Exclusion criteria: children with schistosomiasis
Interventions Single dose versus placebo
1. Mebendazole: 500 mg
2. Placebo
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Cognition tests: card sorting task (coloured cards; cancellation task - striking out of
letter ’s’ in text, number done in a period)
Not included in review: height; weight at baseline; standardized using NCHS standards;
stool examination (intensity index designed for this trial); no nutritional outcomes re-
ported that can be used in the review
Notes Location: South Africa
Community category: 1
No data used in meta-analysis since standard deviations not provided
Source of funding: Janssen Pharmaceutica, South African Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Assigned randomly”, no further details
provided
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Kvalsvig 1991a (Continued)
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “A ‘blind’ procedure was adopted; the re-
search assistant did not know whether
a particular child had received drug or
placebo”, no further details provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details reported. Inclusion of all ran-
domized participants (number evaluable/
number randomized): unclear
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other source of bias
Lai 1995
Methods Quasi-randomized controlled trial
Length of follow up: 2 years
Participants Number analysed for primary outcome: 314
Inclusion criteria: school children aged 8 who provided a stool sample
Exclusion criteria: concurrent illness; anthelminth treatment in previous 3 months
Interventions Multiple doses versus placebo
1.Mebendazole plus pyrantel: 100mgmebendazole and 200mgpyrantel every 3months
for 2 years
2. Placebo: every 3 months for 2 years
Treatment strategy: randomized and treated all children
Outcomes Measured:
1. Hookworm, Trichuris, and Ascaris prevalence
2. Eggs/g faeces
3. Weight and height
Notes Location: Malaysia
Community category: 1
No data used in meta-analysis since standard deviations not provided
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized: block assignment de-
sign by school, then by sex, then by pres-
ence of worms as none, light, or moder-
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Lai 1995 (Continued)
ate/heavy, and then by rank order of body
weight in the group; used odd and even
numbers; in urban area the odd numbered
children were assigned to treatment; in the
peri-urban area the even numbered chil-
dren were assigned to the treatment group
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were blinded; study staff new
which group they were in
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89%(314/353) of randomizedparticipants
were evaluated
Inclusion of all randomized participants
(number evaluable/number randomized):
89% (314/353)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other sources of bias
Le Huong 2007
Methods Randomized controlled trial
Length of follow up: 6 months
Participants Number analysed for primary outcome: 510 randomized
Inclusion criteria: Children in Grades 1-3 with Hb less than 110 g/L but not less than
70 g/L
Exclusion criteria: Haemoglobin (Hb) concentrations <70 g/L
Interventions Multiple dose versus placebo
Factorial design
Mebendazole 500 mg at 0 and 3 months
1. iron-fortified noodles and mebendazole 500 mg;
2. noodles without iron fortificant and mebendazole 500 mg;
3. iron-fortified noodles and placebo;
4. noodles without iron fortificant and placebo; and
5. iron supplementation and mebendazole 500 mg.
Treatment strategy: children screened for anaemia then randomized and all children
treated
Outcomes 1. Haemoglobin - change
2. Prevalence of underweight, stunting and wasting (defined as -2SD for weight-for-
height, height-for-age and weight-for- age using WHO/NCHS reference data)
Not included in review: Ferritin; serum transferrin; worm prevalence; CRP
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Le Huong 2007 (Continued)
Notes Location:Vietnam
Community category: 2
Source of funding: Neys-van Hoogstraten Foundation, Ellison Medical Foundation and
the Ministry of Education and Training, Vietnam
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized, no further details
Allocation concealment (selection bias) Low risk Central allocation. “Randomization was
carried out by a researcher [...] who did not
know the children and could not introduce
bias in the randomization.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel blinded.
“Children, teachers and researchers were
blinded to the treatment.”
Placebo identical to intervention drug
Incomplete outcome data (attrition bias)
All outcomes
Low risk 409/425 participants were evaluated. Rea-
son for drop-out: refusal (n=16, inter-
vention: 4.7%, placebo: 2.3%). Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 96%
(409/425)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported
Other bias Low risk No obvious other sources of bias
Michaelsen 1985
Methods Randomized controlled trial
Length of follow up: 5 months
Participants Number analysed for primary outcome: 121 for nutritional outcomes; age range 5 to 14
years
Inclusion criteria: children from a school identified as having high prevalence of hook-
worm on the basis of a previous survey
Exclusion criteria: children with height above 137 cm girls and 145 cm for boys since
these were the upper limits in the reference ranges
Interventions Single dose versus placebo
1. Tetrachloroethylene: 0.1 mL/kg (max 5 mL dose)
2. Placebo: children’s cough medicine
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Michaelsen 1985 (Continued)
Treatment strategy: randomized and treated all children
Outcomes Measured:
1. Stool: prevalence in subgroup
2. Haemoglobin
3. Weight
4. Height
5. Weight-for-height (WHO reference median 1983)
Reported:
1. Stool prevalence (graph) with 95% CIs
2. Haemoglobin mean and difference (no SD)
3. Weight-for-height %, mean and difference (no SD)
Notes Location: Botswana
Community category: 1
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Random sample of half the children” were
give the treatment and the remaining the
placebo. No further details reported.
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 53%(121/228) of randomizedparticipants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 53% (121/228)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported
Other bias Low risk No obvious other sources of bias
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Miguel 2004 (Cluster)
Methods Cluster phased intervention, which means some comparisons were quasi-randomized.
Method to adjust for clustering: CIs adjusted for clustering in regression modelling,
robust standard errors presented (confirmed in correspondence with authors).
Cluster unit: schools.
Average cluster size: 400
ICCs: not reported.
Length of follow up: one year for phased quasi-randomized comparisons for health
outcomes. Two years for school attendance
Participants Number analysed for primary outcome: For haemoglobin approximately 4% (778/20,
000) - unclear how these were selected. Unclear for nutritional outcomes. Unclear for
exam performance and cognitive tests
Inclusion criteria: none explicitly stated. “Nearly all rural primary schools” in Busia
district, Kenya, involved in a NGO deworming programme were studied, with a total
enrolment of 30,000 pupils aged six to eighteen.Exclusion criteria: girls > 13 years old
Interventions Deworming package of interventions including multiple doses of anthelminth versus no
treatment within phased intervention
1. Albendazole 600mg (Zentel, SZB) every 6 months in 1998 intervention, and alben-
dazole 400mg (Zentel, SZB) in 1999. In addition:
• Worm prevention education (public health lectures, wall charts and teacher
training in worm prevention. Health education on hand washing and wearing shoes to
prevent worm infection.
• Schools with schistosomiasis prevalence over 30% were mass treated with
praziquantel (40mg/kg Bayer) annually. 6/25 schools treated with praziquantel in
1998, and 16/50 treated with praziquantel in 1990.
2. No treatment
Outcomes 1. Weight-for-age Z score difference in end value
2. Haemoglobin difference in end value
3. Exam score performance (ICS administered English, Mathematics and Science-Agri-
culture exams in pupils in grades 3 to 8)
4. Cognitive tests including picture search, Raven matrix, verbal fluency, digit span,
Spanish learning, and a dynamic test using syllogisms
5. Height-for-age Z score difference in end value
6. School participation rate based on external NGO assessment at unannounced visit
Not included in review: worm prevalence and intensity, self reported sickness, worm
prevention behaviours: proportion “clean” as per health worker observation, proportion
wearing shoes as per health worker observation, self-reported contact with fresh-water
in past week, access to home latrine, malaria/fever
Notes This was an econometric analysis of 75 schools with a total of 30,000 pupils enrolled.
The intervention was phased over time, and there were two comparisons, one in 1998
and one in 1999 if the analysis is comparative within each individual year. Schools
in a deworming project were stratified by zone, their involvement with other NGO
programmes, and then listed alphabetically and every third school assigned to start the
programme in 1998, to start it in 1999, or to be a control. The schools are divided into
3 groups: Group 1 schools are in the treatment group throughout. Group 2 schools are
in the control group for the 1998 comparison, but in the treatment group in the 1999
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Miguel 2004 (Cluster) (Continued)
comparison. Group 3 schools are in the control group throughout.
In the description of the intervention two comparisons are thus identified: Group 1
schools versus Group 2 and 3 schools in 1998, andGroup 1 and 2 schools versus Group 3
schools in 1999. However, in a personal correspondence the authors state that there is no
health data for Group 3 schools for 1999. For nutritional and haemoglobin outcomes,
this implies that there is one possible quasi-randomized comparison with contemporary
information in both treatment and control, which is 1998, Group 1 versus Group 2 &
3. However, results for health outcomes are presented for the 1998 comparison of Group
1 (25 schools) versus Group 2 (25 schools)
Number of children followed up for nutritional outcomes in 1998 comparison is unclear.
A sub-sample of the original quasi-randomized comparison appears to have been followed
up for haemoglobin and nutritional outcomes, but it is not clear how this sample was
selected (table V in the paper)
For school attendance, during the study, the authors carry out a rigorous assessment
of participation rate. This was then calculated as a weighted average by school. For
school attendance results are presented for Group 1 versus Group 2 & 3 in 1998 (one
year of treatment, multiple dose), and for Group 1 versus Group 3 in 1999 (two years
of treatment, multiple dose), and for Group 2 versus Group 3 in 1999 (one year of
treatment, multiple dose). Baseline data is presented for attendance at schools, recorded
by school registers in a four week period prior to intervention, recording 97.3% inGroup
1, and 96.3% in Group 2. However the authors state that this is not considered reliable.
There are no comparable baseline values (ie measured in the same way as the outcome
measurement of school attendance) to know whether baseline attendance happens to be
different across groups
Group 1 schools have an overall prevalence of 38% heavy/moderate worm infection in
1998, compared to the initial survey in control schools in 1999, where it was 52%
Academic performance measured by Internationaal Christelijk Steunfonds Africa (ICS)
exam scores in a regression analysis that included school participation during the year of
the exam, and also if it was a year 1 treatment school or a year 2 treatment school. The
authors did not provide the results by the quasi-randomized comparison eligible for this
review (1998 Group 1 versus Group 2 & 3; 1999 Group 1 & 2 versus group 3)
The cognitive tests were carried out in all three groups of schools during 2000. The
authors do not formally report the result in the paper, other than to state that they were
not significant.
27/75 schools were involved in other NGO projects which consisted of financial assis-
tance for textbook purchase and classroom construction, and teacher performance in-
centives. The distribution of these other interventions is not clear, but the authors state
that these schools were stratified according to involvement in these other programmes.
The authors state that health education had a minimal impact on behaviour, and that
any programme effect is almost certainly due to the effect of deworming drugs, rather
than health education.
School participation rate was computed among all pupils enrolled in 1998. Pupils present
on the day of an unannounced NGO visit were considered participant. Pupils had 3.8
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Miguel 2004 (Cluster) (Continued)
observations on average per year
Location: Kenya
Community category: 1
Source of funding: Sponsored by the World Bank and the Partnership for Child Devel-
opment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Schools in a deworming project were strat-
ified by zone, their involvement with other
NGO programmes, and then listed alpha-
betically and every third school assigned to
start the programme in 1998, to start it in
1999, or to be a control
Allocation concealment (selection bias) High risk Not concealed (see above).
Blinding (performance bias and detection
bias)
All outcomes
High risk Pragmatic cluster implementation study
with no blinding.
Incomplete outcome data (attrition bias)
All outcomes
High risk For haemoglobin, weight and height the
outcomes appear to have beenmeasured on
a sub-sample of the quasi-randomized pop-
ulation. For haemoglobin this was approxi-
mately 4% (778/20,000) - it is unclear how
these were selected. The number of par-
ticipants or measurements on which nutri-
tional outcomes are based is not stated. For
exam performance only regression data are
given
Selective reporting (reporting bias) Low risk Outcome data not reported for cognitive
tests, though authors state: Deworming
treatment effects are not significantly dif-
ferent than zero for any component of
the cognitive exam (results available on re-
quest)
Other bias High risk Recruitment bias: Low (no asymmetric mi-
gration between schools)
Baseline imbalance:High (Group 1 schools
have an overall prevalence of 38% heavy/
moderate worm infection in 1998, com-
pared to the initial survey in control schools
in 1999, where it was 52%.)
Loss of clusters: Low (none reported)
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Miguel 2004 (Cluster) (Continued)
Incorrect analysis: Low (correctly adjusted
for clustering).
Comparability with RCTs randomizing in-
dividuals: high (Analysis 4.7)
The intervention was a package includ-
ing deworming drugs for soil transmitted
helminths, praziquantel to treat schistoso-
miasis in schools with >30% prevalence,
and health promotion interventions. In ad-
dition 27/75 schools were involved in other
NGO projects which consisted of finan-
cial assistance for textbook purchase and
classroom construction, and teacher per-
formance incentives. The distribution of
the latter interventions is not clear
These co-interventions confound the po-
tential effects of deworming drugs to treat
STHs. However, the authors kindly pro-
vided a re-analysis of their data, with the
praziquantel treated schools removed from
the analysis. This represents as subgroup
analysis of the original quasi-randomized
comparison
Nga 2009
Methods Randomized controlled trial
Length of follow up: 4 months
Participants Number analysed for primary outcome: 510 randomized
Inclusion criteria: School children aged 6-8 years and written informed consent from
parents/caregivers
Exclusion criteria:Haemoglobin (Hb) concentrations <80 g/L, chronic illness, congenital
abnormalities, mental or severe physical handicap, severe malnutrition ([z-scores for
weight-for-height (WHZ) <-3.0 SD), obesity (BMI >=25 or z-scores for WHZ >+2 SD)
, or receiving deworming within the previous 6 months
Interventions Single dose versus placebo
1. Non-fortified biscuit plus placebo deworming-treatment (placebo);
2. Multi-micronutrient-fortified biscuit plus placebo deworming-treatment;
3. Non- fortified biscuit plus deworming treatment with albendazole(400 mg);
4. Multi-micronutrient-fortified biscuits plus deworming treatment with Albendazole
(400 mg)
Treatment strategy: randomized and treated all children
Outcomes 1. Haemoglobin
2. Mean mid-upper arm circumference
3. Cognitive function
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Nga 2009 (Continued)
4. Change in weight-for-age (WAZ), height-for-age (HAZ), and WHZ, using the Epi-
Info program (version 6.0, CDC) and the National Center for Health Statistics/WHO
nutritional reference data
Not included in review: Changes in zinc, iodine, and ferritin concentration; worm
prevalence
Measured but not reported:
Weight and height recorded at baseline and end point but only baseline data reported.
Skin fold thickness recorded at baseline and end point, but no data reported
Notes Location:Vietnam
Community category: 2
This study was supported by the Neys-van Hoogstraten Foundation, The Netherlands,
and the Ellison Medical Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated. “pupils were allo-
cated to 1 of the 4 intervention groups
based on a computer generated list,
matched on age (12-mo age groups) and
sex, and using a block size of 8 by one of the
researchers not involved in the field work”
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded. “All investigators, field assistants,
teachers, and children did not know the
codes of the study groups.”
Placebo identical to treatment (orange
chewable tablet).
Incomplete outcome data (attrition bias)
All outcomes
Low risk 482/510 randomized participants were
evaluated. Reasons for drop-out: moved=
12, surgery=2, refusal to participate (n =
14), balanced across intervention groups.
Inclusion of all randomized participants
(number evaluable/number randomized):
94.5% (482/510)
Selective reporting (reporting bias) High risk Three outcomes (weight, height and skin
fold thickness) not reported adequately
Other bias Low risk No obvious other source of bias.
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Nokes 1992
Methods Randomized controlled trial
Length of follow up: 2.25 months (9 weeks)
Participants Number analysed for primary outcome: 103; age range 9 to 12 years
Inclusion criteria: children from 3 schools in Mandeville; Trichuris egg counts > 1900,
but low hookworm counts on 2 occasions before the trial separated by 3 months
Exclusion criteria: twins; severe illness; physical handicaps; neurological disorders
Interventions Single dose versus placebo
1. Albendazole: 400 mg daily for 3 days (SmithKlineBeecham)
2. Placebo: identical
Treatment strategy: screened children then randomized and treated infected children
Outcomes Cognitive tests: digit span forwards/backwards; arithmetic and coding from Wechsler
Intelligence Scale for Children; fluency and listening comprehension from the Clinical
Evaluation of Language functions; and matching familiar figures test
Not included in review: stool egg counts at baseline and 10 days (prevalence and arith-
metic mean); height and weight (expressed as % NCHS standard) iron status; school
attendance; IQ; socioeconomic status; educational opportunity measures at baseline
Outcomes not reported: nutritional outcomes at 9 weeks cited as too short a follow-up
period to demonstrate a change. School attendance only measured at baseline
Notes Location: Jamaica
Community category: 1
There was an infected placebo group and an “uninfected control group”
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”; no further details re-
ported
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 73%(103/140) of randomizedparticipants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 73% (103/140)
Selective reporting (reporting bias) Unclear risk Pyschometric tests reported; other out-
comes such as nutrition not reported
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Nokes 1992 (Continued)
Other bias Low risk No obvious other source of bias
Olds 1999
Methods Randomized controlled trial
Length of follow up: 6 months for randomized comparison
Participants Number analysed for primary outcome: 1518 randomized, 90% followed up at 6months
Inclusion criteria: School age children
Exclusion criteria: Failure to submit 2 stool specimens prior to the initial treatment,
known allergy to either drug, treatment with either drug within 6 months, lack of
consent, and marriage or possible pregnancy
Interventions Albendazole (400mg) plus praziquantel (40 mg/ kg)
Praziquantel plus an albendazole placebo
Albendazole plus a praziquantel placebo,
Both placebos.
Outcomes No useable data.
Not included in review:Ultrasound, physical examination and history findings, duplicate
stool and urine measurements of egg counts
Measured but not reported:
Weight, height, skinfold thickness (subscapular, triceps, and abdominal) and haemoglo-
bin recorded at baseline and end point but only baseline data reported. Data for side
effects not useable in review
Notes Location: China, Philippines and Kenya
Community category: 1
randomized comparison up to 6 months at which point all infected children were treated
as needed, and followed up until one year
There was no difference between the side effect rate from albendazole or the double
placebo
Result text: “No statistically significant improvement was seen in haemoglobin after
albendazole treatment. In the study population as a whole, no significant differences
between treatment groups were seen in any of the growth and anthropometric measure-
ments.”
Source of funding: Tropical Disease Research of the World Health Organization
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated. “Randomization lists
were prepared byWHO/TDR using a ran-
domized block design with a block size of
80”
Allocation concealment (selection bias) Low risk Central allocation
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Olds 1999 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, key personnel and outcome
assessment was blinded. “The randomiza-
tion code was not broken until after the 6-
month results were tabulated and submit-
ted to WHO”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1518 participants, 90% at 6 months fol-
low-up, 83% at one year, no further de-
tails. Inclusion of all randomized partici-
pants (number evaluable/number random-
ized): 90% (1366/1518)
Selective reporting (reporting bias) High risk Weight, height, skinfold thickness and hae-
moglobin recorded at baseline and end
point but only baseline data reported
Other bias Low risk No obvious other source of bias
Palupi 1997
Methods Randomized controlled trial
Length of follow up: 9 weeks (2.25 months)
Participants Number analysed for primary outcome: 191
Inclusion criteria: children ages 2 to 5 years registered at village health centres
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Albendazole: 400 mg plus 30 mg elemental iron weekly
2. Elemental iron: 30 mg weekly
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
2. Mean change in height post-treatment
3. Mean change in haemoglobin post-treatment
4. Mean haemoglobin post-treatment
Not included in review: z-scores for height-for-age, weight-for-age, andweight-for-height
(NCHS reference)
Notes Location: Java, Indonesia
Community category: 2
Source of funding: Kimia Farma Indonesia.
Risk of bias
Bias Authors’ judgement Support for judgement
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Palupi 1997 (Continued)
Random sequence generation (selection
bias)
Unclear risk “The children were randomly divided into
three, equal-sized treatment groups”, no
further details reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind, participants
were blinded, unclearwhether provider and
assessor were
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97% (289/299) of enrolled participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 97% (289/299)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other source of bias.
Rousham 1994 (Cluster)
Methods Cluster-randomized controlled trial
Method to adjust for clustering: not adjusted
Cluster unit: village.
Average cluster size: 114.
ICCs: not reported.
Length of follow up: 18 months
Participants Number analysed for primary outcome: 1402
Inclusion criteria: children ages 2 to 6 years from 13 villages surrounding a mother and
child health centre; subgroup living in 8 villages within waking distance of health centre
analysed for additional outcomes
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Mebendazole: 500 mg (Janssen) every 2 months
2. Placebo
3. Pyrantel pamoate and mebendazole: initial dose of 10 mg/kg pyrantel pamoate (Com-
bantrin, Pfizer, UK) then mebendazole 500 mg bimonthly for 8 months (4 doses)
Treatment strategy: randomized and treated all children
Outcomes 1. ANOVAs for change in z-scores for z-scores for height-for-age, weight-for-age, and
weight-for-height (NCHS reference)
2. Change in mid-upper arm circumference at 6, 12, and 18 months (no SD)
3. Other outcomes measured but not reported: height; weight; stool examination for
prevalence and intensity in subgroup (eggs/g: modified sedimentation technique); sub-
group also analysed for intestinal permeability, albumin, alpha-1-antichymotrypsin, to-
tal protein every 2 months
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Rousham 1994 (Cluster) (Continued)
Notes Location: Bangladesh
Community category: 1
No adjustment made for cluster randomization
Source of funding: the Overseas Development Administration and the University of
Cambridge Maintenance Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study was described as randomized, no
further details reported
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and field
workers were blinded, unclear if assessment
was blinded. “The treatment and placebo
tablets were given in a double-blind man-
ner; neither the fieldworkers nor the par-
ents were aware of the group to which they
belonged”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94% (1402/1476) of enrolled participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 94% (1402/1476)
Selective reporting (reporting bias) Low risk Not all pre-specified outcomes reported
Other bias Low risk Recruitment bias: unclear (Not known if
children shift clinics in the light of the in-
tervention)
Baseline imbalance: low (Nodifferences ap-
parent)
Loss of clusters: low (none reported)
Incorrect analysis: not adjusted (high risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Sarkar 2002
Methods Randomized controlled trial
Length of follow up: 4 months (16 weeks)
Participants Number analysed for primary outcome: 81
Inclusion criteria: children ages 2 to 12 living in Mirpur slum infected with Ascaris
Exclusion criteria: none stated
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Sarkar 2002 (Continued)
Interventions Single dose versus placebo
1. Pyrantel pamoate: 11 mg/kg (Combantrin, Pfizer, Bangladesh)
2. Placebo
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Mean change in weight post-treatment
2. Mean weight post-treatment
3. Mean change in height post-treatment
4. Mean height post-treatment
Not included in review: median % weight-for-age, weight-for-height, and height-for-
age
Notes Location: Bangladesh
Community category: 1
Source of funding: research grant from theWorldBank andwas fundedby theBangladesh
National Nutrition Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random table”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind”; “The syrups were identi-
cal in appearance and flavor and were pack-
aged in identical containers. Randomized
patient numbers were labeled on the bot-
tles to maintain the double blind design”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94% (81/85) of randomized participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 94% (81/85)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported
Other bias Low risk No obvious other source of bias
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Simeon 1995
Methods Randomized controlled trial
Length of follow up: 6.5 months (26 weeks)
Participants Number analysed for primary outcome: 392; age range 6 to 12 years
Inclusion criteria: children in grades 2 to 5 of 14 schools in Jamaica with intensities of
Trichura > 1200 eggs/g
Exclusion criteria: children with mental handicaps identified by their teachers
Interventions Multiple doses versus placebo
1. Albendazole: 800 mg (400 mg in each of 2 days), repeated at 3 months and 6 months
2. Identical placebo
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Main study (264 children)
Wide range achievement test: reading, arithmetic, and spelling subtests; school atten-
dance from children with class registers pre- and post-intervention, height-for-age z-
score, body mass index pre- and post-intervention
2. Subgroup 1 (189 infected children from original population)
Digit span; verbal fluency test; visual search; number choice; French vocabulary learning
3. Subgroup 2 (97 children from grade 5)
French learning; digit spans (forward and backward); Corsi block span; verbal fluency;
picture search; silly sentences
Other outcomes measured but not reported: stool at baseline and at 8 weeks after sec-
ond treatment round (Kato): prevalence and intensity, weight, height, z-scores (NCHS
standard)
Notes Location: Jamaica
Community category: 1
Source of funding: grant from the James S. McDonnell Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-numbers table
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Paricipants blinded; unclear whether asses-
sors were
Incomplete outcome data (attrition bias)
All outcomes
Low risk 96%(392/407) of randomizedparticipants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 96% (392/407)
Selective reporting (reporting bias) Low risk All stated outcomes reported
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Simeon 1995 (Continued)
Other bias Low risk No obvious other source of bias
Solon 2003
Methods Randomized controlled trial
Length of follow up: 16 weeks
Participants Number analysed for primary outcome: 808/851
Inclusion criteria: Children in grades 1-6
Exclusion criteria: Children with Haemoglobin < 8 g/dL
Interventions Single dose versus placebo
1. Fortified beverage (multivitamin and iron) twice per day for 16 weeks with an-
thelmintic therapy (Albendazole 400mg)
2. Fortified beverage with placebo anthelmintic therapy
3. Non-fortified beverage with anthelmintic therapy (400mg)
4. Non-fortified beverage with placebo anthelmintic therapy
Outcomes No useable data.
Not included in review: Urine iodine, stool egg count
Measured but not reported:Weight, height, haemoglobin, physical fitness (Harvard step
test), heart rate, cognitive ability measured by the Primary Mental Abilities Test for
Filipino Children. The test measures verbal, non verbal and quantitative skills
Notes Location: Philippines
Community category: 2
Narrative results:
No significant difference in change in weight. Deworming improved the iron status of a
subgroup ofmoderately to severely subjects. Deworming had either no effect or a negative
effect on fitness scores, and the effect on heart rate was inconclusive. Deworming had
either no effect or a negative effect on mental ability scores
Sources of support: The Nutrition Center of the Philippines, The Procter & Gamble Co
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization at individual level, no fur-
ther details.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study. “Both the researchers
and the study participants were blinded to
the treatment assignment of each child”
“Placebo bever-
age and placebo anthelmintic pills were in-
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Solon 2003 (Continued)
distinguishable from their counterparts in
appearance, smell and taste”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 808/851 (95%) enrolled participants were
evaluated, no reasons for withdrawal re-
ported. Inclusion of all randomized partici-
pants (number evaluable/number random-
ized): 95% (808/851)
Selective reporting (reporting bias) High risk Nutritional and haemoglobin outcomes
not fully reported.
Other bias Low risk No obvious other source of bias.
Stephenson 1989
Methods Randomized controlled trial
Length of follow up: 6 months
Participants Number analysed for primary outcome: 150
Inclusion criteria: all available children in lower grades (standards 1 and 2) in Mvindeni
Primary School, Kwale district (unscreened); subgroup of 36 boys chosen; haemoglobin
> 8 g/dL; willing to co-operate in physical tests; pre-pubertal
Exclusion criteria: haemoglobin < 8 g/dL.
Interventions Single dose versus placebo
1. Albendazole: 2 x 200 mg (SmithKline and French)
2. Placebo: identical
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean mid-upper arm circumference
6. Mean change in mid-upper arm circumference
7. Mean triceps skinfold thickness
8. Mean change in triceps skinfold thickness
9. Mean subscapular skinfold thickness
10. Mean change in subscapular skinfold thickness
Not included in review: all above converted to %median for sex and age; prevalence and
mean egg counts (arithmetic and geometric means); Harvard Step Test heart rates and
score for subgroup
Notes Location: Kenya
Community category: 1
Source of funding: Smith Kline & French Laboratories, Ltd., and the Edna McConnell
Clark Foundation, grant 284-0120
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Stephenson 1989 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “allocated at random within sex”, no fur-
ther details reported
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded, tablets identical for
treatment and placebo; “Both examina-
tionswere carried outwith the same teamof
workers, each doing the same procedures,
and were done in a blind fashion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 88%(150/171) of randomizedparticipants
were evaluated, reasons for losses to follow
up not reported. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 88% (150/171)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk No obvious other source of bias
Stephenson 1993
Methods Randomized controlled trial
Length of follow up: 3.6 months (subgroup) and 8.2 months (main study)
Participants Number analysed for primary outcome: 284
Inclusion criteria: all school children (unscreened) in grades 1 to 5 in Mvindeni Primary
School
Subgroup (53 analysed) of 60 boys chosen because haemoglobin > 80 g/L, willing to
cooperate in physical tests and appetite tests, pre-pubertal, infected with at least 1 of
helminths (screened), hookworm < 20,000 eggs/g; hookworm or Trichuris count > 1000
eggs/g or Ascaris > 4000 eggs/g
Exclusion criteria: Severe anaemia (haemoglobin < 75 g/L)
Interventions Multiple doses versus placebo
1. Albendazole (single dose) plus placebo: 600 mg (3 x 200 mg) SmithKline Beecham
at outset, identical placebo at 3.6 months
2. Albendazole (multiple doses): single dose 600 mg repeated at 3.6 months
3. Placebo: identical placebo
Treatment strategy: randomized and treated all children (but infected children for ap-
petite/activity outcomes)
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Stephenson 1993 (Continued)
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean mid-upper arm circumference
6. Mean change in mid-upper arm circumference
7. Mean triceps skinfold thickness
8. Mean change in triceps skinfold thickness
9. Mean subscapular skinfold thickness
10. Mean change in subscapular skinfold thickness
11. Mean haemoglobin post-treatment
12. Mean change in haemoglobin post treatment
Not included in review: prevalence, eggs/g: geometric and arithmetic mean; converted
to percentage of median for age and sex using NCHS references; % weight-for-age, %
height for age; % weight-for-height; % arm circumference for age; % triceps for age; %
subscapular for age; Harvard Step Test; appetite (self-rating and snack consumed intake
in kilojoules)
Notes Location: Kwale, Kenya
Community category: 1
Source of funding: supported in part by Thrasher Research Fund and SmithKline
Beecham, Ltd.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “at randomwithin sex by descending hook-
worm egg count”.
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded, tablets identical for
treatment and placebo; “Both examina-
tions were conducted by the same team,
each doing the same procedures, and were
done in a blind fashion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 86%(284/328) of randomizedparticipants
were evaluated, reasons for losses to follow
up not reported. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 86% (284/328)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk No obvious other source of bias
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Stoltzfus 1997 (Cluster)
Methods Cluster-randomized controlled trial
Method to adjust for clustering: generalised estimating equations
Cluster unit: school.
Average cluster size: 255.
ICCs: not reported.
Length of follow up: 12 months
Participants Number analysed for primary outcome: 3063; mean age 10.5 years
Inclusion criteria: children in grades 1 to 5 from 12 randomly selected schools on Pemba
island; only grades 1 to 4 included in evaluation of nutritional effect
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Mebendazole: 500 mg twice yearly
2. Mebendazole: 500 mg 3 times a year
3. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Weight gain
2. Height gain
3. Change in haemoglobin at 12 months
Estimates are provided from multiple regression models taking into account various
baseline differences for 2 subgroups above and below 10 years old. Unadjusted outcomes
not presented. (These 2 groups were combined in the Dickson 2000a Cochrane Review.
)
Other outcomes measured but not reported: micronutrient status (blood) for protopor-
phyrin and serum ferritin; stool egg count (Kato-Katz); z-scores for height-for-age and
weight-for-height; body mass index
Notes Location: Zanzibar, Tanzania
Community category: 1
Appropriate adjustment made for cluster randomization using general estimating equa-
tion
Source of funding: Funded through cooperative agreement DAN-5116-1-00-8051-00
between The Johns Hopkins University and the Office of Health and Nutrition, United
States Agency for International Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 3 schools randomly selected from each of
the 4 districts, and then allocated
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported
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Stoltzfus 1997 (Cluster) (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 84% (3063/3605) of randomized partici-
pants were evaluated, reasons for losses to
follow up not reported. Inclusion of all ran-
domized participants (number evaluable/
number randomized): 84% (3063/3605)
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported ad-
equately.
Other bias Low risk Recruitment bias: low (Unlikely to change
schools)
Baseline imbalance: low (no differences ap-
parent)
Loss of clusters: low (none reported)
Incorrect analysis: cluster adjusted (low
risk).
Comparability with RCTs randomising in-
dividuals: unclear
Stoltzfus 2001
Methods Randomized control trial (factorial design)
Length of follow up: 12 months
Participants Number analysed for primary outcome: 359 in mebendazole arm aged 6 to 59 months
Inclusion criteria: all children in Kengeja village, with age reported as 3 to 56 months
by parents; 3 months before planned start of trial (pre-school children)
Exclusion criteria: severe anaemia (< 70 g/L)
Interventions Multiple doses versus placebo
1. Mebendazole: 500 mg given every 3 months at home visits
2. Placebo: identical
Treatment strategy: randomized and treated all children
Both groups also received: 0.5 mL ferrous sulfate (20 mg/mL); 10 mg iron daily for 1
year or placebo as per factorial design
Outcomes 1. Cognitive outcomes: motor and language development by parents reporting gross
motor and language milestones using scoring system developed specifically for the trial
2. Anthropometric measures presented in a stratified manner: (< 30 months, > 30
months), and presented as proportion of children with small arm circumference, mild
wasting, and stunting
3. Proportion of children with poor appetite, and proportion with severe anaemia are
presented for the whole group
4. Iron indices (not disaggregated, independent of the iron randomization)
Not included in review: prevalence and egg counts (no SD/SEM); motor and language
scores (results of multiple regression and correlations; raw data not reported) haemoglo-
bin (results not reported by randomized comparisons)
Others measured but not reported: stool (Kato-Katz); weight; height; malaria film; fer-
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Stoltzfus 2001 (Continued)
ritin; appetite as reported by mothers
Notes Location: Zanzibar, Tanzania
Community category: 2
Factorial design, with households randomized to iron, random allocation of mebenda-
zole by child, stratified by iron allocation and age grouped households. An iron with
mebendazole treatment term was tested in all regression models, but it did not reach
significance
Source of funding: Thrasher Research Fund between The Johns Hopkins University and
the United States Agency for International Development, AL Pharma, Baltimore, MD,
and Pharmamed, Malta
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized by “blocks of 4”, no further
details reported
Allocation concealment (selection bias) Low risk Pills in bottles with unique treatment
codes, assignedby 1 investigator, codes kept
in sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and provider were blinded; un-
clear whether assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 52% (359/684) enrolled participants were
evaluated. Inclusion of all randomized par-
ticipants (number evaluable/number ran-
domized): 52% (359/684 = 52%)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias High risk No obvious other source of bias
Sur 2005
Methods Randomized controlled trial
Length of follow up: 12 months
Participants Number analysed for primary outcome: 683
Inclusion criteria: all children aged 2 to 5 in slum area of Tiljala identified and enrolled
Exclusion criteria: major illnesses; birth defects; and unwillingness to participate
Interventions Multiple doses versus placebo
1. Albendazole: 400 mg in a vitamin B complex base liquid; repeated at 6 months
2. Placebo: vitamin B complex base
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Sur 2005 (Continued)
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment (presented graphically)
Other outcomes measured but not reported: stool samples from random sample of 30%
(formalin concentration technique) for prevalence of Ascaris; weight-for-age; diarrhoeal
episodes
Notes Location: India
Community category: 2
Source of funding: the Indian Council of Medical Research, New Delhi, India
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers se-
quence
Allocation concealment (selection bias) Low risk Identical coded bottles
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97% (683/702) of enrolled participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 97% (683/702)
Selective reporting (reporting bias) High risk Incomplete reporting of some outcomes
(prevalence of Ascaris in stools; weight-for-
age; diarrhoeal episodes).
Other bias Low risk No obvious other source of bias
Watkins 1996
Methods Randomized controlled trial
Length of follow up: 6 months
Participants Number analysed for primary outcome: 226 for nutritional outcomes, reduced for cog-
nitive outcomes; age 7 to 12 years
Inclusion criteria: children attending grades 1 to 4 in primary schools in the Guatemala
highlands
Exclusion criteria: > 12 years; deworming medicine in last year
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Watkins 1996 (Continued)
Interventions Multiple doses versus placebo
1. Albendazole: 2 x 200 mg at baseline and 12 weeks
2. Placebo: identical at baseline and 12 weeks
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. School performance: attendance rates of children actively attending school measured
using attendance books, dropout rates
6. Mean mid-upper arm circumference
7. Mean change in mid-upper arm circumference
8. Cognitive tests: Interamerican vocabulary test, Interamerican reading test, Peabody
picture vocabulary test
Not included in review: egg counts (Kato-Katz: arithmetic and geometric mean); z-scores
(NCHS-CDC-WHO reference) for weight-for-age, change in weight-for-age, height,
change inheight, height-for-age, change inheight-for-age, weight-for-height, and change
in height-for-age
Notes Location: Guatemala
Community category: 1
Source of funding: Pew Charitable Trusts, the US Agency for International Develop-
ment University Development and Linkage Program, the Children’s Miracle Network
Telethon, and the ARCS Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “stratified by gender and age and then ran-
domly assigned”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The children and field workers were un-
aware of treatment group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 90%(226/250) of randomizedparticipants
were evaluated. “No differences were de-
tected in treatment group assignment, ini-
tial age, anthropometry, SES, and worm
status between the 228 children who re-
mained in the study and the 18 who
dropped out.” Sample size for nutritional
data is smaller due to missing data. Inclu-
sion of all randomized participants (num-
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Watkins 1996 (Continued)
ber evaluable/number randomized): 90%
(226/250)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk No other obvious source of bias.
Willett 1979
Methods Randomized controlled trial
Length of follow up: 12 months
Participants Number analysed for primary outcome: 268; age range 6 to 91 months
Inclusion criteria: pre-school children from Ubiri village who attended clinic and pro-
duced a stool sample
Exclusion criteria: none stated
Interventions Multiple doses
1. Levamisole syrup: 2.5 mg/kg every 3 months
2. Flavoured sucrose syrup: every 3 months
Treatment strategy: randomized and treated all children
Outcomes 1.Growth rates in both groups, and subgroup of those infected; these have been corrected
for various factors using analysis of covariance (unadjusted data are not reported and the
growth rates are not presented with any measure of variance)
Measured but not reported: height; length; stool egg count in subgroup (Kato method)
; growth rates using least square method
Notes Location: Tanzania
Community category: 3
Source of funding: Research and Publications Committee, University of Dar es Salaam.
Analysis was supported by a training grant (HL 05998-04) from the National Heart,
Lung and Blood Institute, NIH, DHEW Bethesda, MD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-numbers table
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk “children were weighed and measured as
before by a person unaware of their treat-
ment status”; placebo and treatment given
as a flavoured syrup
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Willett 1979 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 78%(268/341) of randomizedparticipants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 78% (268/341)
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported
Other bias Low risk No obvious other source of bias
CI: confidence interval; Community category: a measure of the prevalence and intensity of infection (see Table 1); NCHS: National
Center for Health Statistics: SD: standard deviation; SEM: standard error of the mean.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Araujo 1987 Not a randomized controlled trial.
Beasley 1999 Treatment regimen comprised of albendazole for geohelminths and praziquantel against schistosomiasis versus
placebo
Bhargava 2003 Treatment regimen comprised of albendazole for geohelminths and praziquantel against schistosomiasis versus
placebo
Bhutta 2009 Population with significant comorbidity - 6-24 month old children with severe anaemia (<70 g/L). In popu-
lation with severe anaemia
Boivin 1993 Factorial-designed randomized controlled trial with children allocated to deworming and iron supplementa-
tion, and in which the analysis compares the results for the levamisole and iron group against all the other
groups combined. Thus the analysis is confounded by the iron co-intervention (Included in the Dickson
2000a Cochrane Review).
Cooper 2006 Study of allergy with no outcomes of interest.
Cowden 2000 Not a randomized controlled trial.
Diouf 2002 Intervention comprised mebendazole, vitamin A, and iron supplementation and metronidazole as a combined
intervention versus placebo
Evans 1986 Treatments randomized, but some placebo groups accessed treatment. Analysis was by the treatment received,
and randomization was ignored. (Included in the Dickson 2000a Cochrane Review).
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(Continued)
Fernando 1983 2 villages allocated to treatment or no treatment on the basis of a coin toss. Essentially a cluster-randomized trial
with 2 large clusters (Included in the Dickson 2000a Cochrane Review, which reported that no conclusions
could be drawn from the results due to selective reporting)
Forrester 1998 Treatment regimen comprised of 3 days of albendazole versus 1 day of albendazole and 2 days of placebo
versus 1 day of pyrantel and 2 days of placebo
Friis 2003 Combined treatment regimen albendazole for geohelminths and praziquantel for Schistosoma mansoni versus
placebo.
Gilgen 2001 Population consists of adults.
Gupta 1982 Only two units of allocation for relevant comparison. Children randomly divided into 4 groups, “taking care
that age distribution was similar in each group”. The 4 groups were then allocated 1 of 4 different single
treatment regimens; no details given
Hadidjaja 1998 Cluster-randomized controlled trial with 2 units of allocation tomebendazole and placebo. Authors stated that
there were differences in environmental sanitary conditions in the clusters (Included in the Dickson 2000a
Cochrane Review, but it was noted that the groups were not comparable and there was high loss to follow up)
Hathirat 1992 Treatment regimen comprised of albendazole for geohelminths and iron versus placebo
Jalal 1998 No relevant outcomes.
Jinabhai 2001a Treatment regimen comprised of albendazole for geohelminths and praziquantel against schistosomiasis versus
placebo
Jinabhai 2001b Treatment regimen comprised of albendazole for geohelminths and praziquantel against schistosomiasis versus
placebo
Karyadi 1996 Not a randomized controlled trial.
Krubwa 1974 Not a randomized controlled trial.
Kvalsvig 1991b The researchers were unable to collect outcome data after treatment due to major floods in the area
Latham 1990 Population with schistosomiasis treated with praziquantel.
Marinho 1991 Treatment regimen comprised of mebendazole and metronidazole versus placebo
Mwaniki 2002 Treatment regimen albendazole for geohelminths and praziquantel for schistosomiasis versus placebo
Pollitt 1991 Not described as randomized; conference proceedings.
Rohner 2010 Treatment regimen albendazole for geohelminths and praziquantel for schistosomiasis versus placebo
Steinmann 2008 No relevant outcomes.
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(Continued)
Stephenson 1980 Treatment consisted of levamisole with no untreated controls
Stephenson 1985 Treatment regimen metrifonate used to treat Schistosoma haematobium versus placebo
Tanumihardjo 1996 No relevant outcomes.
Tanumihardjo 2004 The only randomisation is the timing of the deworming medicine
Taylor 2001 Treatment regimen albendazole for geohelminths andpraziquantel for Schistosoma haematobium versus placebo.
Thein-Hlaing 1991 3/21 intervention villages were not randomly allocated, and unclear how intervention and control villages
were allocated as there was a large imbalance (8 intervention and 13 non-intervention villages)
Uscátegui 2009 Study in population with malaria.
Wright 2009 No relevant outcomes.
Yang 2003 Did not consider nutritional or cognitive outcome measures.
Characteristics of ongoing studies [ordered by study ID]
Alam 2006
Trial name or title “Relative efficacy of two regimens of ante-helminthic treatment”
Methods Clinical trial
Participants Total enrolment: 200
Inclusion criteria: age 2 to 5 years; not suffering from serious chronic illness; stool test positive for soil-
transmitted helminths; not taken any anthelminthic drug in previous 6 months; parents/guardian agree their
child’s participation
Exclusion criteria: age < 2 years and > 5 years; stool test negative for any intestinal helminth; suffering from
serious chronic illness; parents/guardian not willing to give consent for their child’s participation; if he/she
receives any anthelminthic drug after survey but before the study interventions
Interventions 1. Conventional treatment of 400 mg of albendazole in a single dose at 6-month interval
2. Intervention group: 400 mg of albendazole in a single-dose treatment at 3-month interval
Outcomes Primary
1. To determine the relative efficacy of de-worming at every 3 months versus every 6 month single dose of
albendazole treatment
Secondary
2. To compare additional morbidity information such as diarrhoeal diseases, respiratory tract infections,
nutritional status and E. histolytica associated morbidity between 2 groups
Starting date Not yet recruiting
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Alam 2006 (Continued)
Contact information Mohammad M AlamMBBS, Principal Investigator, ICDDR,B: Centre for Health and Population Research,
masud icddrb@yahoo.com
Notes ClinicalTrials.gov identifier: NCT00367627
Sources of support: International Centre for Diarrhoeal Disease Research, Bangladesh (sponsor)
Elliot 2007
Trial name or title The impact of helminths on the response to immunization and on the incidence of infection and disease in
childhood in Uganda: design of a randomized, double-blind, placebo-controlled, factorial trial of deworming
interventions delivered in pregnancy and early childhood [ISRCTN32849447]
Methods The trial has three randomized, double-blind, placebo-controlled interventions at two times, in two people: a
pregnant woman and her child. Pregnant women are randomized to albendazole or placebo and praziquantel
or placebo. At age 15 months their children are randomized to three-monthly albendazole or placebo, to
continue to age five years. The proposed designation for this sequence of interventions is a 2 X 2(x2) factorial
design
Participants A cohort of 2500 women has been recruited.
Interventions 1. Praziquantel + albendazole
2. Praziquantel + placebo matching albendazole
3. Placebo matching praziquantel + albendazole
4. Placebo matching praziquantel + placebo matching albendazole
Outcomes The principal outcomes are:
• Immunological responses to BCG and tetanus immunization
• Incidence of infection in childhood with malaria and Mycobacterium tuberculosis.
• Incidence of infectious and atopic disease events in childhood (pneumonia, diarrhoea, malaria,measles,
tuberculosis and vertical HIV transmission; atopic eczema, urticaria, allergic rhinitis and conjunctivitis,
wheeze).
Secondary outcomes are anaemia, growth and development.
Starting date 01/04/2003
Contact information Dr Alison Elliott, Uganda Virus Research Institute, Entebbe, Uganda
Notes Added as of 21/03/2012:
Funding has been awarded to allow follow-up to 2016, this will allow the assessment of outcomes between
ages 5 and 12 years. Additional outcome measures have been added for this age group
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D A T A A N D A N A L Y S E S
Comparison 1. Screened for infection - Single dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 3 149 Mean Difference (IV, Fixed, 95% CI) 0.58 [0.40, 0.76]
2 Height (cm) 2 136 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.15, 0.35]
3 Mid-upper arm circumference
(cm)
3 112 Mean Difference (IV, Fixed, 95% CI) 0.28 [0.12, 0.44]
4 Triceps skin fold thickness (mm) 2 68 Mean Difference (IV, Fixed, 95% CI) 0.77 [0.46, 1.08]
5 Subscapular skin fold thickness
(mm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Body mass index 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7 Haemoglobin (g/dL) 2 108 Mean Difference (IV, Fixed, 95% CI) 0.37 [0.10, 0.64]
Comparison 2. Screened for infection - Multiple dose, outcomes in the first year
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Body mass index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 School attendance (days present
at school)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Comparison 3. Target population treated - Single dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 9 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 High prevalence 4 629 Mean Difference (IV, Random, 95% CI) 0.73 [-0.12, 1.57]
1.2 Moderate prevalence 2 873 Mean Difference (IV, Random, 95% CI) 0.11 [-0.16, 0.38]
1.3 Low prevalence 3 1556 Mean Difference (IV, Random, 95% CI) -0.09 [-0.22, 0.03]
2 Height (cm) 7 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 High prevalence 3 566 Mean Difference (IV, Random, 95% CI) 0.25 [-0.10, 0.60]
2.2 Moderate prevalence 1 191 Mean Difference (IV, Random, 95% CI) -0.20 [-0.47, 0.07]
2.3 Low prevalence 3 1556 Mean Difference (IV, Random, 95% CI) -0.26 [-0.74, 0.21]
3 Mid-upper arm circumference
(cm)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 High prevalence 3 546 Mean Difference (IV, Random, 95% CI) 0.36 [0.08, 0.64]
3.2 Moderate prevalence 1 482 Mean Difference (IV, Random, 95% CI) 0.19 [-0.01, 0.40]
3.3 Low prevalence 1 222 Mean Difference (IV, Random, 95% CI) -0.3 [-0.52, -0.08]
4 Triceps skin fold thickness (mm) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
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4.1 High prevalence 2 339 Mean Difference (IV, Random, 95% CI) 1.50 [0.91, 2.08]
5 Subscapular skin fold thickness
(mm)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 High prevalence 2 339 Mean Difference (IV, Fixed, 95% CI) 1.29 [1.13, 1.44]
6 Haemoglobin (g/dL) 3 1005 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.05, 0.17]
6.1 Moderate prevalence 2 658 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.06, 0.17]
6.2 Low prevalence 1 347 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.24, 0.36]
7 Harvard Step Test (measure of
physical well being)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 High prevalence 2 86 Mean Difference (IV, Fixed, 95% CI) 6.0 [4.31, 7.69]
Comparison 4. Target population treated - Multiple dose, outcomes in the first year
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 7 2460 Mean Difference (IV, Random, 95% CI) 0.06 [-0.17, 0.30]
1.1 High prevalence 2 414 Mean Difference (IV, Random, 95% CI) 0.50 [-0.25, 1.25]
1.2 Moderate prevalence 2 811 Mean Difference (IV, Random, 95% CI) 0.03 [-0.20, 0.26]
1.3 Low prevalence 3 1235 Mean Difference (IV, Random, 95% CI) -0.23 [-0.60, 0.14]
2 Height (cm) 6 1779 Mean Difference (IV, Random, 95% CI) -0.02 [-0.17, 0.12]
2.1 High prevalence 2 415 Mean Difference (IV, Random, 95% CI) 0.02 [-0.15, 0.18]
2.2 Moderate prevalence 1 129 Mean Difference (IV, Random, 95% CI) 0.10 [-0.46, 0.66]
2.3 Low prevalence 3 1235 Mean Difference (IV, Random, 95% CI) -0.17 [-0.59, 0.25]
3 Mid-upper arm circumference
(cm)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 High prevalence 2 395 Mean Difference (IV, Random, 95% CI) 0.24 [-0.07, 0.55]
3.2 Moderate prevalence 1 129 Mean Difference (IV, Random, 95% CI) 0.06 [-0.22, 0.33]
3.3 Low prevalence 1 198 Mean Difference (IV, Random, 95% CI) -0.35 [-0.65, -0.05]
4 Triceps skin fold thickness (mm) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 High prevalence 1 188 Mean Difference (IV, Random, 95% CI) 1.80 [1.52, 2.08]
4.2 Moderate prevalence 1 130 Mean Difference (IV, Random, 95% CI) -0.30 [-1.28, 0.68]
5 Subscapular skin fold thickness
(mm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 High prevalence 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Haemoglobin (g/dL) 4 807 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.14, 0.13]
6.1 Moderate prevalence 2 464 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.15, 0.19]
6.2 Low prevalence 2 343 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.28, 0.17]
7 School attendance (days present
at school)
2 Mean Difference (Random, 95% CI) Subtotals only
7.1 High prevalence (Miguel
1998 comparison)
2 Mean Difference (Random, 95% CI) 0.04 [-0.06, 0.14]
7.2 High prevalence (Miguel
1999 comparison)
2 Mean Difference (Random, 95% CI) 0.02 [-0.04, 0.08]
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Comparison 5. Target population treated - Multiple dose, outcomes after the first year
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 5 Mean Difference (Random, 95% CI) Subtotals only
1.1 High prevalence 1 Mean Difference (Random, 95% CI) 0.0 [-0.14, 0.14]
1.2 Moderate prevalence 1 Mean Difference (Random, 95% CI) 0.15 [-0.02, 0.33]
1.3 Low prevalence 3 Mean Difference (Random, 95% CI) 0.37 [-0.40, 1.15]
2 Height (cm) 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Low prevalence 3 1219 Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.84, 0.31]
3 Haemoglobin (g/dL) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Low prevalence 2 1365 Mean Difference (IV, Fixed, 95% CI) 6.52 [-0.08, 0.08]
4 School attendance (days present
at school)
1 Mean Difference (Fixed, 95% CI) Totals not selected
4.1 High prevalence 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Target population treated - Single dose (low risk of bias for allocation concealment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 2 1029 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.11, 0.19]
1.1 Moderate prevalence 1 682 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.28, 1.28]
1.2 Low prevalence 1 347 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.13, 0.17]
2 Height (cm) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.3 Low prevalence 1 347 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.21, 0.37]
3 Mid-upper arm circumference
(cm)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Moderate prevalence 1 482 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.01, 0.40]
4 Haemoglobin (g/dL) 2 814 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.07, 0.17]
4.1 Moderate prevalence 1 467 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.08, 0.17]
4.2 Low prevalence 1 347 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.24, 0.36]
Comparison 7. Target population treated - Multiple dose, outcomes in the first year (low risk of bias for allocation
concealment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Moderate prevalence 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Haemoglobin (g/dL) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Moderate prevalence 1 326 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.21, 0.16]
95Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school
performance (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 8. Target population treated - Multiple dose, outcomes after the first year (low risk of bias for
allocation concealment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 1 Mean Difference (Fixed, 95% CI) Totals not selected
1.1 High prevalence 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Height (cm) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Low prevalence 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Screened for infection - Single dose, Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 1 Screened for infection - Single dose
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Adams 1994 28 1 (0.32) 27 0.3 (0.51) 62.7 % 0.70 [ 0.47, 0.93 ]
Freij 1979a (1) 6 12.3 (2.91) 7 12.1 (2.29) 0.4 % 0.20 [ -2.68, 3.08 ]
Sarkar 2002 40 0.92 (0.84) 41 0.54 (0.45) 36.9 % 0.38 [ 0.09, 0.67 ]
Total (95% CI) 74 75 100.0 % 0.58 [ 0.40, 0.76 ]
Heterogeneity: Chi2 = 2.92, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 6.35 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours control Favours deworming
(1) End value data
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Analysis 1.2. Comparison 1 Screened for infection - Single dose, Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 1 Screened for infection - Single dose
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Adams 1994 28 0.9 (0.53) 27 0.8 (0.57) 75.6 % 0.10 [ -0.19, 0.39 ]
Sarkar 2002 40 1.2 (1.5) 41 1.1 (0.7) 24.4 % 0.10 [ -0.41, 0.61 ]
Total (95% CI) 68 68 100.0 % 0.10 [ -0.15, 0.35 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours control Favours deworming
Analysis 1.3. Comparison 1 Screened for infection - Single dose, Outcome 3 Mid-upper arm circumference
(cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 1 Screened for infection - Single dose
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Adams 1994 28 0.6 (0.37) 27 0.3 (0.26) 92.9 % 0.30 [ 0.13, 0.47 ]
Freij 1979a (1) 6 14.5 (1.13) 7 14.8 (1.44) 1.3 % -0.30 [ -1.70, 1.10 ]
Freij 1979b (2) 24 14.6 (1.2) 20 14.5 (1.1) 5.7 % 0.10 [ -0.58, 0.78 ]
Total (95% CI) 58 54 100.0 % 0.28 [ 0.12, 0.44 ]
Heterogeneity: Chi2 = 0.98, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00072)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours deworming
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(1) End value data
(2) End value data
Analysis 1.4. Comparison 1 Screened for infection - Single dose, Outcome 4 Triceps skin fold thickness
(mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 1 Screened for infection - Single dose
Outcome: 4 Triceps skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Adams 1994 28 1 (0.69) 27 0.2 (0.47) 98.2 % 0.80 [ 0.49, 1.11 ]
Freij 1979a (1) 6 9.8 (1.51) 7 10.6 (2.59) 1.8 % -0.80 [ -3.07, 1.47 ]
Total (95% CI) 34 34 100.0 % 0.77 [ 0.46, 1.08 ]
Heterogeneity: Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 4.90 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours deworming
(1) End value data
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Analysis 1.5. Comparison 1 Screened for infection - Single dose, Outcome 5 Subscapular skin fold thickness
(mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 1 Screened for infection - Single dose
Outcome: 5 Subscapular skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Adams 1994 28 0.9 (0.53) 27 0.1 (0.94) 0.80 [ 0.39, 1.21 ]
-2 -1 0 1 2
Favours control Favours deworming
Analysis 1.6. Comparison 1 Screened for infection - Single dose, Outcome 6 Body mass index.
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 1 Screened for infection - Single dose
Outcome: 6 Body mass index
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simeon 1995 (1) 206 15.6 (1.3) 201 15.8 (1.4) -0.20 [ -0.46, 0.06 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-0.5 -0.25 0 0.25 0.5
Favours control Favours deworming
(1) End value data
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Analysis 1.7. Comparison 1 Screened for infection - Single dose, Outcome 7 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 1 Screened for infection - Single dose
Outcome: 7 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Adams 1994 (1) 28 10.8 (1.217) 27 10.6 (1.247) 17.2 % 0.20 [ -0.45, 0.85 ]
Stephenson 1993 27 -0.2 (0.6) 26 -0.6 (0.5) 82.8 % 0.40 [ 0.10, 0.70 ]
Total (95% CI) 55 53 100.0 % 0.37 [ 0.10, 0.64 ]
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0080)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours deworming
(1) End value data
Analysis 2.1. Comparison 2 Screened for infection - Multiple dose, outcomes in the first year, Outcome 1
Body mass index.
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 2 Screened for infection - Multiple dose, outcomes in the first year
Outcome: 1 Body mass index
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simeon 1995 (1) 206 15.6 (1.3) 201 15.8 (1.4) -0.20 [ -0.46, 0.06 ]
-1 -0.5 0 0.5 1
Favours control Favours deworming
(1) end value
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Analysis 2.2. Comparison 2 Screened for infection - Multiple dose, outcomes in the first year, Outcome 2
School attendance (days present at school).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 2 Screened for infection - Multiple dose, outcomes in the first year
Outcome: 2 School attendance (days present at school)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simeon 1995 206 67.3 (18.4) 201 69.3 (17.5) -2.00 [ -5.49, 1.49 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours deworming
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Analysis 3.1. Comparison 3 Target population treated - Single dose, Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 3 Target population treated - Single dose
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Hadju 1996 (1) 34 20.3 (3.2) 30 19.9 (2.2) 16.7 % 0.40 [ -0.93, 1.73 ]
Stephenson 1989 78 2.1 (0.79) 72 0.8 (0.85) 28.0 % 1.30 [ 1.04, 1.56 ]
Stephenson 1993 96 3.3 (1.76) 93 2.2 (1.16) 26.8 % 1.10 [ 0.68, 1.52 ]
Watkins 1996 116 0.99 (0.65) 110 0.98 (0.63) 28.4 % 0.01 [ -0.16, 0.18 ]
Subtotal (95% CI) 324 305 100.0 % 0.73 [ -0.12, 1.57 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 75.81, df = 3 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.69 (P = 0.091)
2 Moderate prevalence
Palupi 1997 95 0.51 (0.73) 96 0.45 (0.58) 88.6 % 0.06 [ -0.13, 0.25 ]
Sur 2005 (2) 342 12.6 (5.73) 340 12.1 (4.61) 11.4 % 0.50 [ -0.28, 1.28 ]
Subtotal (95% CI) 437 436 100.0 % 0.11 [ -0.16, 0.38 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.79 (P = 0.43)
3 Low prevalence
Awasthi 2000 592 0.54 (1.34) 395 0.71 (1.23) 34.7 % -0.17 [ -0.33, -0.01 ]
Donnen 1998 112 0.44 (0.72) 110 0.59 (0.74) 28.1 % -0.15 [ -0.34, 0.04 ]
Garg 2002 166 1.21 (0.77) 181 1.19 (0.67) 37.3 % 0.02 [ -0.13, 0.17 ]
Subtotal (95% CI) 870 686 100.0 % -0.09 [ -0.22, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.31, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 5.04, df = 2 (P = 0.08), I2 =60%
-4 -2 0 2 4
Favours control Favours deworming
(1) End value data
(2) End value data
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Analysis 3.2. Comparison 3 Target population treated - Single dose, Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 3 Target population treated - Single dose
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Stephenson 1989 78 2.8 (0.79) 72 2.2 (0.85) 32.8 % 0.60 [ 0.34, 0.86 ]
Stephenson 1993 96 3.8 (1.18) 93 3.7 (1.16) 29.4 % 0.10 [ -0.23, 0.43 ]
Watkins 1996 116 1.44 (0.54) 111 1.38 (0.53) 37.8 % 0.06 [ -0.08, 0.20 ]
Subtotal (95% CI) 290 276 100.0 % 0.25 [ -0.10, 0.60 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 12.82, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Moderate prevalence
Palupi 1997 95 1.2 (0.9) 96 1.4 (1) 100.0 % -0.20 [ -0.47, 0.07 ]
Subtotal (95% CI) 95 96 100.0 % -0.20 [ -0.47, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
3 Low prevalence
Awasthi 2000 592 4.19 (5.08) 395 4.59 (5.25) 25.8 % -0.40 [ -1.06, 0.26 ]
Donnen 1998 112 1.96 (1.99) 110 2.58 (2.05) 31.3 % -0.62 [ -1.15, -0.09 ]
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 42.9 % 0.08 [ -0.21, 0.37 ]
Subtotal (95% CI) 870 686 100.0 % -0.26 [ -0.74, 0.21 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 5.89, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi2 = 4.72, df = 2 (P = 0.09), I2 =58%
-1 -0.5 0 0.5 1
Favours control Favours deworming
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Analysis 3.3. Comparison 3 Target population treated - Single dose, Outcome 3 Mid-upper arm
circumference (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 3 Target population treated - Single dose
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Stephenson 1989 78 0.7 (0.44) 72 0.2 (0.51) 32.6 % 0.50 [ 0.35, 0.65 ]
Stephenson 1993 96 0.8 (0.49) 93 0.3 (0.39) 33.7 % 0.50 [ 0.37, 0.63 ]
Watkins 1996 106 0.39 (0.51) 101 0.3 (0.4) 33.7 % 0.09 [ -0.03, 0.21 ]
Subtotal (95% CI) 280 266 100.0 % 0.36 [ 0.08, 0.64 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 25.85, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 2.55 (P = 0.011)
2 Moderate prevalence
Nga 2009 (1) 122 15.5 (1.1) 118 15.4 (1.1) 54.1 % 0.10 [ -0.18, 0.38 ]
Nga 2009 (2) 120 15.6 (1.2) 122 15.3 (1.2) 45.9 % 0.30 [ 0.00, 0.60 ]
Subtotal (95% CI) 242 240 100.0 % 0.19 [ -0.01, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
3 Low prevalence
Donnen 1998 112 0.11 (0.84) 110 0.41 (0.84) 100.0 % -0.30 [ -0.52, -0.08 ]
Subtotal (95% CI) 112 110 100.0 % -0.30 [ -0.52, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
Test for subgroup differences: Chi2 = 16.30, df = 2 (P = 0.00), I2 =88%
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Analysis 3.4. Comparison 3 Target population treated - Single dose, Outcome 4 Triceps skin fold thickness
(mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 3 Target population treated - Single dose
Outcome: 4 Triceps skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Stephenson 1989 78 1 (0.71) 72 -0.2 (0.68) 50.8 % 1.20 [ 0.98, 1.42 ]
Stephenson 1993 96 2 (1.08) 93 0.2 (0.77) 49.2 % 1.80 [ 1.53, 2.07 ]
Subtotal (95% CI) 174 165 100.0 % 1.50 [ 0.91, 2.08 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 11.46, df = 1 (P = 0.00071); I2 =91%
Test for overall effect: Z = 4.98 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Target population treated - Single dose, Outcome 5 Subscapular skin fold
thickness (mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 3 Target population treated - Single dose
Outcome: 5 Subscapular skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High prevalence
Stephenson 1989 78 0.9 (0.62) 72 -0.3 (0.68) 56.0 % 1.20 [ 0.99, 1.41 ]
Stephenson 1993 96 1.8 (0.88) 93 0.4 (0.77) 44.0 % 1.40 [ 1.16, 1.64 ]
Subtotal (95% CI) 174 165 100.0 % 1.29 [ 1.13, 1.44 ]
Heterogeneity: Chi2 = 1.55, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 16.16 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Target population treated - Single dose, Outcome 6 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 3 Target population treated - Single dose
Outcome: 6 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Nga 2009 (1) 118 12.22 (0.62) 114 12.12 (0.73) 39.2 % 0.10 [ -0.07, 0.27 ]
Nga 2009 (2) 117 11.99 (0.7) 118 12.01 (0.8) 32.3 % -0.02 [ -0.21, 0.17 ]
Palupi 1997 95 0.75 (0.88) 96 0.64 (1.06) 15.6 % 0.11 [ -0.17, 0.39 ]
Subtotal (95% CI) 330 328 87.1 % 0.06 [ -0.06, 0.17 ]
Heterogeneity: Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Low prevalence
Garg 2002 166 0.54 (1.42) 181 0.48 (1.47) 12.9 % 0.06 [ -0.24, 0.36 ]
Subtotal (95% CI) 166 181 12.9 % 0.06 [ -0.24, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 496 509 100.0 % 0.06 [ -0.05, 0.17 ]
Heterogeneity: Chi2 = 0.99, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 3.7. Comparison 3 Target population treated - Single dose, Outcome 7 Harvard Step Test
(measure of physical well being).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 3 Target population treated - Single dose
Outcome: 7 Harvard Step Test (measure of physical well being)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High prevalence
Stephenson 1989 (1) 18 80 (5.51) 15 74 (4.65) 23.9 % 6.00 [ 2.53, 9.47 ]
Stephenson 1993 (2) 27 82 (3.64) 26 76 (3.57) 76.1 % 6.00 [ 4.06, 7.94 ]
Subtotal (95% CI) 45 41 100.0 % 6.00 [ 4.31, 7.69 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 6.94 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Target population treated - Multiple dose, outcomes in the first year, Outcome
1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 4 Target population treated - Multiple dose, outcomes in the first year
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Stephenson 1993 95 3.1 (1.36) 93 2.2 (1.16) 12.7 % 0.90 [ 0.54, 1.26 ]
Watkins 1996 116 1.82 (0.86) 110 1.69 (0.73) 16.0 % 0.13 [ -0.08, 0.34 ]
Subtotal (95% CI) 211 203 28.7 % 0.50 [ -0.25, 1.25 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 13.13, df = 1 (P = 0.00029); I2 =92%
Test for overall effect: Z = 1.30 (P = 0.19)
2 Moderate prevalence
Dossa 2001 31 1.2 (0.6) 33 1.2 (0.5) 14.7 % 0.0 [ -0.27, 0.27 ]
Dossa 2001 37 1.2 (1) 28 1.2 (1.1) 9.6 % 0.0 [ -0.52, 0.52 ]
Sur 2005 (1) 342 12.9 (7.4) 340 12.4 (4.61) 4.7 % 0.50 [ -0.42, 1.42 ]
Subtotal (95% CI) 410 401 28.9 % 0.03 [ -0.20, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
3 Low prevalence
Awasthi 2000 576 0.99 (0.62) 387 0.95 (0.85) 17.8 % 0.04 [ -0.06, 0.14 ]
Donnen 1998 100 1.64 (1.12) 98 2.09 (1.19) 13.6 % -0.45 [ -0.77, -0.13 ]
Kruger 1996 37 2.32 (0.64) 37 2.7 (1.22) 11.0 % -0.38 [ -0.82, 0.06 ]
Subtotal (95% CI) 713 522 42.3 % -0.23 [ -0.60, 0.14 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 10.80, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 1.20 (P = 0.23)
Total (95% CI) 1334 1126 100.0 % 0.06 [ -0.17, 0.30 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 35.84, df = 7 (P<0.00001); I2 =80%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Chi2 = 3.20, df = 2 (P = 0.20), I2 =38%
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Analysis 4.2. Comparison 4 Target population treated - Multiple dose, outcomes in the first year, Outcome
2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 4 Target population treated - Multiple dose, outcomes in the first year
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Stephenson 1993 95 3.6 (1.07) 93 3.7 (1.16) 18.0 % -0.10 [ -0.42, 0.22 ]
Watkins 1996 116 2.45 (0.75) 111 2.39 (0.73) 40.0 % 0.06 [ -0.13, 0.25 ]
Subtotal (95% CI) 211 204 58.0 % 0.02 [ -0.15, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
2 Moderate prevalence
Dossa 2001 37 6.5 (2.6) 28 6 (2.5) 1.3 % 0.50 [ -0.75, 1.75 ]
Dossa 2001 31 6.2 (1) 33 6.2 (1.5) 5.3 % 0.0 [ -0.62, 0.62 ]
Subtotal (95% CI) 68 61 6.6 % 0.10 [ -0.46, 0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
3 Low prevalence
Awasthi 2000 576 2.87 (2.18) 387 2.98 (2.2) 22.2 % -0.11 [ -0.39, 0.17 ]
Donnen 1998 100 7.27 (3.56) 98 8.46 (4.18) 1.8 % -1.19 [ -2.27, -0.11 ]
Kruger 1996 37 5.62 (0.9) 37 5.54 (0.91) 11.4 % 0.08 [ -0.33, 0.49 ]
Subtotal (95% CI) 713 522 35.4 % -0.17 [ -0.59, 0.25 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 4.63, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 992 787 100.0 % -0.02 [ -0.17, 0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.68, df = 6 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 0.77, df = 2 (P = 0.68), I2 =0.0%
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Analysis 4.3. Comparison 4 Target population treated - Multiple dose, outcomes in the first year, Outcome
3 Mid-upper arm circumference (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 4 Target population treated - Multiple dose, outcomes in the first year
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Stephenson 1993 95 0.7 (0.49) 93 0.3 (0.39) 50.4 % 0.40 [ 0.27, 0.53 ]
Watkins 1996 106 0.6 (0.51) 101 0.52 (0.5) 49.6 % 0.08 [ -0.06, 0.22 ]
Subtotal (95% CI) 201 194 100.0 % 0.24 [ -0.07, 0.55 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 11.26, df = 1 (P = 0.00079); I2 =91%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Moderate prevalence
Dossa 2001 37 0.1 (0.8) 28 0.1 (0.9) 43.2 % 0.0 [ -0.42, 0.42 ]
Dossa 2001 31 0.1 (0.7) 33 0 (0.8) 56.8 % 0.10 [ -0.27, 0.47 ]
Subtotal (95% CI) 68 61 100.0 % 0.06 [ -0.22, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
3 Low prevalence
Donnen 1998 100 0.62 (1) 98 0.97 (1.16) 100.0 % -0.35 [ -0.65, -0.05 ]
Subtotal (95% CI) 100 98 100.0 % -0.35 [ -0.65, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Chi2 = 7.55, df = 2 (P = 0.02), I2 =74%
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Analysis 4.4. Comparison 4 Target population treated - Multiple dose, outcomes in the first year, Outcome
4 Triceps skin fold thickness (mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 4 Target population treated - Multiple dose, outcomes in the first year
Outcome: 4 Triceps skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Stephenson 1993 95 2 (1.17) 93 0.2 (0.77) 100.0 % 1.80 [ 1.52, 2.08 ]
Subtotal (95% CI) 95 93 100.0 % 1.80 [ 1.52, 2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.49 (P < 0.00001)
2 Moderate prevalence
Dossa 2001 38 -0.6 (1.3) 28 0.2 (1.7) 50.1 % -0.80 [ -1.55, -0.05 ]
Dossa 2001 31 0 (1.5) 33 -0.2 (1.6) 49.9 % 0.20 [ -0.56, 0.96 ]
Subtotal (95% CI) 69 61 100.0 % -0.30 [ -1.28, 0.68 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 3.36, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 16.31, df = 1 (P = 0.00), I2 =94%
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Analysis 4.5. Comparison 4 Target population treated - Multiple dose, outcomes in the first year, Outcome
5 Subscapular skin fold thickness (mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 4 Target population treated - Multiple dose, outcomes in the first year
Outcome: 5 Subscapular skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High prevalence
Stephenson 1993 95 1.9 (1.07) 93 0.4 (0.77) 1.50 [ 1.23, 1.77 ]
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Analysis 4.6. Comparison 4 Target population treated - Multiple dose, outcomes in the first year, Outcome
6 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 4 Target population treated - Multiple dose, outcomes in the first year
Outcome: 6 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Dossa 2001 34 1.3 (1.5) 34 1.1 (1.2) 4.3 % 0.20 [ -0.45, 0.85 ]
Dossa 2001 38 0.8 (1.3) 32 0.5 (1.2) 5.3 % 0.30 [ -0.29, 0.89 ]
Le Huong 2007 86 1.78 (0.9) 79 1.75 (0.755) 28.4 % 0.03 [ -0.22, 0.28 ]
Le Huong 2007 79 1.46 (0.888) 82 1.54 (0.833) 25.6 % -0.08 [ -0.35, 0.19 ]
Subtotal (95% CI) 237 227 63.6 % 0.02 [ -0.15, 0.19 ]
Heterogeneity: Chi2 = 1.72, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Low prevalence
Goto 2009 (1) 134 9.59 (1.39) 135 9.69 (1.38) 16.5 % -0.10 [ -0.43, 0.23 ]
Kruger 1996 37 0.24 (0.6) 37 0.26 (0.72) 19.9 % -0.02 [ -0.32, 0.28 ]
Subtotal (95% CI) 171 172 36.4 % -0.06 [ -0.28, 0.17 ]
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 408 399 100.0 % -0.01 [ -0.14, 0.13 ]
Heterogeneity: Chi2 = 2.13, df = 5 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.59), I2 =0.0%
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Analysis 4.7. Comparison 4 Target population treated - Multiple dose, outcomes in the first year, Outcome
7 School attendance (days present at school).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 4 Target population treated - Multiple dose, outcomes in the first year
Outcome: 7 School attendance (days present at school)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 High prevalence (Miguel 1998 comparison)
Miguel 2004 (Cluster) (1) 0.093 (0.031) 46.5 % 0.09 [ 0.03, 0.15 ]
Watkins 1996 -0.01 (0.015) 53.5 % -0.01 [ -0.04, 0.02 ]
Subtotal (95% CI) 100.0 % 0.04 [ -0.06, 0.14 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.95, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.74 (P = 0.46)
2 High prevalence (Miguel 1999 comparison)
Miguel 2004 (Cluster) (2) 0.055 (0.028) 43.4 % 0.06 [ 0.00, 0.11 ]
Watkins 1996 -0.01 (0.015) 56.6 % -0.01 [ -0.04, 0.02 ]
Subtotal (95% CI) 100.0 % 0.02 [ -0.04, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.19, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 0.56 (P = 0.57)
-1 -0.5 0 0.5 1
Favours control Favours deworming
(1) Miguel 1998: group 1 vs. 2 and 3
(2) Miguel 1999: group 2 versus 3
115Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school
performance (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.1. Comparison 5 Target population treated - Multiple dose, outcomes after the first year,
Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 5 Target population treated - Multiple dose, outcomes after the first year
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Hall 2006 (Cluster) 0 (0.071) 100.0 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 100.0 % 0.0 [ -0.14, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Moderate prevalence
Alderman 2006 (Cluster) 0.154 (0.08921) 100.0 % 0.15 [ -0.02, 0.33 ]
Subtotal (95% CI) 100.0 % 0.15 [ -0.02, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
3 Low prevalence
Awasthi 2008 (Cluster) (1) 0.98 (0.148) 34.9 % 0.98 [ 0.69, 1.27 ]
Awasthi 2000 -0.05 (0.076) 36.3 % -0.05 [ -0.20, 0.10 ]
Awasthi 2001 (Cluster) 0.17 (0.341) 28.8 % 0.17 [ -0.50, 0.84 ]
Subtotal (95% CI) 100.0 % 0.37 [ -0.40, 1.15 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 38.33, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 2.45, df = 2 (P = 0.29), I2 =18%
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Analysis 5.2. Comparison 5 Target population treated - Multiple dose, outcomes after the first year,
Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 5 Target population treated - Multiple dose, outcomes after the first year
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low prevalence
Awasthi 2008 (Cluster) (1) 25 17.59 (4.5) 25 16.4 (4) 6.0 % 1.19 [ -1.17, 3.55 ]
Awasthi 2000 601 9.94 (4.9) 444 10.35 (5.1) 87.7 % -0.41 [ -1.03, 0.21 ]
Awasthi 2001 (Cluster) 63 16.5 (6.51) 61 16.1 (6.48) 6.3 % 0.40 [ -1.89, 2.69 ]
Subtotal (95% CI) 689 530 100.0 % -0.26 [ -0.84, 0.31 ]
Heterogeneity: Chi2 = 2.00, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Target population treated - Multiple dose, outcomes after the first year,
Outcome 3 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 5 Target population treated - Multiple dose, outcomes after the first year
Outcome: 3 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low prevalence
Awasthi 2000 (1) 601 9.67 (0.65) 444 9.67 (0.66) 93.5 % 0.0 [ -0.08, 0.08 ]
Kirwan 2010 (2) 158 10.04 (1.38) 162 10.03 (1.4) 6.5 % 0.01 [ -0.29, 0.31 ]
Subtotal (95% CI) 759 606 100.0 % 0.00 [ -0.08, 0.08 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Target population treated - Multiple dose, outcomes after the first year,
Outcome 4 School attendance (days present at school).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 5 Target population treated - Multiple dose, outcomes after the first year
Outcome: 4 School attendance (days present at school)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 High prevalence
Miguel 2004 (Cluster) 0.05 (0.028) 0.05 [ 0.00, 0.10 ]
-1 -0.5 0 0.5 1
Favours control Favours deworming
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Analysis 6.1. Comparison 6 Target population treated - Single dose (low risk of bias for allocation
concealment), Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 6 Target population treated - Single dose (low risk of bias for allocation concealment)
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Sur 2005 (1) 342 12.6 (5.73) 340 12.1 (4.61) 3.7 % 0.50 [ -0.28, 1.28 ]
Subtotal (95% CI) 342 340 3.7 % 0.50 [ -0.28, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 Low prevalence
Garg 2002 166 1.21 (0.77) 181 1.19 (0.67) 96.3 % 0.02 [ -0.13, 0.17 ]
Subtotal (95% CI) 166 181 96.3 % 0.02 [ -0.13, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Total (95% CI) 508 521 100.0 % 0.04 [ -0.11, 0.19 ]
Heterogeneity: Chi2 = 1.40, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =29%
-4 -2 0 2 4
Favours control Favours deworming
(1) End value data
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Analysis 6.2. Comparison 6 Target population treated - Single dose (low risk of bias for allocation
concealment), Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 6 Target population treated - Single dose (low risk of bias for allocation concealment)
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
3 Low prevalence
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 100.0 % 0.08 [ -0.21, 0.37 ]
Subtotal (95% CI) 166 181 100.0 % 0.08 [ -0.21, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
-1 -0.5 0 0.5 1
Favours control Favours deworming
Analysis 6.3. Comparison 6 Target population treated - Single dose (low risk of bias for allocation
concealment), Outcome 3 Mid-upper arm circumference (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 6 Target population treated - Single dose (low risk of bias for allocation concealment)
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Nga 2009 (1) 122 15.5 (1.1) 118 15.4 (1.1) 54.1 % 0.10 [ -0.18, 0.38 ]
Nga 2009 (2) 120 15.6 (1.2) 122 15.3 (1.2) 45.9 % 0.30 [ 0.00, 0.60 ]
Subtotal (95% CI) 242 240 100.0 % 0.19 [ -0.01, 0.40 ]
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours deworming
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(1) End value data
(2) End value data
Analysis 6.4. Comparison 6 Target population treated - Single dose (low risk of bias for allocation
concealment), Outcome 4 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 6 Target population treated - Single dose (low risk of bias for allocation concealment)
Outcome: 4 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Nga 2009 (1) 117 11.99 (0.7) 118 12.01 (0.8) 38.3 % -0.02 [ -0.21, 0.17 ]
Nga 2009 (2) 118 12.22 (0.62) 114 12.12 (0.73) 46.4 % 0.10 [ -0.07, 0.27 ]
Subtotal (95% CI) 235 232 84.7 % 0.05 [ -0.08, 0.17 ]
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
2 Low prevalence
Garg 2002 166 0.54 (1.42) 181 0.48 (1.47) 15.3 % 0.06 [ -0.24, 0.36 ]
Subtotal (95% CI) 166 181 15.3 % 0.06 [ -0.24, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 401 413 100.0 % 0.05 [ -0.07, 0.17 ]
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
-2 -1 0 1 2
Favours control Favours deworming
(1) End value data
(2) End value data
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Analysis 7.1. Comparison 7 Target population treated - Multiple dose, outcomes in the first year (low risk of
bias for allocation concealment), Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 7 Target population treated - Multiple dose, outcomes in the first year (low risk of bias for allocation concealment)
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Sur 2005 (1) 342 12.9 (7.4) 340 12.4 (4.61) 0.50 [ -0.42, 1.42 ]
-1 -0.5 0 0.5 1
Favours control Favours deworming
(1) End value data
Analysis 7.2. Comparison 7 Target population treated - Multiple dose, outcomes in the first year (low risk of
bias for allocation concealment), Outcome 2 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 7 Target population treated - Multiple dose, outcomes in the first year (low risk of bias for allocation concealment)
Outcome: 2 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Le Huong 2007 79 1.46 (0.888) 82 1.54 (0.833) 47.4 % -0.08 [ -0.35, 0.19 ]
Le Huong 2007 86 1.78 (0.9) 79 1.75 (0.755) 52.6 % 0.03 [ -0.22, 0.28 ]
Subtotal (95% CI) 165 161 100.0 % -0.02 [ -0.21, 0.16 ]
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours control Favours deworming
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Analysis 8.1. Comparison 8 Target population treated - Multiple dose, outcomes after the first year (low
risk of bias for allocation concealment), Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 8 Target population treated - Multiple dose, outcomes after the first year (low risk of bias for allocation concealment)
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 High prevalence
Hall 2006 (Cluster) 0 (0.071) 0.0 [ -0.14, 0.14 ]
-1 -0.5 0 0.5 1
Favours control Favours deworming
Analysis 8.2. Comparison 8 Target population treated - Multiple dose, outcomes after the first year (low
risk of bias for allocation concealment), Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance
Comparison: 8 Target population treated - Multiple dose, outcomes after the first year (low risk of bias for allocation concealment)
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low prevalence
Awasthi 2001 (Cluster) 63 16.5 (6.51) 61 16.1 (6.48) 0.40 [ -1.89, 2.69 ]
-4 -2 0 2 4
Favours control Favours deworming
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A D D I T I O N A L T A B L E S
Table 1. Detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 helmint* helmint* helmint* helmint$ helmint*
2 Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
3 Necator americanus Necator americanus Necator americanus Necator americanus Necator americanus
4 Ascaris Ascaris Ascaris Ascaris Ascaris
5 Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
6 trichuris trichuris trichuris trichuris trichuris
7 Strongyloid* Strongyloid* Strongyloid* Strongyloid* Strongyloid*
8 albendazole hookworm* hookworm* hookworm$ 1-7/OR
9 mebendazole roundworm* roundworm* roundworm$ albendazole
10 piperazine pinworm* pinworm* pinworm$ mebendazole
11 levamisole whipworm* whipworm* whipworm$ piperazine
12 pyrantel 1-11/OR 1-11/OR 1-11/OR levamisole
13 tiabendazole albendazole albendazole albendazole pyrantel
14 - mebendazole mebendazole mebendazole tiabendazole
15 - piperazine piperazine piperazine 9-14/OR
16 - levamisole levamisole levamisole 8 and 15
17 - pyrantel pyrantel pyrantel Limit 16 to human
18 - tiabendazole tiabendazole tiabendazole -
19 - 13 or 14 or 15 or 16
or 17 or 18
13 or 14 or 15 or 16
or 17 or 18
13 or 14 or 15 or 16
or 17 or 18
-
20 - 12 and 19 12 and 19 12 and 19 -
21 - - Limit 20 to human Limit 20 to human -
aCochrane Infectious Diseases Group Specialized Register.
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bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2011).
Table 2. Haemoglobin search strategy
1 helmint*
2 Ancylostoma duodenale
3 Necator americanus
4 Ascaris
5 Enterobius vermicularis
6 trichuris
7 Strongyloid*
8 hookworm*
9 roundworm*
10 pinworm*
11 whipworm*
12 1-11/OR
13 albendazole
14 mebendazole
15 piperazine
16 levamisole
17 pyrantel
18 tiabendazole
19 13 or 14 or 15 or 16 or 17 or 18
20 haemoglobin
21 hemoglobin
22 anemia
23 anaemia
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Table 2. Haemoglobin search strategy (Continued)
24 HB
25 20 or 21 or 22 or 23 or 24
26 12 and 19 and 25
27 Limit 26 to human
Search terms used in electronic databases in combination with the search strategy for retrieving trials developed by The Cochrane
Collaboration (Lefebvre 2011);
Table 3. Community diagnosis categories and recommended treatment strategies
Community category (WHO
2002)
Prevalencea Proportionb School intervention
1. High prevalence or high in-
tensity
> 70% > 10% Targeted treatment of school-age children 2 to 3 times per year
2.Moderate prevalence and low
intensity
> 50% but < 70% < 10% Targeted treatment of school-age children once per year
3. Low prevalence and low in-
tensity
< 50% < 10% Selective treatment
Category (WHO 2006b) Prevalencea Action to be taken
High risk community > 50% Targeted treatment of pre-school and school-age children 2 or
3 times per year
Low risk community >20% but <50% Targeted treatment of pre-school and school-age children once
per year
aOf any worm infection.
bOf moderate to heavy infections.
Table 4. Data not included in meta-analysis
Screened for infection - single dose (outcomes measured < 1 year)
Nokes 1992
Albendazole
Growth measured but not reported: 9 weeks cited as too short
a follow-up period to demonstrate a change
Screened for infection - multiple dose (outcome measured < 1 year)
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Table 4. Data not included in meta-analysis (Continued)
Simeon 1995
Albendazole
No significant difference in any reported outcome for whole
group.
Height-for-age z-score at baseline in treatment group -0.48 (0.95)
and in placebo group -0.39 (0.90). At follow up in treatment
group -0.48 (0.97) and in placebo group -0.41 (0.89).
Body mass index (kg/m2) at baseline in treatment group 15.3 (1.3)
and in placebo group 15.5 (1.3). At follow up in treatment group
15.6 (1.3) and in placebo group 15.8 (1.4)
Whole target population treated - single dose (outcome measured < 1 year)
Beach 1999
Albendazole
A nutritional benefit of treatment was not detectable after 4
months for the entire study population (853 participants, no
figures provided).
Stratification by infection demonstrated small positive effects in
the treatment group for some anthropometric outcomes. In As-
caris-infected children (51), height gain was 0.62 cm greater than
placebo in the combination treatment group (P = 0.01) at 4
months. In Trichuris-infected children (158), weight gain was 0.
56 kg greater than placebo in the combination treatment group
(P = 0.01) at 4 months
Fox 2005
Albendazole
No results provided for whole study population.
Results for height and weight only presented in the narrative for
subgroups infected with hookworm and Ascaris: no significant
anthropometric changes detected (no figures quoted). In those
infected with Trichuris, weight gain was greater in the albenda-
zole group (difference compared to placebo 0.28 kg, P = 0.038).
Adverse events: no serious adverse events (albendazole 0/46 ver-
sus placebo 0/43). Myalgia and cough were reported significantly
more frequently in the placebo group compared to albendazole
Greenberg 1981
Piperazine citrate
Treatment group tended to show worse nutrition than
placebo.
Comparison showed no significant difference for all measured
anthropometric variables for the total group and for subgroups
defined by severity of infection (no figures provided)
Kloetzel 1982
Mebendazole
No significant difference was found between the groups.
Results reported as the proportion of treatment or control group
that improved, deteriorated, or experienced no change. Unclear
which anthropological measures were used in this categorization
process. Proportions in each category were not significantly dif-
ferent between trial arms (improved: 51% in mebendazole group
versus 49% in control; deteriorated: 35% in mebendazole group
versus 33% in control; no change: 14% in mebendazole group
versus 18% in control; no significance test results quoted)
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Table 4. Data not included in meta-analysis (Continued)
Koroma 1996
Albendazole
Significant increases in weight-for-height, weight-for-age, and
height-for-age z-scores recorded in rural and urban treatment
groups at 6 months.
Mean increase in rural treatment group compared to placebo:
weight-for-height z-score 0.28 (SE 0.17) P < 0.05; weight-for-age
z-score 1.04 (SE 0.03) P < 0.05; and height-for-age z-score 0.83
(SE 0.03) P < 0.001.
Mean increase in urban treatment group compared to placebo:
weight-for-height z-score 1.04 (SE 0.07) P < 0.05; weight-for-age
z-score 1.02 (SE 0.09) P < 0.001; and height-for-age z-score 1.01
(SE 0.02) P <0.05
Michaelsen 1985
Tetra-chlorethylene
No significant difference in change in mean for haemoglobin.
(tetrachloroethylene 0.22 g/100 mL versus placebo 0.09 g/
100 mL; quoted as non-significant) or weight for height at 5
months (tetrachloroethylene -1.3% ofWHO reference mean ver-
sus placebo -0.4%; quoted as non-significant)
Adverse events: 17% (19/119: results not given for separate trial
arms) of the children suffered adverse effects (nausea and ataxia)
that began one and a half hours after treatment. All symptoms
disappearedwithin four hours. Tetrachlorethylene is not in current
use as a deworming drug
Nga 2009
Albendazole
No significant differences in weight-for-height, weight-for-
age, and height-for-age z-scores and skin fold thickness at 4
months.
There was no statistically significant effect of deworming on
weight, height, HAZ scores, WAZ scores, or WHZ scores. There
were no statistically significant differences in skin fold thickness
after four months of intervention
Whole target population treated - multiple dose (outcome measured < 1 year)
Goto 2009
Albendazole plus secnidazole
No significant differences in mean z-scores or prevalence of
stunting, underweight or wasting between the intervention
groups were found, and the changes between intervals (eg be-
tween weeks 0 to 12, 0 to 24, 0 to 36, 12 to 24, etc.) did not
differ significantly between groups.
Height-for-age z-score: at baseline in treatment group -1.08 (1.02)
and in control group -1.21 (1.0). At follow up in treatment group
-1.59 (0.93) and in control group -1.70 (0.93).
Weight-for-age z-score: at baseline in treatment group -1.91 (1.15)
and in control group -1.85 (1.14). At followup in treatment group
-2.62 (1.17) and in control group -2.59 (1.17).
Weight-for-height z-score: at baseline in treatment group -1.25 (1.
18) and in control group -0.96 (1.17). At follow up in treatment
group -1.55 (1.07) and in control group -1.83 (1.06)
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Table 4. Data not included in meta-analysis (Continued)
Hadju 1997
Pyrantel pamoate
Albendazole
No significant differences detected between treatment groups
on basis of multivariate analyses controlling for age, sex, and
‘times’.
Change in weight-for-age z-score: placebo 0.02; pyrantel 1 x treat-
ment 0.03; pyrantel 2 x treatments 0.08; albendazole 1 x treat-
ment -0.10; albendazole 2 x treatments 0.01.
Change in height-for-age z-score: placebo 0.01; pyrantel 1 x treat-
ment 0.00; pyrantel 2 x treatments 0.04; albendazole 1 x treat-
ment -0.07; albendazole 2 x treatments 0.01.
Change in weight-for-height z-score: placebo0.02; pyrantel 1 x treat-
ment 0.08; pyrantel 2 x treatments 0.05; albendazole 1 x treat-
ment -0.07; albendazole 2 x treatments 0.03.
Change mid-arm circumference z-score: placebo -0.09; pyrantel 1
x treatment -0.11; pyrantel 2 x treatments -0.11; albendazole 1 x
treatment -0.07; albendazole 2 x treatments -0.01
Le Huong 2007
Mebendazole
No obvious trend in nutrition variable.
Anthropometric indices were calculated using WHO/NCHS ref-
erence data. Being wasted, stunted and underweight was defined
by z-scores ,< - 2SD for weight-for-height, height-for-age and
weight-for-age, respectively.
Percentage underweight:At baseline Fe 41·9, Fe +MEB 51·9,MEB
50·6, Placebo 45·1; after treatment Fe 33·7, Fe +MEB 46·8,MEB
38, Placebo 35·4.
Percentage stunted: At baseline Fe 30·2, Fe + MEB 31·6, MEB
41·8, Placebo 31·7; after treatment Fe 29·1, Fe +MEB 27·8,MEB
29·1, Placebo 29·3.
Percentage wasted: At baseline Fe 9·3, Fe + MEB 16·5, MEB 13·9,
Placebo 12·2; after treatment Fe 5·8, Fe + MEB 17·7, MEB 13·9,
Placebo 13·4
Miguel 2004 (Cluster) No effect on nutrition or haemoglobin demonstrated
Data from published paper including praziquantel treated clusters
(25 treatment schools versus 25 control schools in 1998 compar-
ison):
It is unclear how many children were followed up for nutritional
outcomes. For haemoglobin a sample of around 4% (778/20,000)
of the quasi-randomized comparison of group 1 versus group 2 in
1998 was analysed. It is unclear how this group was selected
Difference in weight-for age Z score (treatment - control): 0.00
(SE 0.04)
Difference in height-for-age Z score end value (treatment - con-
trol): 0.09 (SE 0.05).
Difference in haemoglobin (g/L) (treatment - control): 1.6 (SE 1.
4)
Stoltzfus 2001
Mebendazole
Mebendazole is reported as significantly reducing the preva-
lence of mild wasting malnutrition in a subgroup of children
aged < 30 months only
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Table 4. Data not included in meta-analysis (Continued)
adjusted odds ratio for mebendazole 0.38 (95% CI 0.16 to 0.
90) for weight-for-height z-score < -1. Mebendazole is reported as
significantly reducing the prevalence of poor appetite across the
whole group (adjusted odds ratio for mebendazole 0.52 (95% CI
0.30 to 0.89) for weight-for-height z-score < -1). Mebendazole
had no impact on iron indices. Adjusted effect on motor scores
had a tendency to favourmebendazole, but this was not significant
Willett 1979
Levamisole
No statistical difference in nutrition in terms of height and
weight differences between the 2 groups.
Growth rates presented are adjusted for a number of variables.
Weight gain (kg/year) in levamisole group 2.08 versus 1.92 in
placebo group (P = 0.06). Height gain (cm/year) in levamisole
group 7.58 versus 7.73 in placebo group (no significance quoted)
Stoltzfus 1997 (Cluster)
Mebendazole
Weight gain: in a subgroup of under 10 year olds, the twice-
yearly treated group experienced significantly greater weight
gain (kg) compared to control (2.38 (SE 0.08) versus 2.11 (SE
0.08), P < 0.05).
In the thrice yearly treatment group the difference was not signif-
icant (2.31 (SE 0.08) versus 2.11 (SE 0.08), no P value stated).
Height gain: in under 10 year olds the thrice-yearly treated group
experienced significantly greater height gain (cm) compared to
control (4.59 (SE 0.07) versus 4.29 (SE 0.07), P < 0.01). In the
twice-yearly treatment group the difference in height gain was
not significant (4.42 (SE 0.07) versus 4.29 (SE 0.07), no P value
stated). There were no significant differences found in the sub-
group of children aged over 10 years.
Haemoglobin change: deworming had no effect on haemoglobin
change in an adjusted analysis presented for the whole study group
(g/L): control 11.3 (SE 1.7); twice-yearly treatment group 10.3
(SE 1.7); and thrice-yearly group 12.7 (SE 1.7)
Whole target population treated - multiple dose (outcome measured > 1 year)
Awasthi 2008 (Cluster) During the study there were 23 deaths, 13 were in the usual
care arm and 10 were in the treatment arm.
These data were not adjusted for cluster randomization.
Lai 1995
Mebendazole plus pyrantel
No difference in height or weight between treatment and con-
trol group at the end of 2-year follow up. Standard deviations
not provided. Results stratified for males and females:
Females: change in height in treatment arm 12.2 cm versus change
in height in placebo arm 12.4 cm; change in weight in treatment
arm 5.6 kg versus change in weight in placebo arm 5.6 kg.
Males: change in height in treatment arm 11.8 cm versus change
in height in placebo arm 11.4cm; change in weight in treatment
arm 5.7 kg versus change in weight in placebo arm 4.7 kg
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Table 4. Data not included in meta-analysis (Continued)
Hall 2006 (Cluster)
Albendazole
Trial authors reported no difference in final and change in
height.
Mid-upper arm circumference and subscapular skinfold thickness
improved significantly in the control group compared to the al-
bendazole group (7.87 versus 7.61, P = 0.005 and 1.22 versus 1.
05, P = 0.005 respectively). These results do not appear to have
been adjusted for cluster randomization. The results that show no
effect, however, will not remain non-significant even after appro-
priate adjustment, though the CIs may change
Rousham 1994 (Cluster)
Mebendazole
ANOVAS of the change in z-scores revealed no significant im-
provement with treatment.
Change in weight-for-age and weight-for-height z-scores were sig-
nificantly worse in the treatment group. Height-for-age z-score
(mebendazole 0.25 v 0.17 in placebo group, P ’non-significant’),
weight-for-age z-score (mebendazole 0.03 versus 0.12 in placebo
group, P < 0.05), weight-for-height z-score (mebendazole -0.25
versus -0.05 in placebo group, P < 0.001), and mid-upper arm
circumference were presented (mebendazole 0.33 versus 0.23 in
placebo group, P ’non-significant’)
Table 5. Trials evaluating psychometric tests of cognition
Trial details Outcome measures Results
Screened for infection - single dose (outcomes measured < 1 year)
Kvalsvig 1991a
Mebendazole versus placebo, 1 month
Card sorting task; cancellation task (num-
ber of letter ’s’ in text deleted in a time pe-
riod)
Changes in cognitive scores are not clearly
reported since “the dose of mebendazole
was inadequate to free children from infec-
tion”
Nokes 1992
Albendazole versus placebo
2.25 months
Digit span (forward and backward); arith-
metic and coding from Wechsler Intelli-
gence Scale for Children; fluency; listening
comprehension from the Clinical Evalua-
tion of Language functions; matching fa-
miliar figures test
Mean test scores pre- and post-intervention
presented with CIs
No comment made on significance of un-
adjusted data.
Results of multiple regression suggest a
greater improvement in treated children
in 3/10 tests (fluency, digit span forwards,
digit span backwards)
Screened for infection - multiple dose (outcome measured < 1 year)
Simeon 1995
Albendazole versus placebo
6.5 months
1. Main study (264 children)
Wide range achievement test: reading,
arithmetic, and spelling sub tests;
2. Subgroup 1 (189 children 189 infected
1. Main study: no difference in any re-
ported outcome measure
2. Subgroup 1: no significant effect on any
of the outcome measures
131Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school
performance (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. Trials evaluating psychometric tests of cognition (Continued)
children from original population)
Digit span; verbal fluency test; visual
search; number choice; French vocabulary
learning
3. Subgroup 2 (97 children from grade 5)
French learning; digit spans (forward and
backward); Corsi block span; verbal flu-
ency; picture search; silly sentences
3. Subgroup 2: no significant improvement
with treatment in any of the tests was found
in multiple regression modelling
Whole target population treated - single dose (outcome measured < 1 year)
Nga 2009
Albendazole
Cognitive performance was measured us-
ing Raven’s Colored Matrices and also a se-
ries of cognitive tests from Wechsler’s In-
telligence Scale for Children III: digit span
backward and forward, block design and
coding
Deworming had no significant effect on
any of the cognitive tests
Solon 2003
Albendazole versus placebo
16 weeks
Cognitive ability was measured using a
standardized written mental-abilities test
called the Primary Mental Abilities Test
for Filipino Children (PMAT-FC). The
test covers general knowledge and compre-
hension, verbal relationships, fundamen-
tal mathematical comprehension and skills,
numerical sequencing, and ability to per-
ceive and apply relationships based on
meaningless stimuli
Deworming had either no effect or a neg-
ative effect on mental ability scores. Data
was not reported
Whole target population treated - multiple dose (outcome measured < 1 year)
Miguel 2004 (Cluster)
Dewormingpackage including albendazole
versus placebo
1 year
1. Exam score performance (measured
by Internationaal Christelijk Steunfonds
Africa (ICS) administered English, Math-
ematics and Science-Agriculture exams) in
pupils in grades 3 to 8
2. Cognitive tests including picture search,
Raven matrix, verbal fluency, digit span,
Spanish learning, and a dynamic test us-
ing syllogisms measured for all three school
groups in 2000
1.The authors did not provide outcomes by
the quasi-randomized comparison eligible
for this review (1998Group 1 versusGroup
2 & 3; 1999 Group 1&2 versus group 3).
Regression modelling, adjusting for partic-
ipation and treatment year presented
2. Outcome data not reported for cogni-
tive tests, though authors state: “Deworm-
ing treatment effects are not significantly
different than zero for any component of
the cognitive exam (results available on re-
quest)”
Stoltzfus 2001
Mebendazole versus placebo, 1 year
Motor and language development by par-
ents reporting gross motor and language
milestones using scoring system developed
specifically for the trial
Unadjusted data not reported.
Treatment had no significant effect on mo-
tor or language development
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Table 5. Trials evaluating psychometric tests of cognition (Continued)
Watkins 1996
Albendazole versus placebo, 6 months
Interamerican vocabulary test; Interameri-
can reading test; Peabody picture vocabu-
lary test
All outcome measures reported as unad-
justed scores.
No difference in any of the tests found be-
tween treatment groups
Whole target population treated - multiple dose (outcome measured > 1 year)
Awasthi 2000
Albendazole versus placebo, 2 years
Developmental status (Denver Question-
naire).
No difference in development between
treatment groups in terms of proportion
with “normal” development
Hall 2006 (Cluster)
Albendazole versus placebo, 2 years
Mathematics test score, Vietnamese test
score.
No statistically significant differences in
test results at start or end of study. These re-
sults have not been adjusted for cluster ran-
domization. They will remain non-signif-
icant, however, even after appropriate ad-
justment, though the CIs may change
Table 6. Trials evaluating school attendance (days present at school).
Trial details Outcome measures Results
Screened for infection - multiple dose (outcome measured < 1 year)
Simeon 1995
Albendazole versus placebo
6.5 months
Main study (264 children).
School attendance from children with class
registers pre- and post-intervention
There was no significant difference be-
tween the treatment and placebo groups at
either baseline or post-test
The mean percentage of school attendance
went from 62.6 (SD 20.4) at baseline to
67.3 (SD 18.4) post-test in the treatment
group, and from 66.3 (SD 20.8) to 69.3
(SD 17.5) in the placebo group
Whole target population treated - multiple dose (outcome measured < 1 year)
Miguel 2004 (Cluster) 1. School participation rate was computed
among all pupils enrolled in 1998 (group 1
versus groups 2 and 3, 1998 comparison)
2. School participation rate was computed
among all pupils enrolled in 1998 (group
2 versus group 3, 1999 comparison)
Pupils present on the day of an unan-
nounced NGO visit were considered par-
ticipant. Pupils had 3.8 observations on av-
erage per year. This was then calculated as
a weighted average by school
In 1998, in the intervention group, school
participation in girls <13 and boys was 84.
1%, and in group 2 it was 73.1%, and in
group 3 it was 76.7% giving a difference of
9.3% (SE 3.1%) between intervention and
comparison (groups 2 and 3)
In 1999, in the intervention group 2,
school participation in girls <13 and boys
was 71.7%, and in the comparison group 3
(groups 3) it was 66.3%, giving a difference
of 5.5% (SE 2.8%)
However, there are no comparable baseline
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Table 6. Trials evaluating school attendance (days present at school). (Continued)
values to knowwhether baseline attendance
happens to be higher in group 1 schools
Watkins 1996
Albendazole versus placebo, 6 months
Attendance rates of children actively at-
tending school.
There was no difference in attendance be-
tween the albendazole and placebo groups
before or after treatment
Treatment group: before treatment: n = 108,
mean = 0.92, SEM = 0.01; after treatment
n = 123 mean = 0.88 SEM = 0.01
Placebo group: before treatment n = 105
mean = 0.90, SEM = 0.01 and after treat-
ment n = 120, mean = 0.89, SEM = 0.01
Whole target population treated - multiple dose (outcome measured > 1 year)
Miguel 2004 (Cluster) 1. School participation rate was computed
among all pupils enrolled in 1998 (Group
1 versus Group 3, 1999 comparison)
Pupils present on the day of an unan-
nounced NGO visit were considered par-
ticipant. Pupils had 3.8 observations on av-
erage per year. This was then calculated as
a weighted average by school
In the intervention group, school partici-
pations in girls <13 and boys was 71.3%,
and in the comparison group (group3) it
was 66.3%, giving a difference of 5% (SE
2.8%)
However, there are no comparable baseline
values to knowwhether baseline attendance
happens to be higher in Group 1 schools
Table 7. Summary of findings A: In children screened for infection, what is the effect of a single dose of deworming drugs?
In children screened for infection, what is the effect of a a single dose of deworming drugs?
Patient or population: children known to be infected with soil-transmitted intestinal worms
Settings: areas endemic for intestinal helminths
Intervention: Single dose deworming drugs
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Assumed risk Corresponding
risk
Control Single dose de-
worming drugs
Weight (kg)
Follow-up: 4 to
16 weeks
The mean gain
in weight in the
control groups
ranged from 0.
30 to 0.54 kg
The mean
gain in weight in
the intervention
groups was
0.58 kg higher
(0.4 to 0.76
149
(3 studies)
⊕⊕©©
low1,2
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Table 7. Summary of findings A: In children screened for infection, what is the effect of a single dose of deworming drugs?
(Continued)
higher)
Haemoglobin
(g/dL)
Follow-
up: 9 weeks to 4
months
The
mean haemoglo-
bin in the con-
trol groups was
10.60 g/dl
The mean hae-
moglobin in the
intervention
groups was
0.37 g/dL
higher
(0.1 to 0.64
higher)
108
(2 studies)
⊕⊕©©
low1,2
Formal tests of
cognition
- - 103
(2 studies)
⊕©©©
very low3,4,5
One trial did not
report the
results, and the
other suggested
improvement in
3 out of 10 tests
after multiple re-
gression analysis
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for risk of bias: none of the studies adequately described allocation concealment to be considered “low risk of bias”
2 Downgraded by 1 for imprecision: the trials are too few and too small to have full confidence in the observed effects
3 Downgraded by 2 for risk of bias: both studies have deficiencies in randomization, concealment and blinding; in addition, one study
did not report on the results, suggesting selective reporting
4 Downgraded by 1 on imprecision: results were not clearly presented and did not include estimates of effect size.
5 Two studies measured cognitive functioning: i) Kvalsvig 1991a, with a follow-up of one month, did not clearly report the changes
in cognitive scores since “the dose of mebendazole was inadequate to free children from infection”; and ii) Nokes 1992, with a follow-
up of nine weeks, reported that results of a multiple regression suggest a greater improvement in treated children in 3/10 tests (fluency,
digit span forwards, digit span backwards).
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Table 8. Summary of findings B: In children living in communities where intestinal helminths are endemic, what is the effect
of a single dose of deworming drugs?
In children living in communities where intestinal helminths are endemic, what is the effect of a single dose of deworming
drugs?
Patient or population: children
Settings: areas endemic for intestinal helminths
Intervention: Single dose deworming drugs
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Assumed risk Corresponding
risk
Control Single dose de-
worming drugs
Weight (kg)
Follow-up: 7
weeks to 1 year
- - 3058
(9 studies)
⊕©©©
very low1,2,3
A positive ef-
fect was demon-
strated in 2 trials
from a single lo-
cationbut not re-
peated elsewhere
Haemoglobin
(g/dL)
Follow-
up: 9 weeks to 6
months
The mean hae-
moglobin in the
control groups
ranged from 12.
01 to 12.12 g/dl
The mean hae-
moglobin in the
intervention
groups was
0.06 g/dL
higher
(0.05 lower to 0.
17 higher)
1005
(3 studies)
⊕⊕⊕©
moderate1
Formal tests of
cognition
- - 1361
(2 studies)
⊕⊕©©
low1,4
One trial
reported that de-
worming had no
effect, and the
other that de-
worm-
ing reduces cog-
nitive scores
Physical well
being
Harvard Step
Test
The mean score
in the control
groups ranged
from 74 to 76 %
The mean score
in the interven-
tion groups was
6% higher
(4.31 to 7.69
higher)
86
(2 studies)
⊕⊕©©
low1,3,5
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Table 8. Summary of findings B: In children living in communities where intestinal helminths are endemic, what is the effect
of a single dose of deworming drugs? (Continued)
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for risk of bias: all studies have 1 or more methodological deficiencies
2 Downgraded by 1 for inconsistency: In two trials from Kenya carried out 15 years ago, the average increase in weight was 1.1 kg and
1.3 kg more in the intervention group. For the other trials, from high (two trials), moderate (two trials) and low (three trials) prevalence
areas, no effect was demonstrated
3 Downgraded by 1 for indirectness: The two studies demonstrating a benefit were conducted in the same primary school in Kenya, in
a population where virtually all of the children had hookworm and Trichuris infection, and about half were also infected with Ascaris.
This result may not be easily generalized to elsewhere.
4 Downgraded by 1 for indirectness: Only two studies have assessed these outcomes. In the Philippines Solon 2003 reports deworming
either has no effect or a negative effect on cognitive test scores, and in Vietnam Nga 2009 reports no difference detected. Data could
not be combined
5 The Harvard Step Test is scored out of 100, and Stephenson 1989 and Stephenson 1993 have both 6% higher value in treated groups.
Table 9. Summary of findings C: Multiple dose deworming drugs for soil-transmitted intestinal worms in children: effects on
nutritional indicators, haemoglobin and school performance (outcomes measured at less than 1 year)
Multiple dose deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemo-
globin and school performance (outcomes measured at less than 1 year)
Patient or population: children
Settings: areas endemic for intestinal helminths
Intervention: Multiple dose deworming drugs
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Assumed risk Corresponding
risk
Control Mul-
tiple dose de-
worming drugs
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Table 9. Summary of findings C: Multiple dose deworming drugs for soil-transmitted intestinal worms in children: effects on
nutritional indicators, haemoglobin and school performance (outcomes measured at less than 1 year) (Continued)
Weight (kg)
Follow-up: 6 to
12 months
The mean gain
in weight in the
control groups
ranged from 0.
95 to 2.70 kg
The mean
gain in weight in
the intervention
groups was
0.06 kg higher
(0.17 lower to 0.
3 higher)
2460
(7 studies)
⊕⊕©©
low1,2
Haemoglobin
(g/dL)
Follow-up: 6 to
11 months
The mean
change in hae-
moglobin in the
control groups
ranged from 0.
26 to 1.75 g/dL
LThe
mean change in
haemoglobin in
the intervention
groups was
0.01 g/dL
higher
(0.14 lower to 0.
13 higher)
807
(4 studies)
⊕⊕©©
low3,4
Formal tests of
cognition
- - Not estimable 30,571
(3 studies5)
⊕⊕©©
low1,6,7
None of the trials
reported a bene-
fit of deworming
School
attendance (%)
Follow-up: 6 to
12 months
Themean school
attendance in the
control group
was 66.3 %
Themean school
attendance in the
intervention
groups was
4 % higher
(6 lower to 14
higher)
30,243
(2 studies8)
⊕⊕©©
low1,9
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for risk of bias: most studies had one or more methodological deficiencies
2 Downgraded by 1 for inconsistency: One study from a very high prevalence setting found a significant benefit (0.9 kg), but other
studies from high prevalence (one trial), moderate prevalence (two trials) and low prevalence settings (three trials) have not found a
difference.
3 Downgraded by 1 for risk of bias: Dossa 2001 and Kruger 1996 have a high risk of bias for incomplete outcome data.
4 Downgraded by 1 for indirectness: none of the studies are from high prevalence settings
5 75 clusters with approximately 30,000 participants and 571 individually randomized participants (varies with outcome measured).
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6 Downgraded by 1 on imprecision: none of the trials found a benefit on cognitive tests, but the data were not presented in a way to
assess combined effects
7 Three studies measured intellectual development: Miguel 2004 (Cluster) measured a range of cognitive tests, but no deworming effect
was demonstrated. Stoltzfus 2001, with a follow-up of 12 months, found that treatment had no significant effect on motor or language
development; ii) Watkins 1996, with a follow-up of six months, found no difference on any of the tests between treatment groups.
8 75 clusters with approximately 30,000 participants and 243 individually randomized participants
9 Downgraded by 1 for indirectness: Most of the data is from a single high prevalence setting in Kenya and the result may not be easily
generalised to elsewhere.
A P P E N D I C E S
Appendix 1. Authors’ judgment on risk of bias
Potential bias Authors’ judgement
Random sequence generation (selection bias) High - not randomized or quasi-randomized
Unclear - States “randomized”, but does not report method
Low - describes method of randomization
Allocation concealment (selection bias) High - not concealed, open label trial for individually randomized, method of
concealment not adequate
Unclear - details of method not reported or insufficient details
Low - central allocation, sequentially numbered opaque sealed envelopes
Blinding (performance bias and detection bias) High - personnel, participants or outcome assessors not blinded
Unclear - no details reported, insufficient details reported
Low - personnel, participants and outcome assessors blinded
Incomplete outcome data (attrition bias) High - losses to follow-up not evenly distributed across intervention and control
group, high attrition rate (20% or more for the main outcome)
Unclear - no details reported, insufficient details reported
Low - no losses to follow-up, losses below 20% and evenly distributed across
groups, intention-to-treat analysis used
Note: for cluster RCTs, the loss relates to the clusters
Selective reporting (reporting bias) High - did not fully report measured or relevant outcomes
Unclear - not enough information reported to judge
Low - all stated outcomes reported
Other bias Low - no obvious other source of bias of concern to reviewers
High - major source of bias such as unexplained differences in baseline charac-
teristics
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WH A T ’ S N E W
Last assessed as up-to-date: 31 May 2012.
Date Event Description
10 October 2012 New citation required but conclusions have not
changed
Updated Summary of Findings, updated abstract, and
minor corrections
10 October 2012 New search has been performed In September 2012, we identified a minor data entry
error with a haemoglobin value, which we corrected
We also received feedback on the GRADE assessments.
This led to changes in the assessment of the quality of
the evidence for several outcomes. Most changes were
towards higher quality evidence. We refined the table
by adding additional footnotes to to clarify the classifi-
cation.The specific changes were:
For single dose weight, screened, GRADE moved from
moderate to low
For single doseHB, haemoglobin GRADEmoved from
low to moderate, after data entry corrected; and for
formal tests, GRADE moved from very low to low
For multiple dose (<1 year), formal tests and schooling
moved from very low to low, following upgrading of
study quality
For multiple doses (>1 year), weight and haemoglobin
moved from very low to low, following upgrading of
study quality; and cognition moved from very low to
low
We adjusted the wording in the abstract to take these
changes into account
H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 2, 1998
Date Event Description
31 May 2012 New search has been performed Substantive update:
1. We added a logic framework to the background.
2. We replaced Awasthi 1995 (unpublished data)
with the published data (Awasthi 2008 (Cluster)). We
received clarification on methods and results from
Miguel and Kremer and included this study in the
review (Miguel 2004 (Cluster)). Also, we tried to
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(Continued)
include the DEVTA (unpublished) completed in 2006
but were unable to as it remains unpublished as of May
2012.
3. We added haemoglobin as a primary outcome
and we added all trials measuring haemoglobin. We
merged end values and change values to simplify the
review. We reanalysed the school attendance data. In
addition, we brought the sensitivity analysis in line
with current best practice (by only including trials with
evidence of allocation concealment).
4. We added Summary of Findings tables. We
adjusted the wording in line with our policy of using
standard words to correspond to quality of the
evidence.
5. In the light of these changes, we rewrote the
review entirely.
31 May 2012 New citation required but conclusions have not changed Review updated, new studies added.
7 May 2008 Amended There are two alterations to the review:
1. We have corrected an error in the discussion. The
sentence that read “There was a weight gain of 2.413 kg
in the treatment parishes and 2.474 kg in the control
parishes at an unspecified follow-up point.” now reads
“There was a weight gain of 2.413 kg in the treatment
parishes and 2.259 kg in the control parishes at an un-
specified follow-up point.”
2. We have detailed our correspondence to date with
Michael Kremer and Edward Miguel in the discussion
12 August 2007 New citation required and conclusions have changed 2007, Issue 4 (substantive update): author team
changed; review title modified from the original title of
“Anthelmintic drugs for treating worms in children: ef-
fects on growth and cognitive performance”; updated
methods, reapplied the inclusion criteria, repeated data
extraction, added new trials, and included additional
analyses as recommended by policy specialists
31 March 2000 New citation required and conclusions have changed 2000, Issue 2 (substantive update): new trials added and
review updated
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C O N T R I B U T I O N S O F A U T H O R S
DTR wrote the protocol, applied inclusion criteria, assessed quality, extracted data, conducted data analysis, and wrote the first draft of
the review. KS-W and NM applied inclusion criteria, assessed quality, extracted data, conducted data analysis, and drafted the results
of the update. SD assessed risk of bias and extracted data for a subset of the trials; and contributed to the analysis and the writing of
the review. PGr provided advice at all stages of the review production, applied inclusion criteria, assessed quality, quality assured data
extraction, helped construct the comparisons, and helped write the review.
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Medical Subject Headings (MeSH)
Anthelmintics [∗pharmacology; therapeutic use]; Child Development [drug effects]; Cognition [∗drug effects]; Growth [drug effects];
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MeSH check words
Adolescent; Child; Child, Preschool; Humans
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